Naphthyridine derivatives as PRC2 inhibitors

Abstract

Disclosed are compounds of formula (I) or (II) that inhibit polycomb repressive complex 2 (PRC2) activity. Specifically, the invention relates to compounds, pharmaceutical compositions, and methods of use, such as methods of treating cancer, using the compounds and pharmaceutical compositions of the invention. [Formula 1] JPEG2022530866000193.jpg51108

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Application No. 62 / 836,840, filed April 22, 2019, the disclosure of which is incorporated herein by reference.

[0002] Technical Field The present invention relates to compounds that inhibit polycomb repressive complex 2 (PRC2). Specifically, the present invention relates to compounds, pharmaceutical compositions containing the compounds, and methods of use thereof. [Background technology]

[0003] Polycomb repressive complex 2 (PRC2) is a multiprotein complex that contributes to epigenetic silencing of target genes to regulate development and homeostasis. The PRC2 complex is composed of three core subunits: enhancer of zeste homolog 2 (EZH2), embryonic ectoderm development protein (EED), and suppressor of zeste 12 (SUZ12). Two additional non-essential subunits, AEBP2 and RbAp48, function to promote the enzymatic activity of the PRC2 complex (see, e.g., Cao et al., (2002) Science 298:1039-1043).

[0004] EZH2, the catalytic subunit of the PRC2 complex, is a histone methyltransferase that functions to silence target genes by trimethylating lysine 27 of histone H3 (H3K27me3). EED is responsible, in part, for the recognition of trimethylated histone H3 lysine 27 and serves as a scaffolding protein for the assembly of the PRC2 complex. The interaction of EZH2 with the EED subunit is essential for the activity and function of the PRC2 complex histone methyltransferase (see, e.g., Denisenko et al., (1998) Mol. Cell Biol. 18:5634-5642).

[0005] Abnormal PRC2 expression has been reported in various cancer cases. EZH2 is overexpressed in high-grade solid tumors, including prostate, breast, skin, bladder, liver, pancreatic, and head and neck cancers. For example, EZH2 transcripts and protein have been consistently elevated in invasive breast cancers compared with normal breast epithelium and have been strongly associated with breast cancer progression. Overexpression of EZH2 in immortalized human breast epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity (Leer et al., (2003) Proc. Natl. Acad. Sci. USA 100(20):11606-11611). Tumors expressing high levels of EZH2 also have a high risk of recurrence after prostatectomy (Varambally et al, (2008) Science 322:1695-1699).

[0006] In addition to overexpression, somatic activating and inactivating mutations of EZH2 subunits have also been reported. Somatic activating mutations of EZH2, resulting in elevated H3K27me3 levels, have been observed in follicular lymphoma and diffuse large B-cell lymphoma (for review, see Helin and Dhanak (2013) Nature 502:480-488; Pasqualucci et al. (2011) Nature Genet. 43(9):830-837). These mutations, along with EZH2 overexpression in various solid tumors, suggest that misregulation of EZH2 may lead to gene silencing by the PRC2 complex, which is important for tumor growth and survival. Interestingly, however, inhibitors of the PRC2 complex that target non-catalytic subunits, such as EED, retain potent activity against cell lines harboring EZH2-activating mutations (e.g., He et al., (2017) Nat Chem Biol.:13(8):922. doi:10.1038 / nchembio0817-922b). Summary of the Invention

[0007] Enhanced PRC2 activity has been shown to contribute to unwanted tumor cell proliferation and invasion, in part through trimethylation of H3K27. Because elevated H3K27me3 levels are thought to contribute to cancer progression in many tumor types, inhibiting PRC2 activity may provide therapeutic benefit against a wide range of cancers. The compounds of the present invention offer potential therapeutic benefit as inhibitors that negatively regulate PRC2 activity in cells or bind to the EED subunit, which may be useful in treating various forms of cancer.

[0008] There is a need to develop novel PRC2 inhibitors that retain potency against EZH2-activating mutations while exhibiting improved cellular potency, efficacy, stability, and safety compared to inhibitors that target the SET domain of EZH2. The compounds and compositions of the present invention advantageously overcome one or more of these drawbacks by providing potent, selective, and orally active compounds that bind to EED and inhibit PRC2 activity regardless of EZH2 mutation status or expression level.

[0009] In one aspect of the present invention, a compound represented by formula (I)

[0010] [ka]

[0011] and pharmaceutically acceptable salts thereof,

[0012] During the ceremony,

[0013] [ka] represents a single or double bond,

[0014] Z is O or S;

[0015] X, O, CR 5 , C.R. 5 OH, or C(R 5 )2, where:

[0016] When X is O,

[0017] [ka] is a single bond,

[0018] X is C(R 5 )2,

[0019] [ka] is a single bond,

[0020] X is CR 5 When OH,

[0021] [ka] is a single bond, or

[0022] X is CR 5 When

[0023] [ka] is a double bond,

[0024] R 1 is an aryl, heteroaryl, -L-cycloalkyl, -N(R 5 )heterocyclyl, or -L-heterocyclyl, which aryl, heteroaryl, and -L-cycloalkyl, -N(R 5 ) heterocyclyl, and the cyclyl portion of -L-heterocyclyl may be one or more R 2 is optionally replaced by

[0025] Each R 2are independently oxo, cyano, halogen, -PO3(C1-C3 alkyl)2, alkoxy, hydroxyalkyl, heteroalkyl, aralkyl, haloalkyl, -COOR 5 , -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -Y 2 -heterocyclyl, -LN(R 5 )2, -OLN(R 5 )2, -C(CF3)N(R 5 )2, -Y 1 -N(R 5 )2, or -Y 2 -N(R 5 )2, and is selected from aralkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 The ring portion of a heterocyclyl may be one or more R 4 is optionally replaced by

[0026] R 3 are independently C1-C3 alkyl or halogen;

[0027] Each R 4 are independently oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, C1-C6 alkyl, or -Y 1 -heterocyclyl, and -Y 1 -heterocyclyl may be one or more R 7 is optionally replaced by

[0028] L is a single bond or C1-C4 alkylene;

[0029] Y 1 is a single bond, —C(O)—, or —NHC(O)—,

[0030] Y2 is a single bond, -S-, -SO-, -SO2-, or -NR 5 SO2-,

[0031] Each R 5 are independently hydrogen or C1-C3 alkyl;

[0032] R 6 are independently hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0033] Each R 7 are independently oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, or C1-C6 alkyl, and

[0034] n is 1 or 2.

[0035] In one aspect of the present invention, a compound represented by formula (II)

[0036] [ka]

[0037] and pharmaceutically acceptable salts thereof,

[0038] During the ceremony,

[0039] [ka] represents a single or double bond,

[0040] A 1 , A 2 , A 3 , and A 4 are each independently N or CR A and A 1 , A 2 , A 3, and A 4 More than two of them are N,

[0041] Z is O or S;

[0042] X, O, CR 5 , C.R. 5 OH, or C(R 5 )2, where:

[0043] When X is O,

[0044] [ka] is a single bond,

[0045] X is C(R 5 )2,

[0046] [ka] is a single bond,

[0047] X is CR 5 When OH,

[0048] [ka] is a single bond, or

[0049] X is CR 5 When

[0050] [ka] is a double bond,

[0051] R 1 is an aryl, heteroaryl, -L-cycloalkyl, -N(R 5 )heterocyclyl, or -L-heterocyclyl, which aryl, heteroaryl, and -L-cycloalkyl, -N(R5 ) heterocyclyl, and the cyclyl portion of -L-heterocyclyl may be one or more R 3 is optionally replaced by

[0052] R 2 are independently C1-C3 alkyl or halogen;

[0053] Each R 3 are independently oxo, cyano, halogen, -PO3(C1-C3 alkyl)2, alkoxy, hydroxyalkyl, heteroalkyl, aralkyl, haloalkyl, -COOR 5 , -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -Y 2 -heterocyclyl, -LN(R 5 )2, -OLN(R 5 )2, -C(CF3)N(R 5 )2, -Y 1 -N(R 5 )2, or -Y 2 -N(R 5 )2, and is selected from aralkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 The ring portion of a heterocyclyl may be selected from one or more independently selected R 6 is optionally replaced by

[0054] R 4 is hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0055] L is a single bond or C1-C4 alkylene;

[0056] Y 1 is a single bond, —C(O)—, or —NHC(O)—,

[0057] Y2 is a single bond, -S-, -SO-, -SO2-, or -NR 5 SO2-,

[0058] Each R 5 are independently hydrogen or C1-C3 alkyl;

[0059] Each R 6 is an oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, C1-C6 alkyl, or -Y 1 -heterocyclyl, and -Y 1 -heterocyclyl may be one or more R 7 is optionally replaced by

[0060] Each R 7 are independently hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0061] Each R A are independently hydrogen, alkoxy, heteroalkyl, -N(R 5 )2, heteroalkylN(R 5 )2, C1-C3 alkyl, -S-C1-C3 alkyl, or aryl; and

[0062] n is 1 or 2.

[0063] In another aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0064] In yet another aspect of the invention, there is provided a method of inhibiting PRC2 activity in a cell, the method comprising contacting the cell with a compound of Formula (I) or Formula (II). In one embodiment, the contacting step occurs in vitro. In one embodiment, the contacting step occurs in vivo.

[0065] Further provided herein is a method of inhibiting cell proliferation in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0066] Further provided herein is a method of treating cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of said compound.

[0067] Also provided herein are methods of treating cancer in a patient, the methods comprising: (a) determining that the cancer is associated with a PRC2 mutation (e.g., a PRC2-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the compound.

[0068] Further provided herein is the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for inhibiting the activity of PRC2.

[0069] Further provided herein is the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for treating a PRC2-associated disease or disorder.

[0070] In another aspect of the present invention, intermediates useful in the preparation of compounds of formula (I) and formula (II) are provided. DETAILED DESCRIPTION OF THE INVENTION

[0071] The present invention relates to PRC2 inhibitors. Specifically, the present invention relates to compounds that bind to EEDs to inhibit PRC2 activity, pharmaceutical compositions containing the compounds in therapeutically effective amounts, and methods of using them.

[0072] definition Unless otherwise specified, all terms and scopes used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, patent applications, and publications referred to herein are incorporated by reference to the extent that they are consistent with this disclosure.

[0073] For clarity, chemical moieties are defined and referred to throughout primarily as monovalent chemical moieties (e.g., alkyl, aryl, etc.). Nevertheless, these terms may be used to suggest corresponding multivalent moieties under appropriate structural circumstances apparent to those skilled in the art. For example, an "alkyl" moiety generally refers to a monovalent radical (e.g., CH3-CH2-), but in some circumstances, a divalent linking moiety may be "alkyl," in which case one skilled in the art will understand that alkyl is a divalent radical (e.g., -CH2-CH2-) equivalent to the term "alkylene." (Similarly, in situations where a divalent moiety is required and "aryl" is specified, one skilled in the art will understand that the term "aryl" refers to the corresponding divalent moiety, i.e., arylene.) All atoms are understood to have the normal number of valencies for bond formation (i.e., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S depending on its oxidation state).

[0074] As used herein, "Polycomb repressive complex 2" or "PRC2 complex" refers to a mammalian multiprotein complex that contains three core subunits, enhancer of zeste homolog 2 (EZH2), embryonic ectoderm development protein (EED), and suppressor of zeste 12 (SUZ12), as well as two additional non-essential subunits, AEBP2 and RbAp48.

[0075] As used herein, "EED" refers to the embryonic ectoderm development protein subunit of the PRC2 complex.

[0076] As used herein, "EZH2" or "EZH2 enzyme" refers to a mammalian histone methyltransferase that is the catalytic subunit of polycomb repressive complex 2 (PRC2), and functions to silence target genes by trimethylating lysine 27 of histone H3 (H3K27me3).

[0077] As used herein, "PRC2 inhibitor" refers to a compound of the present invention represented by Formula (I) as described herein. These compounds can negatively regulate or inhibit all or part of the enzymatic activity of the PRC2 complex. Without wishing to be bound by any theory, the inhibitors of the present invention can inhibit PRC2 enzymatic activity by binding to EEDs to prevent the assembly of the PRC2 complex on the histone H3 tail and inhibit its activity.

[0078] "PRC2-associated disease or disorder," as used herein, refers to a disease or disorder associated with, mediated by, or having an activating EZH2 mutation and / or aberrant expression of PRC2. A non-limiting example of a PRC2-associated disease or disorder is a PRC2-associated cancer.

[0079] The term "amino" refers to -NH2.

[0080] The term "acetyl" refers to -C(O)CH3.

[0081] As used herein, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent, where the alkyl and aryl moieties are as defined herein.

[0082] As used herein, the term "alkyl" refers to straight and branched chain aliphatic groups having 1 to 12 carbon atoms. Thus, "alkyl" includes C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57 10 , C 11 , and C 12Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0083] As used herein, the term "alkenyl" refers to a straight or branched chain unsaturated hydrocarbon having one or more carbon-carbon double bonds and having 2 to 12 carbon atoms. Thus, "alkenyl" includes C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54 10 , C 11 , and C 12 Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0084] As used herein, the term "alkynyl" refers to a straight or branched chain unsaturated hydrocarbon having one or more carbon-carbon triple bonds and having 2 to 12 carbon atoms. Thus, "alkynyl" includes C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54 10 , C 11 , and C 12 Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0085] An "alkylene," "alkenylene," or "alkynylene" group is an alkyl, alkenyl, or alkynyl group, as defined above, that is positioned between and serves to connect two other chemical groups. Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, and butylene. Typical alkenylene groups include, but are not limited to, ethenylene, propenylene, and butenylene. Typical alkynylene groups include, but are not limited to, ethynylene, propynylene, and butynylene.

[0086] The term "alkoxy" refers to -OC1-C6 alkyl.

[0087] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon group having 3 to 12 carbons. Thus, "cycloalkyl" refers to C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, ​​C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, 10 , C 11 , and C 12 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0088] The term "heteroalkyl" refers to an alkyl group, as defined above, where one or more carbon atoms in the chain are independently replaced by O, S, or NR x and R x is hydrogen or C1-C3 alkyl. Examples of heteroalkyl groups include methoxymethyl, methoxyethyl, and methoxypropyl.

[0089] An "aryl" group is a C6-C aryl group containing one to three aromatic rings. 14 It is an aromatic moiety. Therefore, "aryl" refers to C6, C 10 , C 13 , and C 14 Typical aryl groups include C6-C 10 Particular aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and fluorenyl.

[0090] An "aralkyl" or "arylalkyl" group comprises an aryl group covalently bonded to an alkylene group, which in turn is bonded to another group via the alkyl portion. Exemplary aralkyl groups are -(C-C)alkyl(C-C)aryl, including, but not limited to, benzyl, phenethyl, and naphthylmethyl.

[0091] A "heterocyclyl" or "heterocyclic" group is a monocyclic or bicyclic (fused or spiro) ring structure having 3 to 12 atoms (3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 atoms), e.g., 4 to 8 atoms, in which one or more ring atoms are independently -C(O)-, N, NR 5 , O, or S, with the remainder of the ring atoms being quaternary carbon or carbonyl carbons. Examples of heterocyclic groups include, but are not limited to, epoxy, oxiranyl, oxetanyl, azetidinyl, aziridinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, thiazolidinyl, thiatanyl, dithianyl, trithianyl, azathianyl, oxathianyl, dioxolanyl, oxazolidinyl, oxazolidinonyl, decahydroquinolinyl, piperidonyl, 4-piperidonyl, thiomorpholinyl, dimethyl-morpholinyl, and morpholinyl. Specifically excluded from the scope of this term are compounds having adjacent ring O and / or S atoms.

[0092] As used herein, "L-heterocyclyl" refers to a heterocyclyl group that is covalently linked to another group via an alkylene linker, L, where L is C1-C4 alkylene.

[0093] As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 10, 13, or 14 ring atoms, sharing 6, 10, or 14 pi electrons in a cyclic arrangement, and having from 1 to 3 heteroatoms, other than carbon atoms, each independently being N, O, or S. "Heteroaryl" also includes polycyclic (e.g., bicyclic) fused ring systems in which one or more of the fused rings is non-aromatic, provided that at least one ring is aromatic and at least one ring contains an N, O, or S ring atom.

[0094] Examples of heteroaryl groups include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzo[d]oxazol-2(3H)-one, 2H-benzo[b][1,4]oxazin-3(4H)-one, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazoyl, 4aH-carbazoyl, carbolinyl, chromanyl, chromenyl, and cinnolinyl. , furanyl, furazanyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl , oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinu These include clidinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[0095] An "L-heteroaryl," "heteroaralkyl," or "heteroarylalkyl" group includes a heteroaryl group covalently linked to another group via an alkylene linker. Examples of heteroalkyl groups include C1-C6 alkyl groups and heteroaryl groups having 5, 6, 9, or 10 ring atoms. Examples of heteroaralkyl groups include pyridylmethyl, pyridylethyl, pyrrolylmethyl, pyrrolylethyl, imidazolylmethyl, imidazolylethyl, thiazolylmethyl, thiazolylethyl, benzimidazolylmethyl, benzimidazolylethyl, quinazolinylmethyl, quinolinylmethyl, quinolinylethyl, benzofuranylmethyl, indolinylethyl, isoquinolinylmethyl, isoindolylmethyl, cinnolinylmethyl, and benzothiophenylethyl. Specifically excluded from the scope of this term are compounds having adjacent ring O and / or S atoms.

[0096] An "arylene," "heteroarylene," or "heterocyclylene" group is a divalent aryl, divalent heteroaryl, or heterocyclyl group, respectively, as defined above, that is positioned between and serves to connect two other chemical groups.

[0097] As used herein, when a moiety (e.g., cycloalkyl, aryl, heteroaryl, heterocyclyl, urea, etc.) is described as "optionally substituted" without specifying the substituents, it is intended that the group optionally have 1 to 4, preferably 1 to 3, and more preferably 1 or 2 non-hydrogen substituents.

[0098] The terms "halogen" or "halo" as used herein refer to chlorine, bromine, fluorine, or iodine.

[0099] The term "haloalkyl" refers to an alkyl chain in which one or more hydrogens have been replaced by halogen. Exemplary haloalkyls are trifluoromethyl, difluoromethyl, fluorochloromethyl, chloromethyl, and fluoromethyl.

[0100] The term "hydroxyalkyl" refers to an alkyl chain, as defined herein, in which at least one hydrogen of the alkyl chain is replaced with a hydroxyl.

[0101] As used herein, an "effective amount" of a compound is an amount sufficient to negatively regulate or inhibit the activity of the PRC2 complex.

[0102] As used herein, a "therapeutically effective amount" of a compound is an amount sufficient to ameliorate or in some way reduce symptoms, halt or reverse the progression of a disease, or negatively regulate or inhibit the activity of the PRC2 complex. Such an amount can be administered as a single dose or according to a regimen whereby this amount is effective.

[0103] As used herein, "treatment" means any manner in which the symptoms or pathology of a patient's disease, disorder, or condition are ameliorated or otherwise beneficially altered.

[0104] As used herein, "amelioration of symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition" refers to a reduction, whether permanent or temporary, persistent or transient, that can result from or be associated with administration of that composition.

[0105] compound In one aspect of the present invention, a compound represented by formula (I)

[0106] [ka]

[0107] and pharmaceutically acceptable salts thereof,

[0108] During the ceremony,

[0109] [ka] represents a single or double bond,

[0110] Z is O or S;

[0111] X, O, CR 5 , C.R. 5 OH, C(R 5 )2, where:

[0112] When X is O,

[0113] [ka] is a single bond,

[0114] X is C(R 5 )2,

[0115] [ka] is a single bond,

[0116] X is CR 5 When OH,

[0117] [ka] is a single bond, or

[0118] X is CR 5 When

[0119] [ka] is a double bond,

[0120] R 1 is an aryl, heteroaryl, -L-cycloalkyl, -N(R 5 )heterocyclyl, or -L-heterocyclyl, which aryl, heteroaryl, and -L-cycloalkyl, -N(R 5) heterocyclyl, and the cyclyl portion of -L-heterocyclyl may be one or more R 2 is optionally replaced by

[0121] Each R 2 are independently oxo, cyano, halogen, -PO3(C1-C3 alkyl)2, alkoxy, hydroxyalkyl, heteroalkyl, aralkyl, haloalkyl, -COOR 5 , -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -Y 2 -heterocyclyl, -LN(R 5 )2, -OLN(R 5 )2, -C(CF3)N(R 5 )2, -Y 1 -N(R 5 )2, or -Y 2 -N(R 5 )2, and is selected from aralkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 The ring portion of a heterocyclyl may be one or more R 4 is optionally replaced by

[0122] R 3 are independently C1-C3 alkyl or halogen;

[0123] Each R 4 is an oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, C1-C6 alkyl, or -Y 1 -heterocyclyl, and -Y 1 -heterocyclyl may be one or more R 7 is optionally replaced by

[0124] L is a single bond or C1-C4 alkylene;

[0125] Y 1 is a single bond, —C(O)—, or —NHC(O)—,

[0126] Y 2 is a single bond, -S-, -SO-, -SO2-, or -NR 5 SO2-,

[0127] Each R 5 are independently hydrogen or C1-C3 alkyl;

[0128] R 6 are independently hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0129] Each R 7 are independently oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, or C1-C6 alkyl, and

[0130] n is 1 or 2.

[0131] In one embodiment of the compound of Formula (I), Z is O or S. In one embodiment, X is O, CR 5 , C.R. 5 OH, or C(R 5 )2 and X is O,

[0132] [ka] is a single bond, and X is C(R 5 )2,

[0133] [ka] is a single bond, and X is CR 5 When OH,

[0134] [ka] is a single bond, or X is CR 5 When

[0135] [ka] is a double bond. In one embodiment, n is 1. In one embodiment, n is 2.

[0136] In one embodiment of a compound of Formula (I), Z is O, X is O, n is 1,

[0137] [ka] is a single bond. In another embodiment, Z is O and X is CR 5 and

[0138] [ka] is a double bond. In one embodiment, Z is O and X is C(R 5 )2, n is 1,

[0139] [ka] is a single bond. In one embodiment, Z is O and X is CR 5 OH, n is 1,

[0140] [ka] is a single bond. In another embodiment, Z is O and X is C(R 5 )2, n is 2,

[0141] [ka] is a single bond. In another embodiment, Z is S and X is C(R 5 )2, n is 1,

[0142] [ka] is a single bond.

[0143] In one embodiment of the compounds of Formula (I), R 1 is one or more R 2 In certain embodiments, the aryl is optionally substituted with one or more R 2 is phenyl optionally substituted by

[0144] In one embodiment of the compound of Formula (I), aryl is a single R 2 In one embodiment, the aryl is substituted with two R 2 In one embodiment, the aryl is substituted with three R groups. 2 A typical aryl R 2 The groups include halogen, hydroxyl, haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -LN(R 5 )2, -Y 1 -N(R 5 )2, -Y 2 -N(R 5 )2, -Y 2 -haloalkyl, -L-heterocyclyl, or -Y 1 -heterocyclyl, -L-heterocyclyl and -Y 1 The heterocyclyl moiety of the heterocyclyl is one or more R 4 is optionally replaced by

[0145] In one embodiment of the compounds of Formula (I), R 1 Ha-Y 2 In one embodiment, Y is phenyl substituted with -C1-C6 alkyl. 2is a single bond, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 1 Ha-Y 2 -phenyl substituted with C1-C6 alkyl; Y 2 is —SO— and C-C alkyl is methyl. In one embodiment, R 1 is methyl and -Y 2 -C1-C6 alkyl disubstituted phenyl; Y 2 is -SO2- and C1-C6 alkyl is methyl.

[0146] In one embodiment of the compounds of Formula (I), R 1 is one R 2 is phenyl substituted with R 2 is a cyano group.

[0147] In one embodiment of the compounds of Formula (I), R 1 is one R 2 is phenyl substituted with R 2 is -L-heteroaryl. In certain embodiments, -L-heteroaryl is tetrazolyl. In one embodiment, R 1 is one R 2 is phenyl substituted with R 2 is PO3(C1-C3 alkyl). In one embodiment, R 1 is one R 2 is phenyl substituted with R 2 HA-COOR 5 In one embodiment, R 1 is one R 2 is phenyl substituted with R 2 -OLN(R 5 )2. In one embodiment, R 1 is one R 2 is phenyl substituted with R 2 is an aralkyl.

[0148] In one embodiment of the compounds of Formula (I), R 1 is at least one R 2is phenyl substituted with R 2 -LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene. In one embodiment, each R 5 is independently hydrogen. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, R 1 is -LN(R 5 )2 and is phenyl further substituted with one or more halogen and / or C1-C6 alkyl.

[0149] In one embodiment of the compounds of Formula (I), R 1 is one R 2 is phenyl substituted with R 2 Ha-Y 1 -N(R 5 )2. In one embodiment, Y 1 is -C(O)-, and each R 5 is C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, Y 1 is -C(O)-, and each R 5 is hydrogen. In one embodiment, Y 1 is -C(O)- and one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, R 1 -Y 1 -N(R 5 )2 and is phenyl further substituted with one or more halogen and / or C1-C6 alkyl.

[0150] In one embodiment of the compounds of Formula (I), R 1 Ha-Y 2 -phenyl substituted with haloalkyl; Y 2is -S- or -SO2-, and haloalkyl is trifluoromethyl.

[0151] In one embodiment of the compounds of Formula (I), R 1 is at least one -L-heterocyclyl or -Y 1 -phenyl substituted with heterocyclyl, each heterocyclyl being one or more R 4 In one embodiment, R 1 is one R 2 is phenyl substituted with R 2 is one or more R 4 -Y optionally replaced by 1 -heterocyclyl. In one embodiment, Y 1 is -C(O)- and heterocyclyl is piperazinyl optionally substituted with C1-C3 alkyl.

[0152] In certain embodiments of compounds of Formula (I), R 2 The group is one or more R 4 In one embodiment, L is methylene and heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. In one embodiment, L is methylene and heterocyclyl is azetindyl, pyrrolidinyl, piperidinyl, piperazinyl, piperazinone, tetrahydropyranyl, morpholinyl, thiomorpholinyl, or diazapanyl, each of which is optionally substituted with one or more R 4 A typical R 4 Groups include oxo, halogen, hydroxyalkyl, and C1-C3 alkyl.

[0153] In one embodiment of the compounds of Formula (I), R 1 is one or more R 4 -Y optionally replaced by 1 -heterocyclyl. 1is -C(O)-, and heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl, each optionally further substituted with one or more halogens.

[0154] In one embodiment of the compounds of Formula (I), R 1 is one or more R 4 In certain embodiments, -L-heteroaryl is tetrazolyl.

[0155] In one embodiment of the compounds of Formula (I), R 1 is phenyl substituted with PO(C-C alkyl). In another embodiment, R 1 HA-COOR 5 In one embodiment, R 1 is hydroxyalkyl, -OLN(R 5 )2, or phenyl substituted with aralkyl.

[0156] In one embodiment of the compounds of Formula (I), R 1 is one or more R 2 In certain embodiments, heteroaryl is pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, pyridyl, pyridinyl-2-one, pyrazinyl, pyridazinyl, pyrimidinyl, or 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, each of which may be substituted with one or more R 4 is optionally replaced by

[0157] In one embodiment of the compounds of Formula (I), heteroaryl is a single R 2 In one embodiment, the heteroaryl is substituted with two R 2 In one embodiment, the heteroaryl is substituted with three R groups. 2 Exemplary heteroaryl R groups are substituted. 2The groups include amino, cyano, halogen, alkoxy, hydroxyalkyl, heteroalkyl, haloalkyl, -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -LN(R 5 )2, or -Y 1 -N(R 5 )2, including -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 The heterocyclyl ring may be formed from one or more R 4 is optionally replaced by

[0158] In one embodiment of the compounds of Formula (I), R 4 is amino, hydroxyl, cyano, alkoxy, or halogen. 7 is C1-C3 alkyl. In one embodiment, R 4 is a halogen, which is fluorine or chlorine. In one embodiment, R 4 is alkoxy, where the alkoxy is methoxy or ethoxy. In one embodiment, R 4 is cycloalkyl, where the cycloalkyl is cyclopropyl. In one embodiment, R 4 The group may be one or more independently selected R 7 is further substituted with

[0159] In another embodiment of the compounds of Formula (I), R 1 is heteroaryl, and each R 2are independently hydroxyalkyl, heteroalkyl, or haloalkyl. In some embodiments, hydroxyalkyl is hydroxymethyl, hydroxyethyl, 2-methyl, or 2-hydroxypropyl. In some embodiments, heteroalkyl is methoxymethyl or methoxyethyl. In some embodiments, haloalkyl is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, or trifluoroethyl.

[0160] In certain embodiments of compounds of Formula (I), R 1 is heteroaryl, and R 2 Ha-Y 1 -C1-C6 alkyl, where Y 1 is a single bond, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 2 Ha-Y 1 -C1-C6 alkyl, where Y 1 is —C(O)—, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 1 is -NHC(O)-, and the C1-C6 alkyl moiety is methyl.

[0161] In one embodiment of the compounds of Formula (I), R 1 is heteroaryl, and R 2 Ha-Y 2 -C1-C6 alkyl, where -Y 2 is -SO2- and C1-C6 alkyl is methyl. In another embodiment, R 2 Ha-Y 2 -C1-C6 alkyl, where -Y 2 is -SO2- and C1-C6 alkyl is methyl.

[0162] In one embodiment of the compounds of Formula (I), R 1 is heteroaryl, and R 2 is one or more R 4 -Y optionally replaced by 1 -heterocyclyl. In one embodiment, Y1 is a single bond. In another embodiment, Y 1 is —C(O)—. In one embodiment, Y 1 is a single bond, and heterocyclyl is azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. 4 is C1-C3 alkyl. In one embodiment, the C1-C3 alkyl is selected from one or more independently selected R 7 In one embodiment, R 4 is a halogen.

[0163] In one embodiment of the compound of Formula (I), the heteroaryl is selected from the group consisting of at least one R 2 is replaced by R 2 is -L-heterocyclyl and one or more R 4 In one embodiment, L is ethylene and heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. In one embodiment, L is methylene and heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, piperazinone, tetrahydropyranyl, morpholinyl, thiomorpholinyl, or diazapanyl, each of which is optionally substituted with one or more R 4 is optionally replaced by

[0164] In one embodiment of the compounds of Formula (I), R 4 The groups are independently -LN(R 5 )2, hydroxyl, cyano, alkoxy, or halogen. In one embodiment, R 4 is C1-C3 alkyl. In one embodiment, R 4 is a halogen, which is fluorine or chlorine. In one embodiment, R 4 is alkoxy, where the alkoxy is methoxy or ethoxy. In one embodiment, R 4 is cycloalkyl, where the cycloalkyl is cyclopropyl. In one embodiment, R 4-LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene. In one embodiment, each R 5 is independently hydrogen. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 is C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl.

[0165] In one embodiment of the compounds of Formula (I), R 1 is heteroaryl, and R 2 -LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene, ethylene, or propylene. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, each R 5 are independently hydrogen.

[0166] In one embodiment of the compounds of Formula (I), R 1 is heteroaryl, and R 2 is one or more R 4 In one embodiment, L is a single bond. In one embodiment, L is C1-C3 alkylene. In one embodiment, C1-C3 alkylene is methylene. In one embodiment, the heteroaryl of -L-heteroaryl is pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, thiazolyl, or pyridazinyl. In one embodiment, the heteroaryl of -L-heteroaryl is pyridyl. In one embodiment, the heteroaryl of -L-heteroaryl is selected from one or more independently selected R 7 is further substituted with

[0167] In one embodiment of the compounds of Formula (I), R 1 There are two R 2 R is a heteroaryl substituted with a group; 2 The groups are independently two -Y 1 -C1-C6 alkyl group, -Y 1 -C1-C6 alkyl and alkoxy, -Y 1 -C1-C6 alkyl and cycloalkyl, -Y 1 -C1-C6 alkyl and haloalkyl, -Y 1 -C1-C6 alkyl and amino, two alkoxy groups, alkoxy and halogen, alkoxy and cyano, and amino and haloalkyl. 2 Ha-Y 1 -C1-C6 alkyl, where each Y 1 is a single bond and each C1-C6 alkyl is methyl, ethyl, or isopropyl. In one embodiment, cycloalkyl is cyclopropyl. In one embodiment, alkoxy is methoxy. In one embodiment, halogen is fluorine or chlorine. In one embodiment, haloalkyl is trifluoromethyl or trifluoroethyl.

[0168] In one embodiment of the compounds of Formula (I), R 1 is one or more R 2 In one embodiment, L is a single bond and heterocyclyl is tetrahydrofuranyl, piperidinyl, piperazinyl, or morpholinyl. In one embodiment, L is methylene and heterocyclyl is azetidinyl, pyrrolidinyl, or

[0169] [ka] In certain embodiments, heterocyclyl is independently selected from oxo, halogen, alkoxy, hydroxyl, and -Y 1 -one or more R selected from C1-C6 alkyl 4where Y is a single bond or -C(O)-.

[0170] In one embodiment of a compound of Formula (I), n is 0. In one embodiment, n is 1 and R 3 is a halogen. In some embodiments, the halogen is fluorine or chlorine. In one embodiment, the halogen is fluorine.

[0171] In one embodiment of the compounds of Formula (I), R 6 is hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl. 6 is hydrogen. In other embodiments, R 6 is methyl, ethyl, or propyl.

[0172] In one embodiment of the compounds of Formula (I), R 4 The cyclyl portion of the group is 7 In one embodiment, R 7 is an oxo, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, or C1-C3 alkyl. In one embodiment, R 7 is C1-C3 alkyl, and the C1-C3 alkyl is methyl, ethyl, or isopropyl. 7 is a halogen, which is fluorine or chlorine. In some embodiments, R 7 is oxo.

[0173] In one embodiment of the compounds of Formula (I), R 4 The cyclyl portion of the group is 7 In one embodiment, two R 7 Each group is a halogen and each halogen is fluorine.

[0174] In one embodiment, the compound of formula (I) is

[0175] [ka] is.

[0176] In another aspect of the present invention, a compound represented by formula (II)

[0177] [ka]

[0178] and pharmaceutically acceptable salts thereof,

[0179] During the ceremony,

[0180] [ka] represents a single or double bond,

[0181] A 1 , A 2 , A 3 , and A 4 are each independently N or CR A and A 1 , A 2 , A 3 , and A 4 More than two of them are N,

[0182] Z is O or S;

[0183] X, O, CR 5 , C.R. 5 OH, or C(R 5 )2, where:

[0184] When X is O,

[0185] [ka] is a single bond,

[0186] X is C(R 5)2,

[0187] [ka] is a single bond,

[0188] X is CR 5 When OH,

[0189] [ka] is a single bond, or

[0190] X is CR 5 When

[0191] [ka] is a double bond,

[0192] R 1 is an aryl, heteroaryl, -L-cycloalkyl, -N(R 5 )heterocyclyl, or -L-heterocyclyl, which aryl, heteroaryl, and -L-cycloalkyl, -N(R 5 ) heterocyclyl, and the cyclyl portion of -L-heterocyclyl may be one or more R 3 is optionally replaced by

[0193] R 2 are independently C1-C3 alkyl or halogen;

[0194] Each R 3 are independently oxo, cyano, halogen, -PO3(C1-C3 alkyl)2, alkoxy, hydroxyalkyl, heteroalkyl, aralkyl, haloalkyl, -COOR 5 , -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2-C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -Y 2 -heterocyclyl, -LN(R 5 )2, -OLN(R 5 )2, -C(CF3)N(R 5 )2, -Y 1 -N(R 5 )2, or -Y 2 -N(R 5 )2, and is selected from aralkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 The ring portion of a heterocyclyl may be selected from one or more independently selected R 6 is optionally replaced by

[0195] R 4 is hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0196] L is a single bond or C1-C4 alkylene;

[0197] Y 1 is a single bond, —C(O)—, or —NHC(O)—,

[0198] Y 2 is a single bond, -S-, -SO-, -SO2-, or -NR 5 SO2-,

[0199] Each R 5 are independently hydrogen or C1-C3 alkyl;

[0200] Each R 6 is an oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -LN(R 5 )2, C1-C6 alkyl, or -Y 1 -heterocyclyl, and -Y 1 -heterocyclyl may be one or more R 7is optionally replaced by

[0201] Each R 7 are independently hydrogen, C1-C3 alkyl, halogen, haloalkyl, hydroxyalkyl, or heteroalkyl;

[0202] Each R A are independently hydrogen, alkoxy, heteroalkyl, -N(R 5 )2, heteroalkylN(R 5 )2, C1-C3 alkyl, -S-C1-C3 alkyl, or aryl; and

[0203] n is 1 or 2.

[0204] In one embodiment of the compound of formula (II), A 3 is N. In one embodiment, A 3 is N and A 1 , A 2 , and A 4 are CR A In one embodiment, A 1 and A 2 R A The group is hydrogen, and A 4 R A In another embodiment of the compound of formula (II), A is an alkoxy group. 2 and A 4 are CR A and A 1 and A 3 are each N. In one embodiment, A 1 and A 3 are N and A 4 R A The group is hydrogen, and A 2 R A The group is alkoxy.

[0205] In one embodiment of the compound of formula (II), A 2 is N and A 1 , A 3 , and A 4 are CR AIn one embodiment, A 2 is N and A 1 and A 4 Each R A The group is hydrogen, and A 3 R A The group may be an alkoxy, heteroalkyl, -N(R 5 )2, heteroalkylN(R 5 )2, C1-C3 alkyl, -S-C1-C3 alkyl, or aryl.

[0206] In another embodiment of the compound of formula (II), A 2 and A 4 are N and A 1 and A 3 are CR A In one embodiment, A 2 and A 4 are N and A 1 R A The group is hydrogen, and A 3 R A The group may be an alkoxy, heteroalkyl, -N(R 5 )2, heteroalkylN(R 5 )2, C1-C3 alkyl, -S-C1-C3 alkyl, or aryl.

[0207] In another embodiment of the compound of formula (II), A 4 is N and A 1 , A 2 , and A 3 are CR A In one embodiment, A 4 is N and A 1 and A 2 R A Each group is hydrogen, and A 3 R A The group is alkoxy.

[0208] In one embodiment of the compound of formula (II),

[0209] [ka] teeth,

[0210] [ka] is selected from the group consisting of

[0211] In the formula, each R A is as defined in formula (II).

[0212] In one embodiment of the compound of formula (II), Z is O or S. In one embodiment, X is O, CR 5 , C.R. 5 OH, or C(R 5 )2 and X is O,

[0213] [ka] is a single bond, and X is C(R 5 )2,

[0214] [ka] is a single bond, and X is CR 5 When OH,

[0215] [ka] is a single bond, or X is CR 5 When

[0216] [ka] is a double bond. In one embodiment, n is 1. In one embodiment, n is 2.

[0217] In one embodiment of the compound of Formula (II), Z is O, X is O, n is 1,

[0218] [ka] is a single bond. In another embodiment, Z is O and X is CR 5 and

[0219] [ka] is a double bond. In one embodiment, Z is O and X is C(R 5 )2, n is 1,

[0220] [ka] is a single bond. In one embodiment, Z is O and X is CR 5 OH, n is 1,

[0221] [ka] is a single bond. In another embodiment, Z is O and X is C(R 5 )2, n is 2,

[0222] [ka] is a single bond. In another embodiment, Z is S and X is C(R 5 )2, n is 1,

[0223] [ka] is a single bond.

[0224] In one embodiment of the compound of Formula (II), R 1 is one or more R 3 In certain embodiments, the aryl is optionally substituted with one or more R 3 is phenyl optionally substituted by

[0225] In one embodiment of the compound of Formula (II), aryl is a single R 3 In one embodiment, the aryl is substituted with two R 3 In one embodiment, the aryl is substituted with three R groups. 3 A typical aryl R 3 The groups include halogen, hydroxyl, haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -LN(R 5 )2, -Y 1 -N(R 5 )2, -Y 2 -N(R 5 )2, -Y 2 -haloalkyl, -L-heterocyclyl, or -Y 1 -heterocyclyl, -L-heterocyclyl and -Y 1 The heterocyclyl portion of the heterocyclyl may be one or more independently selected R 6 is optionally replaced by

[0226] In one embodiment of the compound of Formula (II), R 1 Ha-Y 2 In one embodiment, Y is phenyl substituted with -C1-C6 alkyl. 2 is a single bond, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 1 Ha-Y 2 -phenyl substituted with C1-C6 alkyl; Y 2 is —SO— and C-C alkyl is methyl. In one embodiment, R 1 is methyl and -Y 2 -C1-C6 alkyl disubstituted phenyl, and Y 2 is -SO2- and C1-C6 alkyl is methyl.

[0227] In one embodiment of the compound of Formula (II), R 1 is one R 3 is phenyl substituted with R 3 is a cyano group.

[0228] In one embodiment of the compound of Formula (II), R 1 is one R 3 is phenyl substituted with R 3 is -L-heteroaryl. In certain embodiments, -L-heteroaryl is tetrazolyl. In one embodiment, R 1 is one R 3 is phenyl substituted with R 4 is PO3(C1-C3 alkyl). In one embodiment, R 1 is one R 3 is phenyl substituted with R 4 HA-COOR 5 In one embodiment, R 1 is one R 3 is phenyl substituted with R 4 -OLN(R 5 )2 and L is C1-C4 alkylene. In one embodiment, R 1 is one R 3 is phenyl substituted with R 3 is an aralkyl.

[0229] In one embodiment of the compound of Formula (II), R 1 is at least one R 3 is phenyl substituted with R 3 -LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene. In one embodiment, each R 5 is independently hydrogen. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, R 1 is -LN(R 5 )2 and is phenyl further substituted with one or more halogen and / or C1-C6 alkyl.

[0230] In one embodiment of the compound of Formula (II), R 1 is one R 3 is phenyl substituted with R 3 Ha-Y 1 -N(R 5 )2. In one embodiment, Y 1 is -C(O)-, and each R 5 is C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, Y 1 is -C(O)-, and each R 5 is hydrogen. In one embodiment, Y 1 is -C(O)- and one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, R 1 -Y 1 -N(R 5 )2 and is phenyl further substituted with one or more halogen and / or C1-C6 alkyl.

[0231] In one embodiment of the compound of Formula (II), R 1 Ha-Y 2 -phenyl substituted with haloalkyl; Y 2 is -S- or -SO2-, and haloalkyl is trifluoromethyl.

[0232] In one embodiment of the compound of Formula (II), R 1 is at least one -L-heterocyclyl or -Y 1 -phenyl substituted with heterocyclyl, each heterocyclyl being selected from one or more independently selected R 6 In one embodiment, R 1 is one R 3 is phenyl substituted with R 3 is one or more independently selected R 6 -Y optionally replaced by 1 -heterocyclyl. In one embodiment, Y 1is -C(O)- and heterocyclyl is piperazinyl optionally substituted with C1-C3 alkyl.

[0233] In certain embodiments of the compound of Formula (II), R 3 The group is one or more R 6 In one embodiment, L is methylene and heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. In one embodiment, L is methylene and heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, piperazinone, tetrahydropyranyl, morpholinyl, thiomorpholinyl, or diazapanyl, each independently selected from one or more R 6 A typical R 7 Groups include oxo, halogen, hydroxyalkyl, and C1-C3 alkyl.

[0234] In one embodiment of the compound of Formula (II), R 1 is one or more independently selected R 6 -Y optionally replaced by 1 -heterocyclyl. 1 is -C(O)-, and heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl, each optionally further substituted with one or more halogens.

[0235] In one embodiment of the compound of Formula (II), R 1 is one or more independently selected R 6 In certain embodiments, -L-heteroaryl is tetrazolyl.

[0236] In one embodiment of the compound of Formula (II), R 1 is phenyl substituted with PO(C-C alkyl). In another embodiment, R1 HA-COOR 5 In one embodiment, R 1 is hydroxyalkyl, -OLN(R 5 )2, or phenyl substituted with aralkyl.

[0237] In one embodiment of the compound of Formula (II), R 1 is one or more independently selected R 3 In certain embodiments, heteroaryl is pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, pyridyl, pyridinyl-2-one, pyrazinyl, pyridazinyl, pyrimidinyl, or 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, each independently selected from one or more R 3 is optionally replaced by

[0238] In one embodiment of the compound of Formula (II), the heteroaryl is a single R 3 In one embodiment, the heteroaryl is substituted with two R 3 In one embodiment, the heteroaryl is substituted with three R groups. 3 Exemplary heteroaryl R groups are substituted. 3 The groups include amino, cyano, halogen, alkoxy, hydroxyalkyl, heteroalkyl, haloalkyl, -Y 2 -haloalkyl, -Y 1 -C1-C6 alkyl, -Y 2 -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y 1 -heterocyclyl, -LN(R 5 )2, or -Y 1 -N(R 5 )2, including -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y 1 -the heterocyclyl ring may be selected from one or more independently selected R 6 is optionally replaced by

[0239] In one embodiment of the compound of Formula (II), R 6 is amino, hydroxyl, cyano, alkoxy, or halogen. 6 is C1-C3 alkyl. In one embodiment, R 6 is a halogen, which is fluorine or chlorine. In one embodiment, R 6 is alkoxy, where the alkoxy is methoxy or ethoxy. In one embodiment, R 6 is cycloalkyl, which cycloalkyl is cyclopropyl.

[0240] In another embodiment of the compound of Formula (II), R 1 is heteroaryl, and each R 3 are independently hydroxyalkyl, heteroalkyl, or haloalkyl. In some embodiments, hydroxyalkyl is hydroxymethyl, hydroxyethyl, 2-methyl, or 2-hydroxypropyl. In some embodiments, heteroalkyl is methoxymethyl or methoxyethyl. In some embodiments, haloalkyl is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, or trifluoroethyl.

[0241] In certain embodiments of the compound of Formula (II), R 1 is heteroaryl, and R 3 Ha-Y 1 -C1-C6 alkyl, where Y 1 is a single bond, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 4 Ha-Y 1 -C1-C6 alkyl, where Y 1 is —C(O)—, and C1-C6 alkyl is methyl, ethyl, or isopropyl. 1 is -NHC(O)-, and the C1-C6 alkyl moiety is methyl.

[0242] In one embodiment of the compound of Formula (II), R 1 is heteroaryl, and R 3 Ha-Y 2 -C1-C6 alkyl, where -Y 2 is -SO2- and C1-C6 alkyl is methyl. In another embodiment, R 4 Ha-Y 2 -C1-C6 alkyl, where Y 2 is -S- and C1-C6 alkyl is methyl.

[0243] In one embodiment of the compound of Formula (II), R 1 is heteroaryl, and R 3 is one or more independently selected R 6 -Y optionally replaced by 1 -heterocyclyl. In one embodiment, Y 1 is a single bond. In another embodiment, Y 1 is —C(O)—. In one embodiment, Y 1 is a single bond, and heterocyclyl is azetidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. 6 is C1-C3 alkyl. In one embodiment, R 6 is a halogen.

[0244] In one embodiment of the compound of Formula (II), the heteroaryl is selected from at least one R 3 is replaced by R 3 is -L-heterocyclyl and one or more R 6 In one embodiment, L is ethylene and heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, or 4-methyl-piperazinyl. In one embodiment, L is methylene and heterocyclyl is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, piperazinone, tetrahydropyranyl, morpholinyl, thiomorpholinyl, or diazapanyl, each independently selected from one or more R 6is optionally replaced by

[0245] In one embodiment of the compound of Formula (II), R 6 are independent, -LN(R 5 )2, hydroxyl, cyano, alkoxy, or halogen. In one embodiment, R 6 is C1-C3 alkyl. In one embodiment, R 6 is a halogen, which is fluorine or chlorine. In one embodiment, R 6 is alkoxy, where the alkoxy is methoxy or ethoxy. In one embodiment, R 7 is cycloalkyl, where the cycloalkyl is cyclopropyl. In one embodiment, R 6 -LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene. In one embodiment, each R 5 is independently hydrogen. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 is C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl.

[0246] In one embodiment of the compound of Formula (II), R 1 is heteroaryl, and R 6 -LN(R 5 )2. In one embodiment, L is a single bond. In one embodiment, L is methylene, ethylene, or propylene. In one embodiment, each R 5 is independently C1-C3 alkyl. In one embodiment, each C1-C3 alkyl is methyl. In one embodiment, one R 5 are C1-C3 alkyl and the others are hydrogen. In one embodiment, one C1-C3 alkyl is methyl. In one embodiment, each R 5 are independently hydrogen.

[0247] In one embodiment of the compound of Formula (II), R 1 is heteroaryl, and R 3 is one or more independently selected R 6 In one embodiment, L is a single bond. In one embodiment, L is C1-C3 alkylene. In one embodiment, C1-C3 alkylene is methylene. In certain embodiments, the heteroaryl of -L-heteroaryl is pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, thiazolyl, or pyridazinyl. In one embodiment, the heteroaryl of -L-heteroaryl is pyridyl.

[0248] In one embodiment of the compound of Formula (II), R 1 There are two R 3 R is a heteroaryl substituted with a group; 3 The groups are independently two -Y 1 -C1-C6 alkyl group, -Y 1 -C1-C6 alkyl and alkoxy, -Y 1 -C1-C6 alkyl and cycloalkyl, -Y 1 -C1-C6 alkyl and haloalkyl, -Y 1 -C1-C6 alkyl and amino, two alkoxy groups, alkoxy and halogen, alkoxy and cyano, and amino and haloalkyl. 3 Ha-Y 1 -C1-C6 alkyl, where each Y 1 is a single bond and each C1-C6 alkyl is methyl, ethyl, or isopropyl. In one embodiment, cycloalkyl is cyclopropyl. In one embodiment, alkoxy is methoxy. In one embodiment, halogen is fluorine or chlorine. In one embodiment, haloalkyl is trifluoromethyl or trifluoroethyl.

[0249] In one embodiment of the compound of Formula (II), R 1 is one or more independently selected R 3In one embodiment, L is a single bond and heterocyclyl is tetrahydrofuranyl, piperidinyl, piperazinyl, or morpholinyl. In one embodiment, L is methylene and heterocyclyl is azetidinyl, pyrrolidinyl, or

[0250] [ka] In certain embodiments, heterocyclyl is independently selected from oxo, halogen, alkoxy, hydroxyl, and -Y 1 -one or more R selected from C1-C6 alkyl 3 where Y 1 is a single bond or -C(O)-.

[0251] In one embodiment, the compound of formula (II) is

[0252] [ka]

[0253] [ka]

[0254] [ka] is.

[0255] In one aspect of the invention, the compound is

[0256] [ka] is.

[0257] The compounds of the present invention can be used in pharmaceutical compositions.

[0258] Pharmaceutical Composition In another aspect, the present invention provides a pharmaceutical composition comprising a PRC2 inhibitor according to the present invention and a pharmaceutically acceptable carrier, excipient, or diluent.The compounds of the present invention can be formulated by methods well known in the art and prepared for any administration, including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal.In one embodiment, the compounds of the present invention are administered intravenously in a hospital environment.In other embodiments, administration may be preferably via the oral route.

[0259] The characteristics of the carrier will depend on the route of administration. As used herein, the term "pharmaceutically acceptable" refers to a non-toxic material that is compatible with a biological system, such as a cell, cell culture, tissue, or organism, and does not interfere with the effectiveness of the biological activity of the active ingredient. Thus, in addition to the inhibitor, the composition according to the present invention may contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The preparation of pharmaceutically acceptable formulations is described, for example, in Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

[0260] As used herein, the term " pharmaceutically acceptable salt " refers to a salt that maintains the desired biological activity of the compound identified above and exhibits minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. This compound can also be administered as a pharmaceutically acceptable quaternary salt known to those skilled in the art. The salts specifically include quaternary ammonium salts of the formula --NR+Z--, where R is hydrogen, alkyl, or benzyl, and Z is a counterion including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).

[0261] The active compound is contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver a therapeutically effective amount to the patient without causing serious toxic effects to the patient being treated. Dosages of active compound for all of the above-mentioned conditions range from about 0.01 to 300 mg per kg of recipient body weight per day, preferably 0.1 to 100 mg per kg, and more typically 0.5 to about 25 mg per kg. A typical topical dose range is 0.01 to 5% wt / wt in a suitable carrier. Effective dosage ranges for pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative itself exhibits activity, the effective dosage can be estimated as described above using the weight of the derivative or by other means known to those skilled in the art.

[0262] Pharmaceutical compositions containing the compounds of the invention can be used in the methods described herein.

[0263] How to use In yet another aspect, the present invention provides a method for inhibiting PRC2 activity in a cell, the method comprising the step of contacting a cell in which inhibition of PRC2 activity is desired with a compound of the present invention comprising Formula (I) and Formula (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing said compound or a pharmaceutically acceptable salt thereof.

[0264] The compositions and methods provided herein are particularly considered useful for inhibiting PRC2 activity in cells. In one embodiment, cells in which inhibition of PRC2 activity is desired are contacted with a therapeutically effective amount of a compound of the present invention comprising Formula (I) and Formula (II) to negatively regulate PRC2 activity. In other embodiments, a therapeutically effective amount of a pharmaceutically acceptable salt or pharmaceutical composition containing a compound of Formula (I) and Formula (II) may be used.

[0265] By negatively regulating PRC2 activity, particularly in cells that overexpress EZH2 enzyme or have somatic mutations that activate EZH2 enzyme, the method is designed to restore normal cellular transcriptional expression patterns, for example, by modifying the methylation pattern of H3K27, to inhibit unwanted cell proliferation resulting from enhanced PRC2 activity in cells. The cells may be contacted with a single dose or multiple doses according to a specific treatment regimen to affect the desired negative regulation of PRC2. The degree of histone H3K27 monomethylation and dimethylation can be monitored in cells using well-known methods, including those described in Example A below, to evaluate the effectiveness of the treatment, and the dose may be adjusted appropriately by the participating medical professional.

[0266] In another aspect, there is provided a method of treating cancer, comprising administering to a patient with cancer a therapeutically effective amount of a compound of the present invention comprising Formula (I) and Formula (II) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof.

[0267] The compositions and methods provided herein can be used to treat a wide variety of cancers, including tumors such as prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, testicular cancer, etc. More specifically, cancers that can be treated by the compositions and methods of the present invention include, but are not limited to, tumor types such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate, and thyroid cancers and sarcomas. More specifically, these compounds are effective against cardiac cancers: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; lung cancers: bronchogenic carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma; gastrointestinal cancers: esophageal cancer (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma); stomach cancer (carcinoma, lymphoma, leiomyosarcoma); pancreatic cancer Cancer (tubular adenocarcinoma, insulinoma, glucagon-producing tumor, gastrinoma, carcinoid tumor, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), and colon cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), genitourinary tract cancer: kidney cancer (adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethral cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), and testicular cancer ( Seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenocarcinoma, lipoma), liver cancer: hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma, bile duct cancer: gallbladder carcinoma, ampullary carcinoma, and intrahepatic cholangiocarcinoma, bone cancer: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma (bone cartilage exostosis), Benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor, Cancers of the nervous system: cancer of the skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), cancer of the meninges (meningioma, meningeal sarcoma, gliomatosis), cancer of the brain (astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma), Cancers of the gynecological system: cancer of the uterus (endometrial cancer),Cervical cancer (pre-tumor cervical dysplasia) dysplasia), ovarian cancer (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulvar cancer (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube cancer (carcinoma), blood cancer (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, and non-Hodgkin's lymphoma), skin cancer (malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic It can be used to treat tumors such as psoriasis, lipomas, angiomas, dermatofibromas, keloids, and psoriasis; and adrenal carcinoma: neuroblastoma. In one embodiment, the cancer is diffuse large B-cell lymphoma (DLBCL).

[0268] The concentration and route of administration to patients vary depending on the cancer to be treated.The compound, or its pharmaceutically acceptable salt, or pharmaceutical composition comprising such compound and salt can be co-administered with other anti-tumor compounds, such as chemotherapeutic agents, or can be used in combination with other treatments, such as radiation or surgical intervention, as a pre- or post-operative adjuvant.The degree of histone H3K27 monomethylation and dimethylation can be monitored in patients using well-known methods, including those described in Example A below, along with other prognostic or biological factors, to evaluate the effectiveness of treatment, and the dosage can be adjusted appropriately by participating medical professionals.

[0269] General Reaction Schemes, Intermediates, and Examples General reaction scheme The compounds of the invention can be prepared using commercially available reagents and intermediates in the synthetic methods and reaction schemes described herein, or can be prepared using other reagents and conventional methods well known to those skilled in the art.

[0270] For example, compounds of the present invention including formula (I) and formula (II) and intermediates thereof can be prepared according to general reaction schemes I-IV.

[0271] [ka]

[0272] In General Reaction Scheme I, compound 6 is an example of formula (II), where A 2 and A 3 are both nitrogen, and A 1 and A 4 Both are CR A and R A is H. In this general reaction scheme I, 5-chloropyrido[3,4-d]pyridazine 1 is reacted with R 2 The reaction is, for example, a nucleophilic substitution, to give compound 3. Compound 3 is then treated with a halogenating reagent such as NBS to give the corresponding halide compound 4. Halide compound 4 is then reacted with a boronic acid derivative YR in the presence of a suitable base, for example sodium carbonate, to give compound 5. 1 Upon exposure to a metal-mediated reaction with a binding partner such as 5, the title compound 6 can be formed.

[0273] [ka]

[0274] In General Reaction Scheme II, compound 9 is an example of formula (II), where A 2 is nitrogen, and A 4 is nitrogen or CR A Either A 1 and A 3 Both are CR A and R A is H. In General Reaction Scheme II, 5-chloro-8-halopyrido[4,3-d]pyrimidine 7, where X can be bromine or iodine, is reacted with R 2The halide compound 8 is then reacted with an amine such as amine 2 optionally substituted by, for example, a nucleophilic substitution, to give compound 8. The halide compound 8 is then reacted with a boronic acid derivative YR in the presence of a suitable base, for example, sodium carbonate. 1 Upon exposure to a metal-mediated reaction with a binding partner such as 5, the title compound 9 can be formed.

[0275] [ka]

[0276] In General Reaction Scheme III, compound 18 is an example of formula (II), where A 2 is nitrogen, and A 1 and A 4 Both are CR A and R A is H and A 3 is a CR as defined in formula (II) A In General Reaction Scheme II, 1-chloro-6-methoxy-2,7-naphthyridine 10 is reacted with R 2 The reaction is for example a nucleophilic substitution, which gives compound 11. Compound 11 is then treated with a halogenating reagent such as NBS to give the corresponding halide compound 12. Halide compound 12 can then be converted to a boronic acid derivative YR in the presence of a suitable base, for example sodium carbonate. 1Compound 13 can be formed by exposure to a metal-mediated reaction with a binding partner such as 5. Compound 13 can then be treated with a weak acid such as pyridine hydrochloride to form compound 14. Compound 14 can then be transformed to the monocarbamate in a protic solvent, such as methanol, via treatment with a decarbonate such as BocO, followed by treatment with an acid such as potassium carbonate, to give monoprotected compound 15. Compound 15 can be reacted with a halide RX 16, e.g., a nucleophilic substitution reaction, to give compound 17. The protecting group on compound 17 can then be removed with an acid such as TFA to form the title compound 18.

[0277] [ka]

[0278] In General Reaction Scheme IV, compound 22 is an example of formula (II), where A 4 is nitrogen, and A 1 ~A 3 All R A Three CRs with H A In General Reaction Scheme IV, 5-chloro-1,6-naphthyridine 19 is reacted with R 2 The reaction is, for example, a nucleophilic substitution, to give compound 20. Compound 20 is then treated with a halogenating reagent such as NBS to give the corresponding halide compound 21. Halide compound 20 is then reacted with a boronic acid derivative YR in the presence of a suitable base, for example sodium carbonate, to give the corresponding halide compound 22. 1 Upon exposure to a metal-mediated reaction with a binding partner such as 5, the title compound 22 can be formed.

[0279] [ka]

[0280] A typical intermediate A, intermediate A-1 (compound 4 in General Reaction Scheme 1), can be used to synthesize compounds of formula (II), where A 2 and A 3 are both nitrogen, and A 1 and A 4 Both are CR A and R A is H.

[0281] Step A: To a stirred solution of ethyl pyridazine-4-carboxylate (3.00 g, 19.7 mmol, 1.00 equiv.) in HSO (75.0 mL, concentrated) at 15 °C, 2-hydroperoxy-2-methyl-propane (5.33 g, 59.2 mmol, 5.67 mL, 3.00 equiv.) and a saturated aqueous solution of FeSO.7HO (16.5 g, 59.2 mmol, 3.00 equiv.) were added dropwise simultaneously. After the addition, the mixture was stirred at 15 °C for 5 h. The reaction mixture was then adjusted to pH = 7 with NH.HO and extracted with ethyl acetate (50.0 mL × 3). The combined organic phase was washed with brine (100 mL × 3), dried, and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 2 / 1) to give ethyl 5-methylpyridazine-4-carboxylate (2.80 g, 16.9 mmol, yield 85.5%) as a red oil.

[0282] A mixture of ethyl 5-methylpyridazine-4-carboxylate (2.80 g, 16.9 mmol, 1.00 equiv.) in DMF-DMA (20.1 g, 169 mmol, 22.4 mL, 10.0 equiv.) was stirred at 120 °C for 5 h. The reaction mixture was then concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3 / 1 to 0 / 1) to give ethyl 5-ethyl(E)-5-(2-(dimethylamino)vinyl)pyridazine-4-carboxylate (2.80 g, 12.7 mmol, 75.1% yield) as a yellow solid.

[0283] Step B: To a solution of ethyl (E)-5-(2-(dimethylamino)vinyl)pyridazine-4-carboxylate (2.80 g, 12.7 mmol, 1.00 equiv) in ethanol (50.0 mL) was added NHOAc (9.75 g, 127 mmol, 10.0 equiv), and the mixture was stirred at 90 °C for 1 h. The reaction mixture was concentrated in vacuo. The residue was triturated with water, and the precipitate was dried under vacuum to give pyrido[3,4-d]pyridazin-5(6H)-one (1.50 g, 10.2 mmol, 80.6% yield) as a gray solid.

[0284] 1 H NMR (400MHz, DMSO-d6) δ=11.55(brs,1H),9.58(d,J=1.6Hz,1H),9.56(s,1H),7.72(d,J=7.2Hz,1H),6.66(d,J=6.8Hz,1H).

[0285] A mixture of pyrido[3,4-d]pyridazin-5(6H)-one (500 mg, 3.40 mmol, 1.00 equiv.) in POCl3 (13.2 g, 86.1 mmol, 8.00 mL, 25.3 equiv.) and DIPEA (1.10 g, 8.50 mmol, 1.48 mL, 2.50 equiv.) was stirred at 100 °C for 1 h. The reaction mixture was then poured into ice water and extracted with DCM (50.0 mL × 2). The combined organic phases were washed with aqueous sodium bicarbonate and brine, then dried and evaporated to give the crude product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 4 / 1 to 2 / 1) to give 5-chloropyrido[3,4-d]pyridazine, compound 1 (100 mg, 556 μmol, 16.4% yield, 92.0% purity) as a yellow solid. LC-MS[M+1]: 166.1.

[0286] Step C: To a solution of 5-chloropyrido[3,4-d]pyridazine (125 mg, 695 μmol, 1.00 equiv) in DMF (3.00 mL), KF (161 mg, 2.78 mmol, 65.1 μL, 4.00 equiv) and 5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (compound 4, 174 mg, 1.04 mmol, 1.50 equiv) were added, and the mixture was stirred under a nitrogen atmosphere at 120° C. for 1 h. The reaction mixture was diluted with ethyl acetate (40.0 mL) and washed with brine (20.0 mL × 3), and the combined organic phase was dried and concentrated in vacuo. The crude product was purified by preparative TLC (SiO, dichloromethane / methanol = 20 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (140 mg, 473 μmol, 68.0% yield) as a yellow solid. LC-MS [M+H]: 297.0.

[0287] Intermediate A-1: ​​To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (0.12 g, 405 μmol, 1.00 equiv) in DCM (6.00 mL) was added NBS (72.0 mg, 405 μmol, 1.00 equiv) at 0° C. The mixture was stirred at 0° C. for 30 min. The reaction mixture was then quenched with water (2 mL), and the organic phase was separated, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 3 / 1 to 1 / 0) to give 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (140 mg, 373 μmol, 92.1% yield) as a yellow solid. LC-MS [M+H]: 375.1.

[0288] [ka]

[0289] Exemplary intermediates A and A-2 can be used to synthesize compounds of formula (II), where A 2 and A 4 are both nitrogen, and A 1 and A 3 Both are CR A and R A is H.

[0290] Step A: A mixture of ethyl 3-oxobutanoate (8.03 g, 61.8 mmol, 7.79 mL, 1.00 equiv.) and 1,3,5-triazine (5.00 g, 61.7 mmol, 1.00 equiv.) was added to a freshly prepared solution of sodium ethoxide (1.68 g, 24.7 mmol, 0.40 equiv.) in ethanol (18.0 mL) at 20 °C. The reaction was heated at 90 °C under a nitrogen atmosphere for 3 h, and then the ethanol was removed under vacuum. Water (50.0 mL) was added to the reaction mixture, and the pH was adjusted with concentrated HCl until the solution reached pH = 3. The mixture was filtered, and the solid was washed with acetone (20.0 mL) and dried to give pyrido[4,3-d]pyrimidin-5-ol (1.4 g, 9.52 mmol, 15.43% yield) as a yellow solid.

[0291] 1 H NMR (400MHz, DMSO-d6) δ=11.87(br,s,1H),9.41(s,1H),9.32(s,1H),7.72(d,J=7.2Hz,1H),6.57(d,J=7.2Hz,1H).

[0292] Step B: I2 (1.10 g, 4.34 mmol, 874 μL, 1.28 equiv) was added to a suspension of pyrido[4,3-d]pyrimidin-5-ol (500 mg, 3.40 mmol, 1.00 equiv) in sodium hydroxide (0.40 M, 17.0 mL, 2.00 equiv). The reaction mixture was heated at 80°C for 18 h. The mixture was then cooled to 20°C, and the resulting precipitate was filtered. The collected solid was washed with water (15.0 mL), dried, and concentrated to give 8-iodopyrido[4,3-d]pyrimidin-5-ol (800 mg, 2.93 mmol, 86.22% yield) as a yellow solid.

[0293] 1 H NMR (400MHz, DMSO-d6) δ=12.17(brs,1H),9.42(s,1H),9.33(s,1H),8.13(s,1H).

[0294] A solution of 8-iodopyrido[4,3-d]pyrimidin-5-ol (300 mg, 1.10 mmol, 1.00 equiv) in POCl3 (14.9 g, 96.9 mmol, 9.00 mL, 88.1 equiv) was heated at 100 °C for 48 h. The reaction mixture was concentrated under reduced pressure, and the residue was poured into ice water (10.0 mL). The resulting mixture was treated with potassium carbonate (2 M, 10.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 5-chloro-8-iodo-pyrido[4,3-d]pyrimidine (300 mg, 1.03 mmol, 93.67% yield) as a yellow solid, which was used without further purification.

[0295] Intermediate A-2: To a mixture of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (86.0 mg, 515 μmol, 1.50 equiv) and 5-chloro-8-iodo-pyrido[4,3-d]pyrimidine (100 mg, 343 μmol, 1.00 equiv) in DMF (1.00 mL) was added potassium fluoride (59.8 mg, 1.03 mmol, 24.1 μL, 3.00 equiv) in one portion under a N atmosphere at 20° C. The mixture was stirred at 120° C. for 2 h. Water (5.00 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (5.00 mL × 3). The combined organic phases were dried and concentrated to give N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-8-iodopyrido[4,3-d]pyrimidin-5-amine (100 mg, 237 μmol, 69.0% yield) as a yellow solid.

[0296] 1 H NMR(400MHz, CDCl3) δ=9.35(s,1H),9.11(s,1H),8.66(s,1H),6.80-6.74(t,J=8.8,1H),6.58(dd,J=4.0,8.4Hz ,1H),5.96(t,J=4.4,1H),4.74(d,J=5.6Hz,2H),4.58-4.53(m,3H),3.32(t,J=8.8Hz,2H).

[0297] [ka]

[0298] Exemplary intermediates A and A-3 can be used to synthesize compounds of formula (II), where A 2 is nitrogen, and A 1 , A 3 , and A 4 All are CR A and R A is H.

[0299] To a solution of 4-bromo-1-chloro-2,7-naphthyridine (100 mg, 411 μmol, 1.00 equiv.) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (82.5 mg, 493 μmol, 1.20 equiv.) in DMF (1.00 mL) was added DIEA (106 mg, 821 μmol, 143 μL, 2.00 equiv.). The mixture was stirred at 85° C. for 1 hour. After completion of the reaction, the mixture was triturated in water (5.00 mL), and the solid was collected by filtration and dried under vacuum to give 4-bromo-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-2,7-naphthyridin-1-amine (130 mg) as a gray solid, which was used without further purification. LC-MS [M+H]: 374.0.

[0300] [ka]

[0301] Exemplary intermediate A, intermediate A-4 (compound 12 in General Reaction Scheme III) can be used to synthesize compounds of formula (II), where A 2 is N and A 1 and A 4 Both are CR A In this example, RA is H and A 3 is CR A and in this example, R A is alkoxy.

[0302] Step A: To a mixture of 6-methoxy-4-methylnicotinic acid (1.00 g, 5.98 mmol, 1.00 equiv.) and 4-methylmorpholine (1.51 g, 15.0 mmol, 1.64 mL, 2.50 equiv.) in DMF (20.0 mL), ammonium chloride (1.92 g, 36.0 mmol, 6.00 equiv.), EDCI (1.72 g, 8.97 mmol, 1.50 equiv.), and HOBt (1.21 g, 8.97 mmol, 1.50 equiv.) were added in one portion at 25 °C under a N atmosphere. The mixture was stirred at 25 °C for 2 h. After this time, water (20.0 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10.0 mL × 5). The combined organic phase was washed with brine, dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was triturated with petroleum ether (10.0 mL) to give a suspension which was filtered, and the filter cake was washed with petroleum ether (3 mL), collected, and concentrated to give 6-methoxy-4-methylnicotinamide (800 mg, 4.81 mmol, 80.5% yield) as an off-white solid.

[0303] 1 H NMR (400MHz, DMSO-d6) δ=8.22(s,1H),7.72(s,br,1H),7.35(s,br,1H),6.69(s,1H),3.92-3.80(m,3H),2.37(s,3H).

[0304] Step B: A medium pressure flask containing a mixture of 6-methoxy-4-methylnicotinamide (800 mg, 4.81 mmol, 1.00 equiv) and DMF-DMA (12.9 g, 108 mmol, 14.4 mL, 22.5 equiv) was heated at 115 °C for 1 h. The DMF-DMA was removed under reduced pressure to give a residue. The residue was triturated with petroleum ether (2.00 mL) to give N-((dimethylamino)methylene)-6-methoxy-4-methylnicotinamide (900 mg, 4.07 mmol, 84.5% yield) as a white solid.

[0305] 1H NMR (400MHz, CDCl3) δ=9.02(s,1H),8.50(s,1H),6.49(s,1H),3.89(s,3H),3.10(d,J=5.6Hz,6H),2.55(s,3H).

[0306] To a solution of N-((dimethylamino)methylene)-6-methoxy-4-methylnicotinamide (800 mg, 3.62 mmol, 1.00 equiv) in THF (16 mL) was added t-BuOK (1.00 M, 4.70 mL, 1.30 equiv). The reaction mixture was stirred at 80 °C for 3 h, then water (10 mL) was added to the reaction mixture and further acidified with HCl (2.00 M) to pH = 5. The reaction was extracted with ethyl acetate (5 mL × 8). The organic phase was separated, dried, and concentrated to give 6-methoxy-2,7-naphthyridin-1-ol (500 mg, 2.84 mmol, 78.5% yield) as a white solid.

[0307] 1 H NMR (400MHz, CD3OD) δ=9.14(s,1H),7.27(d,J=7.2Hz,1H),6.89(s,1H),6.54(d,J=7.6Hz,1H),4.04(s,3H).

[0308] Step C: A solution of 6-methoxy-2,7-naphthyridin-1-ol (500 mg, 2.84 mmol, 1.00 equiv) and DIEA (733 mg, 5.68 mmol, 988 μL, 2.00 equiv) in phosphorus oxychloride (8.25 g, 53.8 mmol, 5.00 mL, 19.0 equiv) was stirred at 100 °C for 2 h. The phosphorus oxychloride was removed under reduced pressure to give a residue, and then ethyl acetate (10.0 mL) was added to the reaction mixture, and the reaction was quenched with ice water (2.00 mL). The organic phase was separated, washed with saturated sodium bicarbonate (10.0 mL), then brine (10.0 mL), dried, and concentrated to give crude 1-chloro-6-methoxy-2,7-naphthyridine (500 mg) as a yellow solid.

[0309] Step D: To a mixture of 1-chloro-6-methoxy-2,7-naphthyridine (500 mg, 2.57 mmol, 1.00 equiv) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (472 mg, 2.83 mmol, 1.10 equiv) in DMF (1.00 mL) was added DIEA (996 mg, 7.71 mmol, 1.34 mL, 3.00 equiv) in one portion under a N atmosphere at 20 °C. The mixture was stirred at 100 °C for 2 h. The reaction mixture was quenched by adding water (3.00 mL) at 20 °C, then diluted with ethyl acetate (3 mL) and extracted with ethyl acetate (3.00 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (400 mg, 1.03 mmol, yield 40.2%, purity 84.0%) as a white solid.

[0310] 1 H NMR(400MHz,CDCl3) δ=8.87(s,1H),7.99(d,J=6.0Hz,1H),6.89-6.81(m,1H),6.79(s,1H),6.76(d,J=5.6Hz,1H),6.68-6.61(m,1H),5.72(br s,1H),4.82(d,J=5.6Hz,2H),4.64-4.55(m,3H),4.02(s,3H),3.38(t,J=8.8Hz,2H).

[0311] Intermediate A-4: A mixture of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (120 mg, 369 μmol, 1.00 equiv.) and NBS (45.0 mg, 253 μmol, 0.07 equiv.) in dichloromethane (1.50 mL) was stirred at 0 °C for 0.5 h. The reaction mixture was evaporated to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 1 / 1) to give 4-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (180 mg, 445 μmol, 85.2% yield) as a pale yellow solid. LC-MS [M+H]: 404.0.

[0312] [ka]

[0313] Exemplary intermediate A, intermediate A-5 (compound 21 in General Reaction Scheme IV) can be used to synthesize compounds of formula (II), where A 4 is nitrogen, and A 1 ~A 3 All are CR A and R A is H.

[0314] Step A: To a solution of 5-chloro-1,6-naphthyridine (60.0 mg, 365 μmol, 1.00 equiv.) in dimethyl sulfoxide (1.00 mL) was added potassium fluoride (42.4 mg, 729 μmol, 17.1 μL, 2.00 equiv.) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (73.1 mg, 437 μmol, 1.20 equiv.). The mixture was stirred at 130° C. for 1 hour. The mixture was poured into ice water (5.00 mL) and stirred for 15 minutes. The aqueous phase was extracted with ethyl acetate (5.00 mL × 3). The combined organic phase was washed with brine (5.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=3 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1,6-naphthyridin-5-amine (70.0 mg, 237 μmol, 65.0% yield) as a white solid.

[0315] 1 H NMR(400MHz,DMSO-d6) δ=8.91(dd,J=1.6,4.4Hz,1H),8.72(d,J=8.4Hz,1H),8.08(d,J=6.0Hz,1H),7.98(t,J=5.2Hz,1H),7.48(dd,J=4.4,8.4Hz,1H),6.98 (d,J=6.0Hz,1H),6.93-6.86(m,1H),6.64(dd,J=4.0,8.8Hz,1H),4.69(d,J=5.2Hz,2H),4.49(t,J=8.8Hz,2H),3.24(t,J=8.8Hz,2H). LC-MS[M+H]:295.9.

[0316] To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1,6-naphthyridin-5-amine (50.0 mg, 169 μmol, 1.00 equiv.) in DCM (0.50 mL) was added N-bromo-succinimide (27.1 mg, 152 μmol, 0.90 equiv.). The mixture was stirred at 0° C. for 1 h. The mixture was concentrated in vacuo to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=2 / 1) to give 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1,6-naphthyridin-5-amine (52.0 mg, 139 μmol, 82.1% yield) as a white solid.

[0317] 1 H NMR(400MHz,DMSO-d6) δ=9.03(dd,J=1.2,4.4Hz,1H),8.79(dd,J=1.2,8.4Hz,1H),8.32(s,1H),8.23(br t,J=5.2Hz,1H),7.61(dd,J=4.4,8.4Hz,1H),6.94-6.86(m,1H),6.65(dd,J=4.0 ,8.8Hz,1H),4.67(d,J=5.2Hz,2H),4.50(t,J=8.8Hz,2H),3.23(t,J=8.8Hz,2H).

[0318] [ka]

[0319] Exemplary intermediate B, intermediate B-1, can be used to synthesize compounds of formula I or formula II, where Z is O, n is 1, and X is C(R 5 )2,

[0320] [ka] is a single bond. To a mixture of 3-bromophenol (10.0 g, 57.8 mmol, 1.00 equiv.) and 2-bromo-1,1-diethoxyethane (13.7 g, 69.4 mmol, 10.4 mL, 1.20 equiv.) in DMF (100 mL) was added potassium carbonate (24.0 g, 173 mmol, 3.00 equiv.). The resulting mixture was stirred at 110 °C under a nitrogen atmosphere for 12 hours. The reaction mixture was diluted with petroleum ether (100 mL), washed with brine (50.0 mL × 4), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether) to give 1-bromo-3-(2,2-diethoxyethoxy)benzene (17.0 g, 48.2 mmol, 83.4% yield, 82.0% purity) as a pale yellow oil.

[0321] 1 H NMR(400MHz, CDCl3) δ=7.17-7.07(m,3H),6.88-6.84(m,1H),4.82(t,J=5.2Hz,1H),3.99(d,J=5.2Hz,2 H),3.80-3.74(m,1H),3.80-3.73(m,2H),3.68-3.61(m,2H),1.25(t,J=7.2Hz,6H).

[0322] To a solution of polyphosphoric acid (21.5 g, 63.6 mmol, 1.50 equiv) in toluene (80.0 mL) was added 1-bromo-3-(2,2-diethoxyethoxy)benzene (15.0 g, 42.5 mmol, 1.00 equiv) at 90 °C. The mixture was stirred at 90 °C for 2 h and then concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether) to give 4-bromobenzofuran (5.20 g, 13.2 mmol, 31.0% yield, 50.0% purity) as a yellow oil.

[0323] 1H NMR(400MHz, CDCl3) δ=7.70(s,1H),7.67(d,J=2.0Hz,1H),7.61(d,J=2.4Hz,1H),7.47(d,J=8.4Hz,2H),7.41(d,J=8 .0Hz,1H),7.37(dd,J=1.6,8.4Hz,1H),7.21-7.15(m,1H),6.85-6.80(m,1H),6.78-6.73(m,1H).

[0324] To a solution of 4-bromobenzofuran (5.20 g, 13.2 mmol, 1.00 equiv.) in DMAC (50.0 mL) was added zinc cyanide (6.85 g, 58.3 mmol, 4.42 equiv.) and Pd(PPh3)4 (1.52 g, 1.32 mmol, 0.100 equiv.). The mixture was stirred at 140 °C for 12 h under a nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate (80.0 mL), washed with brine (50.0 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 0 / 1) to give benzofuran-4-carbonitrile (1.60 g, 10.1 mmol, 76.2% yield, 90.0% purity) as a pale yellow oil.

[0325] 1 H NMR (400MHz, CDCl3) δ=7.80(d,J=2.0Hz,1H),7.75(d,J=8.4Hz,1H),7.60(d,J=8.0Hz,1H),7.38(t,J=8.4Hz,1H),7.03-7.00(m,1H).

[0326] To a solution of benzofuran-4-carbonitrile (750 mg, 4.72 mmol, 1.00 equiv.) in methyl alcohol (10.0 mL) was added BocO (3.09 g, 14.2 mmol, 3.00 equiv.) and Pd / C (4.72 mmol, 10.0 wt.%, 1.00 equiv.). The mixture was stirred under hydrogen (50.0 psi) at 30 °C for 24 h. The reaction mixture was filtered and concentrated under reduced pressure to give the crude material, which was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 50 / 1) to give tert-butyl N-(2,3-dihydrobenzofuran-4-ylmethyl)carbamate (140 mg, 562 μmol, 11.9% yield) as a colorless oil.

[0327] 1 H NMR(400MHz,CDCl3) δ=7.10(t,J=8.0Hz,1H),6.74(dd,J=8.0,14.0Hz,2H),4.75(br s,1H),4.59(t,J=8.8Hz,2H),4.28(br d,J=5.6Hz,2H),3.20(t,J=8.8Hz,2H),1.47(s,9H).

[0328] To a solution of tert-butyl N-(2,3-dihydrobenzofuran-4-ylmethyl)carbamate (140 mg, 562 μmol, 1.00 equiv) in DCM (2.00 mL) was added TFA (640 mg, 5.62 mmol, 416 μL, 10.0 equiv). The mixture was stirred at 25°C for 1 h. The reaction mixture was diluted with DCM (10.0 mL) and added to saturated aqueous potassium carbonate (10.0 mL). The biphasic mixture was stirred at 25°C for 0.5 h. The organic phase was separated, dried over sodium sulfate, and concentrated in vacuo to give 2,3-dihydrobenzofuran-4-ylmethanamine (80.0 mg, 483 μmol, 85.9% yield, 90.0% purity) as a yellow solid.

[0329] 1H NMR (400MHz, CDCl3) δ=7.13(t,J=8.0Hz,1H),6.84(d,J=7.6Hz,1H),6.72(d,J=8.0Hz,1H),4.60(t,J=8.8Hz,2H),3.82(s,2H),3.20(t,J=8.8Hz,2H).

[0330] [ka]

[0331] A second exemplary intermediate B, intermediate B-2, can be used to synthesize compounds of formula (I) or formula (II), where Z is O, n is 1, and X is CR 5 and

[0332] [ka] is a double bond. To a mixture of 5-fluorobenzofuran-4-carbonitrile (250 mg, 1.47 mmol, 1.00 equiv.) and Raney Ni (126 mg, 1.47 mmol, 1.00 equiv.) in methyl alcohol (6.60 mL) was added ammonium hydroxide (1.60 mL). The mixture was purged with nitrogen and stirred under a hydrogen atmosphere at 25 °C for 12 h. The reaction mixture was filtered and concentrated under reduced pressure to give (5-fluorobenzofuran-4-yl)methanamine (220 mg, 1.20 mmol, 81.3% yield, 90.0% purity) as a brown oil.

[0333] 1 H NMR (400MHz, CDCl3) δ=7.67(s,1H),7.33(brd,J=5.6Hz,1H),7.04(brt,J=9.6Hz,1H),6.90(s,1H),4.54-3.78(m,2H).

[0334] [ka]

[0335] A third exemplary intermediate B, intermediate B-3, can be used to synthesize compounds of formula I, where Z is O, n is 1, and X is C(R 5 )2,

[0336] [ka] is a single bond. To a solution of benzofuran-4-carboxylic acid (900 mg, 5.55 mmol, 1 equiv.) in MeOH (9.00 mL) was added palladium on activated carbon (20.0 mg, 555 μmol, 10.0 wt%, 0.10 equiv.) under nitrogen. The tube was evacuated and purged with hydrogen several times. The mixture was stirred under hydrogen (50.0 psi) at 25 °C for 12 h. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give 2,3-dihydrobenzofuran-4-carboxylic acid (750 mg, 3.66 mmol, 65.9% yield, 80.0% purity) as a white solid.

[0337] 1 H NMR (400MHz, DMSO-d6) δ=7.38(d,J=8.0Hz,1H),7.20(t,J=8.0Hz,1H),6.97(d,J=8.0Hz,1H),4.54(t,J=8.8Hz,2H),3.45(br t,J=8.8Hz,2H).

[0338] To a solution of 2,3-dihydrobenzofuran-4-carboxylic acid (750 mg, 3.66 mmol, 1.00 equiv.) in DMF (1.00 mL) was added Pd(OAc)2 (82.1 mg, 366 μmol, 0.10 equiv.) and NCS (586 mg, 4.39 mmol, 1.20 equiv.). The reaction was stirred at 110 °C under a nitrogen atmosphere for 12 h. The reaction mixture was filtered and concentrated in vacuo, and the resulting residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 5 / 1 to dichloromethane / methanol = 10 / 1) to give 5-chloro-2,3-dihydrobenzofuran-4-carboxylic acid (600 mg, crude) as a yellow oil. LC-MS: [M+1] 198.9.

[0339] To a solution of 5-chloro-2,3-dihydrobenzofuran-4-carboxylic acid (600 mg, 3.02 mmol, 1.00 equiv.) in DMF (5.00 mL) was added ammonium chloride (242 mg, 4.53 mmol, 1.50 equiv.), HATU (2.30 g, 6.04 mmol, 2.00 equiv.), and DIEA (1.17 g, 9.06 mmol, 1.58 mL, 3.00 equiv.). The reaction mixture was stirred at 25 °C for 12 h and concentrated in vacuo to give the crude material, which was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give 5-chloro-2,3-dihydrobenzofuran-4-carboxamide (700 mg, 2.83 mmol, 93.8% yield, 80.0% purity) as a white solid.

[0340] 1 H NMR (400MHz, DMSO-d6) δ=7.87(br s,1H),7.63(br s,1H),7.17(d,J=8.4Hz,1H),6.79(d,J=8.4Hz,1H),4.58(t,J=8.8Hz,2H),3.18(t,J=8.8Hz,2H).

[0341] To a solution of 5-chloro-2,3-dihydrobenzofuran-4-carboxamide (300 mg, 1.21 mmol, 1.00 equiv) in THF (5.00 mL) was added BH3-DMS (10.0 M, 607 μL, 5.00 equiv) dropwise. The reaction was stirred at 70 °C for 2.5 h, quenched with MeOH (5.00 mL), and concentrated in vacuo to give a residue. Water (20.0 mL) was added to the residue, and the mixture was extracted with DCM (20.0 mL × 3). The combined organic phases were washed with brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give (5-chloro-2,3-dihydrobenzofuran-4-yl)methanamine (240 mg, crude) as a brown oil. LC-MS: [M-16] 167.1.

[0342] [ka]

[0343] A fourth exemplary intermediate B, intermediate B-4, can be used to synthesize compounds of formula I, where Z is O, n is 1, and X is C(R 5 )2,

[0344] [ka] is a single bond. To a solution of 3-bromo-4-fluorophenol (100 g, 524 mmol, 1.00 equiv.) and 2-bromo-1,1-diethoxyethane (124 g, 628 mmol, 94.5 mL, 1.20 equiv.) in DMF (600 mL) was added potassium carbonate (217 g, 1.57 mol, 3.00 equiv.). The mixture was stirred at 110 °C for 12 h under a nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate (500 mL), washed with brine (500 mL x 5), and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 20 / 1) to give 2-bromo-4-(2,2-diethoxyethoxy)-1-fluorobenzene (171 g, 501 mmol, 95.7% yield, 90.0% purity) as a pale yellow oil.

[0345] 1 H NMR(400MHz, CDCl3) δ=7.12(dd,J=2.8,5.6Hz,1H),7.06-6.98(m,1H),6.84(td,J=3.2,9.2Hz,1H),4.81(t,J=5. 2Hz,1H), 3.96(d,J=5.2Hz,2H),3.81-3.72(m,2H),3.68-3.59(m,2H),1.25(t,J=7.2Hz,6H).

[0346] To a solution of PPA (254 g, 752 mmol, 1.50 equiv.) in toluene (1.30 L) was added 2-bromo-4-(2,2-diethoxyethoxy)-1-fluoro-benzene (171 g, 501 mmol, 1.00 equiv.) at 90 °C. The mixture was stirred at 95 °C for 2 h and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether) to give 4-bromo-5-fluoro-benzofuran (87.3 g, 203 mmol, 40.5% yield, 50.0% purity) as a yellow oil. To a mixture of 4-bromo-5-fluorobenzofuran (85.5 g, 398 mmol, 1.00 equiv.) and 6-bromo-5-fluorobenzofuran (85.5 g, 398 mmol, 1.00 equiv.) in DMAC (1.50 L) was added zinc cyanide (31.1 g, 264 mmol, 0.67 equiv.) and Pd(PPh3)4 (23.0 g, 19.9 mmol, 0.05 equiv.). The mixture was stirred at 90 °C under a nitrogen atmosphere for 12 hours. The reaction mixture was diluted with ethyl acetate (1.00 L) and filtered. The filtrate was washed with brine (1.00 L × 3), and the organic layer was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether / ethyl acetate=1 / 0 to 50 / 1) to give 4-bromo-5-fluoro-benzofuran (78 g, crude) as a white solid.

[0347] To a solution of 4-bromo-5-fluorobenzofuran (87.3 g, 203 mmol, 1.00 equiv.) in DMAC (600 mL) was added zinc cyanide (94.6 g, 805 mmol, 3.97 equiv.) and Pd(PPh3)4 (23.5 g, 20.3 mmol, 0.10 equiv.). The mixture was stirred at 110 °C for 12 h under a nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate (500 mL), washed with brine (400 mL × 5), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 50 / 1) to give 5-fluorobenzofuran-4-carbonitrile (20.0 g, 118 mmol, 58.1% yield, 95.0% purity) as a white solid.

[0348] 1 H NMR (400MHz, CDCl3) δ=7.84(d,J=2.0Hz,1H),7.73-7.67(m,1H),7.14(t,J=9.2Hz,1H),7.02-6.96(m,1H).

[0349] To a solution of 5-fluorobenzofuran-4-carbonitrile (19.6 g, 116 mmol, 1.00 equiv.) in methyl alcohol (1.00 L) was added di-tert-butyl dicarbonate (75.7 g, 347 mmol, 3.00 equiv.) and Pd / C 10 wt.% (1.16 g). The mixture was stirred at 35 °C under a hydrogen gas atmosphere (50.0 psi) for 24 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 3 / 1) to give tert-butyl N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]carbamate (22.0 g, 78.2 mmol, 67.7% yield, 95.0% purity) as a white solid.

[0350] 1 H NMR(400MHz,CDCl3) δ=6.82-6.76(m,1H),6.62(dd,J=4.0,8.8Hz,1H),4.88(br s,1H),4.60(t,J=8.8Hz,2H),4.30(br d,J=6.0Hz,2H),3.30(br t,J=8.8Hz,2H),1.44(s,9H).

[0351] To a solution of tert-butyl N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]carbamate (22.0 g, 78.2 mmol, 1.00 equiv) in DCM (200 mL) was added TFA (89.2 g, 782 mmol, 57.9 mL, 10.0 equiv). The mixture was stirred at 25 °C for 0.5 h and then quenched with saturated aqueous potassium carbonate (200 mL). The mixture was stirred at 25 °C for 0.5 h. The organic phase was separated, dried over sodium sulfate, and concentrated in vacuo to give (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (13.0 g, 73.9 mmol, 94.5% yield, 95.0% purity) as a pale yellow oil.

[0352] 1 H NMR (400MHz, CDCl3) δ=6.85-6.76(m,1H),6.60(dd,J=4.0,8.8Hz,1H),4.61(t,J=8.8Hz,2H),3.82(s,2H),3.24(t,J=8.8Hz,2H).

[0353] Alternatively, intermediate B-2 may be prepared on a larger scale as follows.

[0354] To a solution of 3-bromo-4-fluorophenol (1.00 kg, 5.24 mol, 1.00 equiv.) and CsCO (3.41 kg, 10.5 mol, 2.00 equiv.) in DMF (5.00 L) was added the compound 2-bromo-1,1-diethoxyethane (1.24 kg, 6.28 mol, 1.20 equiv.) in one portion. The suspension was stirred at 110 °C for 12 h. TLC (petroleum ether / ethyl acetate = 10 / 1, R f =0.50), the reaction was deemed complete. The reaction mixture was filtered, diluted with water (15.0 L), and extracted with MTBE (5.00 L × 2). The combined organic layers were washed with brine (3.00 L), dried over Na2SO4, filtered, and concentrated under reduced pressure to give compound 2-bromo-4-(2,2-diethoxyethoxy)-1-fluorobenzene (1.61 kg, crude) as a yellow oil.

[0355] Two reactions were carried out in parallel on the same scale and combined during workup. To a mixture of polyphosphoric acid (1.30 kg) in toluene (2.40 L) was added 2-bromo-4-(2,2-diethoxyethoxy)-1-fluorobenzene (800 g, 2.60 mol, 1.00 equiv.) in one portion at 90 °C. The mixture was stirred at 90 °C for 3 h. TLC (petroleum ether / EtOAc = 10 / 1, R f The reaction was deemed complete by a pH of 0.6. The two reactions were combined before workup. This mixture was poured into water (6.00 L) and extracted with MTBE (6.00 L x 2). The combined organic layers were washed with brine (5.00 L x 2), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 0 to 100 / 1) to give an approximately 1:1 mixture of 4-bromo-5-fluorobenzofuran and 6-bromo-5-fluorobenzofuran (800 g, 3.72 mol, 71.4% yield) as a brown oil.

[0356] Two reactions were run in parallel on the same scale and combined during workup. To a mixture of 4-bromo-5-fluorobenzofuran (150 g, 698 mmol, 1.00 equiv.) and 6-bromo-5-fluorobenzofuran (150 g, 698 mmol, 1.00 equiv.) in DMA (2.40 L) was added Zn(CN) (49.2 g, 419 mmol, 0.60 equiv.) and Pd(PPh) (40.3 g, 34.9 mmol, 0.05 equiv.) in one portion at 25 °C under N. The mixture was stirred at 90 °C for 12 h. TLC (petroleum ether / EtOAc = 10 / 1) showed consumption of the unwanted isomer (6-bromo-5-fluorobenzofuran). The two reactions were combined prior to workup. The mixture was diluted with EtOAc (5.00 L) and filtered. The filtrate was poured into water (8.00 L), and the mixture was extracted with EtOAc (3.00 L × 2). The combined organic phase was washed with brine (4.00 L × 2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 0 to 5 / 1) to give the compound 4-bromo-5-fluorobenzofuran (340 g) as a yellow oil.

[0357] Two reactions were carried out in parallel on the same scale and combined during workup. To a mixture of 4-bromo-5-fluorobenzofuran (170 g, 791 mmol, 1.00 equiv.) in DMA (1.30 L), Zn(CN) (92.8 g, 791 mmol, 1.00 equiv.) and Pd(PPh) (91.4 g, 79.1 mmol, 0.10 equiv.) were added in one portion at 25 °C under N. The resulting mixture was stirred at 120 °C for 12 h. TLC (petroleum ether / EtOAc = 10 / 1) showed the reaction was complete. The two reactions were combined prior to workup, and the mixture was poured into water (3.00 L) and EtOAc (4.00 L), filtered, and the filtrate was extracted with EtOAc (2.00 L × 2). The combined organic layers were washed with brine (3.00 L × 2), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 0 to 50 / 1) to give the compound 5-fluorobenzofuran-4-carbonitrile (120 g, 745 mmol, 47.1% yield) as a yellow oil.

[0358] 1 H NMR (400MHz, CD3OD) δ 8.06(d,J=2.0Hz,1H),7.82-7.86(m,1H),7.23-7.28(m,1H),7.02(d,J=2.0Hz,1H).

[0359] Two reactions were carried out in parallel on the same scale and combined during workup. To a solution of the compound 5-fluorobenzofuran-4-carbonitrile (60.0 g, 372 mmol, 1.00 equiv.) in MeOH (1.50 L), BocO (122 g, 559 mmol, 1.50 equiv.) and Pd / C (12.0 g, 10 wt%) were added under N2. The suspension was evacuated and purged with H2 several times, and the mixture was stirred under H2 (50 psi) at 50 °C for 12 h. TLC (petroleum ether / EtOAc = 10 / 1) showed the reaction was complete. The two reactions were combined and filtered before workup. The filtrate was concentrated to give a residue which was triturated with petroleum ether (500 mL), filtered, and dried under vacuum at 45° C. to give tert-butyl ((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (100 g, 374 mmol, 50.2% yield) as a white solid.

[0360] 1 H NMR (400MHz, CDCl3) δ 6.76-6.81(m,1H),6.60-6.63(m,1H),4.60(t,J=8.8Hz,2H),4.29-4.31(m,2H),3.30(t,J=8.8Hz,2H),1.44(s,9H).

[0361] Two reactions were carried out in parallel on the same scale and combined during workup. To a mixture of tert-butyl ((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (50.0 g, 187 mmol, 1.00 equiv) in EtOAc (400 mL) was added HCl / EtOAc (300 mL, 4 M) in one portion under N at 25 °C. The resulting mixture was stirred for 4 h, at which time TLC (petroleum ether / EtOAc = 5 / 1) showed the reaction to be complete. The two reactions were combined and filtered before workup, and the filter cake was washed with MTBE (100 mL × 2). The filter cake was dissolved in water (200 mL) and the pH was adjusted to 9 with saturated KCO at 0 °C, followed by extraction with DCM (200 mL × 4). The combined organic phases were washed with brine (200 mL × 2), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (50.0 g, 299 mmol, 79.9% yield) as a brown oil.

[0362] 1 H NMR (400MHz, DMSO-d6) δ 8.57(br.s.,3H),6.97(m,1H),6.77-6.80(m,1H),4.55-4.59(m,2H),3.94(s,2H),3.37-3.42(m,2H).

[0363] [ka]

[0364] A fifth exemplary intermediate B, intermediate B-5, can be used to synthesize compounds of formula I, where Z is S, n is 1, and X is C(R 5 )2,

[0365] [ka] is a single bond. A mixture of 3-bromo-4-fluoro-benzenethiol (4.50 g, 21.7 mmol, 1.00 equiv.), 2-bromo-1,1-diethoxy-ethane (4.71 g, 23.9 mmol, 3.60 mL, 1.10 equiv.), and potassium carbonate (3.60 g, 26.1 mmol, 1.20 equiv.) in DMF (50.0 mL) was purged with nitrogen. The mixture was stirred under a nitrogen atmosphere at 80 °C for 0.5 h. The mixture was concentrated in vacuo to give a residue, which was purified by column chromatography (petroleum ether / ethyl acetate, 20 / 1 to 5 / 1) to give 2-bromo-4-(2,2-diethoxyethylsulfanyl)-1-fluoro-benzene (6.2 g, 19.2 mmol, 88.3% yield) as a colorless liquid.

[0366] 1 H NMR(400MHz, CDCl3) δ=7.63(dd,J=2.4,6.4Hz,1H),7.32(ddd,J=2.4,4.4,8.8Hz,1H),7.03(t,J=8.4Hz,1H),4.63(t, J=5.6Hz,1H),3.72-3.65(m,2H),3.57-3.51(m,2H),3.08(d,J=5.6Hz,2H),1.20(t,J=7.2Hz,6H).

[0367] To a solution of polyphosphoric acid (39 g, 710 μL, 1.00 equiv.) in chlorobenzene (70.0 mL), 2-bromo-4-(2,2-diethoxyethylsulfanyl)-1-fluoro-benzene (5.9 g, 18.3 mmol, 1.00 equiv.) was added, and the resulting mixture was stirred at 130 °C for 12 h. The mixture was concentrated in vacuo to give a residue. The residue was purified by column chromatography (petroleum ether) to give 4-bromo-5-fluoro-benzothiophene (2.50 g, 10.8 mmol, 29.8% yield, 50% purity) as a colorless liquid.

[0368] 1H NMR (400MHz, CDCl3) δ=7.75(dd,J=4.4,8.8Hz,1H),7.61(d,J=5.6Hz,1H),7.49(d,J=5.6Hz,1H),7.17(t,J=8.8Hz,1H).

[0369] To a solution of 4-bromo-5-fluorobenzothiophene (1.25 g, 5.41 mmol, 1.00 equiv.) in DMAC (12.0 mL) was added zinc cyanide (953 mg, 8.11 mmol, 515 μL, 1.50 equiv.) and Pd(PPh3)4 (938 mg, 811 μmol, 0.150 equiv.). The mixture was stirred at 100 °C under a nitrogen atmosphere for 12 h. Water (50.0 mL) was added, and the mixture was extracted with ethyl acetate (80.0 mL × 3). The combined organic layers were concentrated in vacuo to give a residue. The residue was purified by column chromatography (petroleum ether) to give 5-fluorobenzothiophene-4-carbonitrile (530 mg, 2.99 mmol, 27.7% yield) as a white solid.

[0370] 1 H NMR (400MHz, CDCl3) δ=8.05(dd,J=4.4,8.8Hz,1H),7.80(d,J=5.6Hz,1H),7.57(d,J=5.6Hz,1H),7.23(t,J=8.8Hz,1H).

[0371] To a mixture of 5-fluorobenzothiophene-4-carbonitrile (300 mg, 1.69 mmol, 1.00 equiv) in THF (2.00 mL), BH3-Me2S (10 M, 677 μL, 4.00 equiv) was added at 0 °C, and the mixture was stirred at 75 °C for 6 h. The mixture was cooled to room temperature, quenched with ethanol (10.0 mL), and the pH was adjusted to 3 with aqueous HCl (2 M). The mixture was concentrated in vacuo to a residue, to which water (20.0 mL) was added. The aqueous mixture was extracted with ethyl acetate (40.0 mL × 4), and the combined organic layers were concentrated to give (5-fluorobenzothiophen-4-yl)methanamine (150 mg, 828 μmol, 48.9% yield) as a yellow solid.

[0372] [ka]

[0373] A sixth exemplary intermediate B, intermediate B-6, can be used to synthesize compounds of formula I, where Z is O, n is 2, and X is C(R 5 )2,

[0374] [ka] is a single bond.

[0375] To a solution of 2-bromo-6-hydroxy-benzaldehyde (0.30 g, 1.49 mmol, 1.00 equiv) and ethyl 2-diethoxyphosphorylacetate (669 mg, 2.98 mmol, 592 μL, 2.00 equiv) in DMF (3.00 mL) was added NaH (119 mg, 2.98 mmol, 60% purity, 2.00 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at 40 °C for 12 h. The reaction mixture was then diluted with ethyl acetate (50.0 mL) and quenched with water (10.0 mL). The combined organic phase was washed with brine (30.0 mL × 3), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10 / 1 to 4 / 1) to give ethyl (E)-3-(2-bromo-6-hydroxy-phenyl)prop-2-enoate (380 mg, 1.37 mmol, 92.0% yield, 98.0% purity) as a white solid.

[0376] 1 H NMR(400MHz,CD3OD) δ=8.02(d,J=16.0Hz,1H),7.15(dd,J=1.2,8.0Hz,1H),7.06(t,J=8.0Hz,1H),6.97(d,J=16 .0Hz,1H),6.86(d,J=8.0Hz,1H),4.56(s,1H),4.25(q,J=7.2Hz,2H),1.33(t,J=7.2Hz,3H).

[0377] To a solution of ethyl (E)-3-(2-bromo-6-hydroxyphenyl)prop-2-enoate (380 mg, 1.37 mmol, 1.00 equiv.) in THF (5.00 mL) and water (5.00 mL) was added NaOAc (225 mg, 2.75 mmol, 2.00 equiv.) and 4-methylbenzenesulfonohydrazide (512 mg, 2.75 mmol, 2.00 equiv.). The mixture was stirred at 70 °C for 12 h. The mixture was cooled to room temperature and extracted with ethyl acetate (20 mL × 2). The combined organic phase was washed with brine (30 mL × 3), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give ethyl 3-(2-bromo-6-hydroxy-phenyl)propanoate (380 mg, 1.32 mmol, yield 96.2%, purity 95.0%) as a pale yellow oil.

[0378] 1 H NMR(400MHz, CDCl3) δ=8.27(s,1H),7.14(dd,J=1.2,8.0Hz,1H),6.99(t,J=8.0Hz,1H),6.93-6.88(m,1H),4.1 7(q,J=7.2Hz,2H),3.50(s,1H),3.10-3.03(m,2H),2.87-2.79(m,2H),1.28-1.24(m,3H).

[0379] To a solution of ethyl 3-(2-bromo-6-hydroxyphenyl)propanoate (0.10 g, 348 μmol, 1.00 equiv.) in THF (2.00 mL) was added LAH (39.6 mg, 1.04 mmol, 3.00 equiv.) at 0° C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (0.50 mL) and diluted with DCM (30.0 mL). The mixture was dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by preparative TLC (SiO, PE:EA=2:1) ​​to afford 3-bromo-2-(3-hydroxypropyl)phenol (70.0 mg, 297 μmol, 85.4% yield, 98.0% purity) as a yellow oil.

[0380] 1 H NMR(400MHz,CDCl3) δ=7.66(br s,1H),7.14(dd,J=1.2,8.0Hz,1H),6.97(t,J=8.0Hz,1H),6.84(dd,J=1.2 ,8.0Hz,1H),3.64(t,J=5.6Hz,2H),3.03-2.94(m,2H),2.01-1.90(m,2H).

[0381] Iodine (3.30 g, 13.0 mmol, 2.62 mL, 1.65 equiv) was added to a solution of imidazole (2.42 g, 35.5 mmol, 4.50 equiv) and PPh3 (3.72 g, 14.2 mmol, 1.80 equiv) in DCM (40.0 mL) at 0 °C. The reaction mixture was stirred for 15 min, followed by the dropwise addition of 3-bromo-2-(3-hydroxypropyl)phenol (1.85 g, 7.89 mmol, 1.00 equiv) in DCM (10.0 mL). The reaction mixture was protected from light and stirred at room temperature for 12 h. The mixture was diluted with DCM (50.0 mL) and washed with brine (40.0 mL × 2). The combined organic phase was dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 20 / 1) to give 3-bromo-2-(3-iodopropyl)phenol (2.10 g, 6.16 mmol, 78.1% yield) as a white solid.

[0382] To a solution of 3-bromo-2-(3-iodopropyl)phenol (2.10 g, 6.16 mmol, 1.00 equiv) in acetone (50.0 mL) was added K2CO3 (1.70 g, 12.3 mmol, 2.00 equiv). The mixture was stirred at 50 °C for 12 h. The reaction mixture was filtered and concentrated in vacuo. The crude material was purified by column chromatography (SiO2, petroleum ether) to give 5-bromochroman (1.20 g, 5.63 mmol, 91.5% yield, 100% purity) as a pale yellow oil.

[0383] A mixture of 5-bromochroman (0.10 g, 469 μmol, 1.00 equiv.), Zn(CN) (110 mg, 939 μmol, 2.00 equiv.), and Pd(PPh) (81.4 mg, 70.4 μmol, 0.15 equiv.) in DMAC (1.00 mL) was purged with nitrogen. The mixture was stirred at 100 °C for 8 h. The reaction mixture was diluted with ethyl acetate (20.0 mL) and washed with brine (15.0 mL × 3). The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by preparative TLC (SiO, PE:EA = 10:1) to give chroman-5-carbonitrile (60.0 mg, 377 μmol, 80.3% yield) as a pale yellow oil.

[0384] 1 H NMR(400MHz, CDCl3) δ=7.22-7.18(m,1H),7.18-7.13(m,1H),7.02(dd,J=1.2,8.0Hz,1H),4.28-4.19(m,2H),2.97(t,J=6.4Hz,2H),2.16-2.02(m,2H).

[0385] To a solution of chroman-5-carbonitrile (60.0 mg, 377 μmol, 1.00 equiv.) in THF (3.00 mL) was added LAH (57.2 mg, 1.51 mmol, 4.00 equiv.) at 0° C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (1.00 mL) and diluted with DCM (30 mL). The mixture was dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give chroman-5-ylmethanamine (70.0 mg, crude) as a pale yellow oil.

[0386] [ka]

[0387] A seventh exemplary intermediate B, intermediate B-7, can be used to synthesize compounds of formula I, where Z is O, n is 1, and X is C(R 5 )2,

[0388] [ka] is a single bond, with two hydrogens replaced by deuterium.

[0389] To a solution of 5-fluorobenzofuran-4-carbonitrile (2.00 g, 12.4 mmol, 1.00 equiv) in dimethyl sulfoxide (20.0 mL) was added hydrogen peroxide (7.04 g, 62.1 mmol, 5.96 mL, 30% purity, 5.00 equiv) and potassium carbonate (1.72 g, 12.4 mmol, 1.00 equiv) at 0 °C. The mixture was stirred at 25 °C for 1 h. The residue was poured into ice water (5.00 mL) and stirred for 10 min. The mixture was filtered and concentrated in vacuo to give 5-fluorobenzofuran-4-carboxamide (1.80 g, 10.1 mmol, 81.0% yield) as a white solid.

[0390] 1H NMR (400MHz, DMSO-d6) δ=8.11(d,J=2.0Hz,1H),7.81(br s,1H),7.73(dd,J=4.0,8.8Hz,2H),7.23(dd,J=9.2,10.4Hz,1H),7.10(d,J=1.2Hz,1H).

[0391] A solution of 5-fluorobenzofuran-4-carboxamide (1.80 g, 10.1 mmol, 1.00 equiv) in methyl alcohol (4.00 mL) was charged with hydrogen (50 psi) and Pd / C (500 mg, 50% purity). The mixture was stirred at 35° C. for 12 hours. The mixture was filtered and concentrated in vacuo to give 5-fluoro-2,3-dihydrobenzofuran-4-carboxamide (1.60 g, 8.83 mmol, 87.9% yield) as a white solid. LC-MS [M+H]: 182.2.

[0392] 1 H NMR (400MHz, DMSO-d6) δ=7.82-7.55(m,2H),6.96(t,J=8.8Hz,1H),6.79(dd,J=4.0,8.8Hz,1H),4.54(t,J=8.8Hz,2H),3.25(t,J=8.8Hz,2H).

[0393] To a solution of 5-fluoro-2,3-dihydrobenzofuran-4-carboxamide (1.60 g, 8.83 mmol, 1.00 equiv) in tetrahydrofuran (20.0 mL) was added lithium aluminum deuteride (670 mg, 17.7 mmol, 911 μL, 2.00 equiv) at 0° C. The mixture was stirred at 60° C. for 12 h. The mixture was quenched with water (1.60 mL) (stirring for 15 min), followed by sodium hydroxide (1.50 mL, 15% aqueous solution) (15 min) and water (4.80 mL) (30 min). The suspension was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (basic condition) to give (5-fluoro-2,3-dihydrobenzofuran-4-yl)methan-d2-amine (0.80 g, 4.56 mmol, 51.6% yield, 96.4% purity) as a red oil.

[0394] 1 H NMR (400MHz, chloroform-d) δ=6.82-6.76(m,1H),6.59(dd,J=4.0,8.8Hz,1H),4.59(t,J=8.8Hz,2H),3.23(t,J=8.8Hz,2H).

[0395] [ka]

[0396] An eighth exemplary intermediate B, intermediate B-8, can be used to synthesize compounds of formula I, where Z is O, n is 1, and X is C(R 5 )2,

[0397] [ka] is a single bond, and two hydrogens in the linker and two hydrogens on the furan moiety are replaced with deuterium.

[0398] To a solution of 5-fluorobenzofuran-4-carbonitrile (100 mg, 620 μmol, 1.00 equiv.) in methanol-d4 (1.00 mL) was added di-tert-butyl dicarbonate (135 mg, 620 μmol, 143 μL, 1.00 equiv.) and palladium on carbon (100 mg, 10.0 wt.%, 0.09 equiv.). The mixture was stirred at 35°C under a deuterium atmosphere (15 psi) for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to give tert-butyl ((5-fluoro-2,3-dihydrobenzofuran-4-yl-2,3-d2)methyl-d2)carbamate (45.0 mg, 166 μmol, 26.7% yield) as a white solid.

[0399] 1H NMR(400MHz,CDCl3) δ=6.82-6.76(m,1H),6.62(dd,J=3.6,8.4Hz,1H),4.86(br s,1H),4.57(br d,J=10.0Hz,1H),3.27(br d,J=6.8Hz,1H),1.46-1.41(s,9H).

[0400] To a solution of tert-butyl ((5-fluoro-2,3-dihydrobenzofuran-4-yl-2,3-d2)methyl-d2)carbamate (40.0 mg, 147 μmol, 1.00 equiv.) in dichloromethane (2.00 mL) was added trifluoroacetic acid (109 μL, 1.47 mmol, 10.0 equiv.). The mixture was stirred at 25° C. for 1 hour and then concentrated under reduced pressure to give a residue. The residue was added to saturated sodium bicarbonate (2.00 mL) and stirred for 5 minutes. The aqueous phase was extracted with ethyl acetate (2.00 mL × 3). The combined organic phase was washed with brine (2.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give dideuterio-(2,3-dideuterio-5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (25.0 mg, crude) as a white solid, which was used without further purification.

[0401] [ka]

[0402] A ninth exemplary intermediate B, intermediate B-9, can be used to synthesize compounds of formula I, where Z is O, n is 1, and X is O;

[0403] [ka] is a single bond.

[0404] To a solution of 5-fluoro-1,3-benzodioxole (500 mg, 3.57 mmol, 1.00 equiv) in THF (5.00 mL) was added n-BuLi (2.50 M, 1.57 mL, 1.10 equiv) dropwise at −78°C. The mixture was stirred at −78°C for 15 min, followed by the dropwise addition of DMF (235 mg, 3.21 mmol, 247 μL, 0.90 equiv), and stirring was continued at −78°C for 0.5 h. The mixture was poured into saturated aqueous ammonium chloride solution (5.00 mL) and stirred for 15 min. The aqueous phase was extracted with ethyl acetate (6.00 mL × 2). The combined organic phase was washed with brine (6.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-fluoro-1,3-benzodioxole-4-carbaldehyde (370 mg, 2.20 mmol, 61.7% yield) as a white solid.

[0405] 1 H NMR (400MHz, DMSO-d6) δ=10.07(s,1H),7.12(dd,J=4.4,8.4Hz,1H),6.72(dd,J=8.8,11.6Hz,1H),6.17(s,2H).

[0406] To a solution of 5-fluoro-1,3-benzodioxole-4-carbaldehyde (200 mg, 1.19 mmol, 1.00 equiv.) in ethyl alcohol (6.00 mL) was added hydroxylamine hydrochloride (248 mg, 3.57 mmol, 3.00 equiv.) and triethylamine (827 μL, 5.95 mmol, 5.00 equiv.). The mixture was stirred at 15° C. for 0.5 h, and the mixture was concentrated under reduced pressure to give a residue. The residue was triturated with water (3.00 mL × 2), filtered, and the filter cake was collected and dried under reduced pressure to give 5-fluoro-1,3-benzodioxole-4-carbaldehyde oxime (200 mg, 1.09 mmol, 91.8% yield) as a white solid.

[0407] 1H NMR (400MHz, DMSO-d6) δ=11.68(s,1H),8.08(s,1H),6.91(br dd,J=4.0,8.4Hz,1H),6.77-6.65(m,1H),6.12(s,2H).

[0408] To a solution of 5-fluoro-1,3-benzodioxole-4-carbaldehyde oxime (280 mg, 2.07 mmol, 1.00 equiv.) in methyl alcohol (3.00 mL) was added Pd / C (2.07 mmol, 10% purity, 1.00 equiv.) and di-tert-butyl dicarbonate (906 mg, 4.15 mmol, 953 μL, 2.00 equiv.). The mixture was stirred under a hydrogen atmosphere (15 psi) at 25 °C for 12 h. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 2 / 1) to give tert-butyl N-[(5-fluoro-1,3-benzodioxol-4-yl)methyl]carbamate (350 mg, 1.71 mmol, 82.3% yield) as a white solid. LC-MS[M-55]:214.1.

[0409] To a solution of tert-butyl ((5-fluorobenzo[d][1,3]dioxol-4-yl)methyl)carbamate (85.0 mg, 316 μmol, 1.00 equiv) in DCM (1.00 mL) was added TFA (0.30 mL). The mixture was stirred at 25 °C for 0.5 h. The reaction mixture was neutralized with saturated aqueous potassium carbonate (5.00 mL) and stirred for 30 min. The aqueous phase was extracted with DCM (5.00 mL × 2). The combined organic phases were washed with brine (5.00 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (5-fluorobenzo[d][1,3]dioxol-4-yl)methanamine (45.0 mg, 266 μmol, 84.3% yield) as a yellow oil.

[0410] 1H NMR (400MHz, CDCl3) δ=6.63(dd,J=4.4,8.4Hz,1H),6.52(dd,J=8.4,10.4Hz,1H),6.00(s,2H),3.89(s,2H).

[0411] [ka]

[0412] Exemplary intermediates C, C-1 can be used to synthesize compounds of formula (I) or formula (II), where R 1 is a disubstituted heteroaryl. A mixture of 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (370 mg, 1.78 mmol, 1.00 equiv.), 2-iodopropane (907 mg, 5.33 mmol, 533 µL, 3.00 equiv.), and cesium carbonate (2.32 g, 7.11 mmol, 4.00 equiv.) in acetonitrile (7.00 mL) was purged with nitrogen and then stirred at 90 °C for 4 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate, 1 / 0 to 3 / 1) to give a mixture of 1-isopropyl-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (170 mg, 34.4% yield, 90.0% purity) and 1-isopropyl-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (170 mg, 34.4% yield, 90.0% purity) as a pale yellow oil. LC-MS [M+H]: 251.4.

[0413] 1 H NMR (400MHz, CDCl3) δ=7.73(s,0.6H),7.65(s,1H),4.50-4.36(m,2H),2.45(s,2H),2.40(s,3H),1.50-1.44(m,12H),1.31(s,22H).

[0414] [ka]

[0415] A second exemplary intermediate C, intermediate C-2, can be used to synthesize compounds of Formula I and Formula II, where R 1 is a disubstituted heteroaryl. A mixture of 5-bromo-2-methoxy-4-methyl-pyridine (350 mg, 1.73 mmol, 1.00 equiv.), bis(pinacolato)diboron (2.20 g, 8.66 mmol, 5.00 equiv.), potassium acetate (527 mg, 5.37 mmol, 3.10 equiv.), and Pd(dppf)Cl2 (127 mg, 173 μmol, 0.10 equiv.) in dioxane (5.00 mL) was purged with nitrogen and stirred at 90 °C for 3 h. The residue was diluted with ethyl acetate (3.00 mL) and extracted with ethyl acetate (2.00 mL × 3). The combined organic layers were washed with brine (2.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate, 100 / 1 to 20 / 1) to give 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (150 mg, 546 μmol, 31.5% yield, 90.6% purity) as a white solid.

[0416] 1 H NMR (400MHz, CDCl3) δ=8.47(s,1H),6.51(s,1H),3.93(s,3H),2.45(s,3H),1.33(s,12H).

[0417] [ka]

[0418] A third exemplary intermediate C, intermediate C-3, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted heteroaryl. A mixture of cyclopropanecarboxamidine-HCl (5.00 g, 59.4 mmol, 1.00 equiv.), ethyl 3-oxobutanoate (7.74 g, 59.4 mmol, 7.51 mL, 1.00 equiv.), and sodium ethoxide (8.09 g, 119 mmol, 2.00 equiv.) in ethanol (500 mL) was purged with nitrogen and then stirred at 25 °C for 12 h. The residue was dissolved in water (25.0 mL) and the pH was adjusted to 4 with HCl (1 M). After cooling to 5 °C, the solid was collected and dried under reduced pressure to give 2-cyclopropyl-6-methyl-pyrimidin-4-ol (4.00 g, 26.6 mmol, 44.8% yield, 100% purity) as a white solid. LC-MS [M+H]: 151.3.

[0419] 1 H NMR (400MHz, DMSO-d6) δ=12.45(s,1H),5.93(s,1H),2.07(s,3H),1.90-1.85(m,1H),1.00-0.97(m,4H).

[0420] A mixture of 2-cyclopropyl-6-methyl-pyrimidin-4-ol (4.00 g, 26.6 mmol, 1.00 equiv.), bromine (4.34 g, 27.2 mmol, 1.40 mL, 1.00 equiv.), and potassium hydroxide (1.49 g, 26.6 mmol, 1.00 equiv.) in water (32.6 mL) was stirred under a nitrogen atmosphere at 25 °C for 2 h. The solid was filtered to give 5-bromo-2-cyclopropyl-6-methyl-pyrimidin-4-ol (2.76 g, 9.31 mmol, 35.0% yield, 77.3% purity) as a white solid. LC-MS [M+3]: 231.0.

[0421] A mixture of 5-bromo-2-cyclopropyl-6-methyl-pyrimidin-4-ol (2.50 g, 8.44 mmol, 1.00 equiv) and dimethylformamide (1.54 g, 21.1 mmol, 1.62 mL, 2.50 equiv) in toluene (36.9 mL) was added dropwise to a solution of phosphorus oxychloride (1.57 g, 10.2 mmol, 951 μL, 1.21 equiv) in toluene (9.20 mL) at 0 °C. The mixture was then stirred at 25 °C under a nitrogen atmosphere for 3 h. The mixture was poured into sodium carbonate (1.00 M, 55.2 mL) and extracted with ethyl acetate (10.0 mL × 3). The combined organic phases were concentrated to give the compound 5-bromo-4-chloro-2-cyclopropyl-6-methyl-pyrimidine (2.31 g, 4.51 mmol, 53.5% yield, 48.4% purity) as a yellow oil. LC-MS [M+3]: 249.1.

[0422] A mixture of 5-bromo-4-chloro-2-cyclopropyl-6-methyl-pyrimidine (2.31 g, 9.33 mmol, 1.00 equiv.) and 4-methylbenzenesulfonohydrazide (5.91 g, 31.7 mmol, 3.40 equiv.) in chloroform (4.30 mL) was stirred at 90 °C for 16 h under a nitrogen atmosphere. The solid was filtered and rinsed with dichloromethane (20.0 mL) to give N'-(5-bromo-2-cyclopropyl-6-methyl-pyrimidin-4-yl)-4-methyl-benzenesulfonohydrazide (1.60 g, 4.02 mmol, 43.1% yield, 99.8% purity) as a white solid. LC-MS [M+3]: 399.2.

[0423] 1 H NMR(400MHz,DMSO-d6) δ=10.08(br s,1H),7.64(d,J=8.4Hz,2H),7.34(d,J=8.0Hz,2H),2.44(br s,3H),2.37(s,3H),2.05-1.83(m,1H),1.05-0.90(m,2H),0.87-0.75(m,2H).

[0424] A mixture of N'-(5-bromo-2-cyclopropyl-6-methyl-pyrimidin-4-yl-4-methyl-benzenesulfonohydrazide (1.60 g, 4.02 mmol, 1.00 equiv) and aqueous sodium carbonate (0.57 M, 90.6 mL, 12.8 equiv) was stirred at 90 °C for 1 h under a nitrogen atmosphere. The mixture was diluted with ethyl acetate (50.0 mL), and the organic phase was separated and concentrated to give 5-bromo-2-cyclopropyl-4-methyl-pyrimidine (620 mg, 2.59 mmol, 64.6% yield, 89.2% purity) as a brown oil. LC-MS [M+H]: 213.2.

[0425] 1 H NMR (400MHz, CDCl3) δ=8.49(s,1H),2.56(s,3H),2.25-2.08(m,1H),1.19-0.99(m,4H).

[0426] A mixture of 5-bromo-2-cyclopropyl-4-methyl-pyrimidine (580 mg, 2.43 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (863 mg, 3.40 mmol, 1.40 equiv.), potassium acetate (715 mg, 7.28 mmol, 3.00 equiv.), and Pd(dppf)Cl (88.8 mg, 121 μmol, 0.05 equiv.) in dioxane (5.00 mL) was purged with nitrogen and then stirred under a nitrogen atmosphere at 90 °C for 4 h. The residue was diluted with water (3.00 mL) and extracted with ethyl acetate (2.00 mL × 3). The combined organic layers were washed with brine (2.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate, 100 / 1 to 10 / 1) to give 2-cyclopropyl-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.00 g, 1.92 mmol, 79.2% yield, 50.0% purity) as a yellow oil.

[0427] 1H NMR (400MHz, CDCl3) δ=8.73(s,1H),2.62(s,3H),2.27-2.14(m,1H),1.34(s,12H),1.18-1.13(m,2H),1.07-1.01(m,2H).

[0428] [ka]

[0429] A fourth exemplary intermediate C, intermediate C-4, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted heteroaryl. A mixture of sodium (111 mg, 4.82 mmol, 1.00 equiv) in methanol (772 mg, 24.1 mmol, 975 μL, 5.00 equiv) was stirred at 25 °C for 0.5 h. To this solution, 5-bromo-2-chloro-4-methyl-pyrimidine (1.00 g, 4.82 mmol, 1.00 equiv) was added, and the mixture was stirred at 25 °C for 2 h. The reaction was quenched after the addition of water (5 mL). The aqueous phase was extracted with ethyl acetate (10.0 mL × 3), and the combined organic phases were washed with brine (10.0 mL × 3), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give 5-bromo-2-methoxy-4-methyl-pyrimidine (500 mg, 2.46 mmol, 51.1% yield) as a red oil. LC-MS: [M+1] 203.1.

[0430] To a solution of 5-bromo-2-methoxy-4-methyl-pyrimidine (500 mg, 2.46 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (813 mg, 3.20 mmol, 1.30 equiv.), and potassium acetate (483 mg, 4.93 mmol, 2.00 equiv.) in dioxane (5.00 mL) was added Pd(dppf)Cl (180 mg, 246 μmol, 0.10 equiv.) under a nitrogen atmosphere. The resulting mixture was stirred at 105 °C for 2 h. The mixture was concentrated in vacuo to give the crude material, which was purified by column chromatography (petroleum ether / ethyl acetate, 1 / 0 to 1:1) to give 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (150 mg, 539 μmol, 21.9% yield, 90.0% purity) as a red oil.

[0431] 1 H NMR (400MHz, MeOD) δ=8.69(s,1H),4.03(s,3H),2.65(s,3H),1.38(s,12H).

[0432] [ka]

[0433] A fifth exemplary intermediate C, intermediate C-5, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted heteroaryl. To a solution of isopropanol (869 mg, 14.5 mmol, 1.11 mL, 3.00 equiv) in THF (10.0 mL), NaH (578 mg, 14.5 mmol, 60.0% purity, 3.00 equiv) was added portionwise at 0 °C. The mixture was stirred at 0 °C for 0.5 h. 5-Bromo-2-chloro-4-methyl-pyrimidine (1.00 g, 4.82 mmol, 1.00 equiv) was added, and the mixture was stirred at 25 °C for 3 h. The mixture was poured into water (20.00 mL), and the aqueous phase was extracted with ethyl acetate (20.0 mL × 3). The combined organic phase was washed with brine (20.0 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated to give 5-bromo-2-isopropoxy-4-methyl-pyrimidine (600 mg, 2.60 mmol, 53.9% yield) as a yellow oil.

[0434] To a solution of 5-bromo-2-isopropoxy-4-methyl-pyrimidine (300 mg, 1.30 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (429 mg, 1.69 mmol, 1.30 equiv.), and potassium acetate (255 mg, 2.60 mmol, 2.00 equiv.) in dioxane (5.00 mL) was added Pd(dppf)Cl (95.0 mg, 130 μmol, 0.10 equiv.) The mixture was stirred at 105 °C under a nitrogen atmosphere for 2 h. The mixture was concentrated in vacuo to give the crude material, which was purified by column chromatography (petroleum ether / ethyl acetate, 1 / 1 to dichloromethane:methanol, 10 / 1) to give 2-isopropoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (60.0 mg, 216 μmol, 16.6% yield) as a white oil. LC-MS: [M+1] 279.3.

[0435] [ka]

[0436] A sixth exemplary intermediate C, intermediate C-6, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted aryl. To a solution of 1-bromo-4-fluoro-2-methyl-benzene (1.00 g, 5.29 mmol, 1.00 equiv) in DMF (10.0 mL) was added NaSMe (869 mg, 5.29 mmol, 1.00 equiv). The mixture was stirred at 50 °C for 12 h. The reaction mixture was diluted with ethyl acetate (50.0 mL), and the organic layer was washed with brine (40.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 1-bromo-2-methyl-4-methylsulfanyl-benzene (900 mg, crude) as a pale yellow oil.

[0437] 1 H NMR (400MHz, CD3OD) δ=7.42(d,J=8.4Hz,1H),7.17(d,J=2.0Hz,1H),6.97(dd,J=2.0,8.4Hz,1H),2.45(s,3H),2.35(s,3H).

[0438] To a solution of 1-bromo-2-methyl-4-methylsulfanyl-benzene (900 mg, 4.15 mmol, 1.00 equiv) in DCM (9.00 mL) was added m-CPBA (1.43 g, 8.29 mmol, 2.00 equiv) at 0 °C. The reaction mixture was stirred at 25 °C for 2 h. The reaction mixture was diluted with DCM (20.0 mL) and washed with saturated aqueous potassium carbonate (20.0 mL × 3) and brine (20.0 mL × 2). The organic phase was concentrated under reduced pressure to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate, 1 / 0 to 3 / 1) to give 1-bromo-2-methyl-4-methylsulfonyl-benzene (370 mg, 1.41 mmol, 34.0% yield, 95.0% purity) as a white solid.

[0439] 1H NMR (400MHz, MeOD) δ=7.87(d,J=1.6Hz,1H),7.82(d,J=8.4Hz,1H),7.66(dd,J=2.0,8.4Hz,1H),3.12(s,3H),2.50(s,3H).

[0440] 1-Bromo-2-methyl-4-methylsulfonyl-benzene (170 mg, 648 μmol, 1.00 equiv.), potassium acetate (127 mg, 1.30 mmol, 2.00 equiv.), Pd(dppf)Cl (47.4 mg, 64.8 μmol, 0.100 equiv.), and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-1,3,2-dioxaborolane) (247 mg, 972 μmol, 1.50 equiv.) were dissolved in dioxane (3.00 The mixture, dissolved in 1 mL of 4,4,5,5-tetramethyl-2-(2-methyl-4-methylsulfonyl-phenyl)-1,3,2-dioxaborolane, was purged with nitrogen. The resulting reaction mixture was stirred at 105° C. for 1 h. The mixture was filtered and concentrated under reduced pressure to give a residue. The crude material was purified by preparative TLC (petroleum ether / ethyl acetate, 5 / 1) to give 4,4,5,5-tetramethyl-2-(2-methyl-4-methylsulfonyl-phenyl)-1,3,2-dioxaborolane (110 mg, 338 μmol, 52.1% yield, 90.9% purity) as a colorless oil. LC-MS [M+H]: 296.9.

[0441] [ka]

[0442] A seventh exemplary intermediate C, intermediate C-7, can be used to synthesize compounds of Formula I or Formula II, where R 1is a monosubstituted aryl. To a solution of 1-(4-bromophenyl)ethanone (1.00 g, 5.02 mmol, 1.00 equiv.) and pyrrolidine (1.79 g, 25.1 mmol, 2.10 mL, 5.00 equiv.) in methanol (16.0 mL) was added NaBH3CN (347 mg, 5.53 mmol, 1.10 equiv.). The mixture was stirred at 20 °C for 24 h. Water (4.00 mL) was added to the mixture, and the aqueous phase was extracted with ethyl acetate (5.00 mL). The combined organic phase was washed with brine (2.00 mL), dried over anhydrous Na2SO4, filtered, and concentrated to give 1-[1-(4-bromophenyl)ethyl]pyrrolidine (1.00 g, 3.93 mmol, 78.3% yield) as a yellow oil.

[0443] To a solution of 1-[1-(4-bromophenyl)ethyl]pyrrolidine (400 mg, 1.57 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (799 mg, 3.15 mmol, 2.00 equiv.), and potassium acetate (308 mg, 3.15 mmol, 2.00 equiv.) in dioxane (2.00 mL) was added Pd(dppf)Cl (115 mg, 157 μmol, 0.100 equiv.). The reaction mixture was stirred at 105 °C under a nitrogen atmosphere for 2 h. The mixture was concentrated in vacuo to give a residue. The crude material was purified by column chromatography (petroleum ether / ethyl acetate, 1 / 0 to 1 / 1) to give 1-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]pyrrolidine (110 mg) as a red oil.

[0444] [ka]

[0445] An eighth exemplary intermediate C, intermediate C-8, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted heteroaryl. To a solution of n-butyllithium (2.50 M, 1.80 mL, 1.00 equiv) in THF (12 mL) was added i-PrMgCl (2.00 M, 1.12 mL, 0.500 equiv) dropwise over 1 minute at 0 °C under a nitrogen atmosphere. The mixture was stirred at 0 °C for 5 minutes, followed by the addition of 5-bromo-4-chloro-2-methoxypyridine (1.00 g, 4.50 mmol, 1.00 equiv), after which the mixture was stirred at 0 °C for 45 minutes. To this solution was added 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (836 mg, 4.50 mmol, 917 μL, 1.00 equiv), and the mixture was stirred for an additional 15 minutes, followed by 3 hours at 20 °C. The reaction mixture was quenched at 20° C. by adding saturated aqueous ammonium chloride (20.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 4-chloro-2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.00 g, 3.71 mmol, 82.5% yield) as a gray solid, which was used in the next step without further purification.

[0446] 1 H NMR (400MHz, CDCl3) δ=8.47(s,1H),6.77(s,1H),3.97(s,3H),1.38(s,12H).

[0447] [ka]

[0448] A ninth exemplary intermediate C, intermediate C-9, can be used to synthesize compounds of Formula I or Formula II, where R 1is a trisubstituted heteroaryl. A mixture of 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 450 μmol, 1.00 equiv.), isopropyl iodide (306 mg, 1.80 mmol, 180 μL, 4.00 equiv.), and cesium carbonate (587 mg, 1.80 mmol, 4.00 equiv.) in acetonitrile (3.00 mL) was purged with nitrogen and then stirred at 65 °C for 4 h. The mixture was filtered and the solvent removed in vacuo to give 1-isopropyl-3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (100 mg, 368 μmol, 81.8% yield, 97.3% purity) as a green oil. LC-MS [M+H]: 265.

[0449] [ka]

[0450] A tenth exemplary intermediate C, intermediate C-10, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted heteroaryl. A mixture of 3-bromo-6-fluoro-2-methyl-pyridine (1.00 g, 5.26 mmol, 1.00 equiv.) and N-methylpiperazine (685 mg, 6.84 mmol, 759 μL, 1.30 equiv.) was stirred at 110 °C for 12 h. The mixture was diluted with ethyl acetate (50 mL), washed with brine (20 mL × 3), dried over anhydrous Na2SO4, filtered, and concentrated to give 1-(5-bromo-6-methyl-2-pyridyl)-4-methyl-piperazine (1.10 g, 4.07 mmol, 77.4% yield) as a yellow solid. LC-MS [M+H]: 272.1.

[0451] To a solution of 1-(5-bromo-6-methyl-2-pyridyl)-4-methyl-piperazine (400 mg, 1.48 mmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (752 mg, 2.96 mmol, 2.00 equiv.), and potassium acetate (291 mg, 2.96 mmol, 2.00 equiv.) in dioxane (2.00 mL) was added Pd(dppf)Cl (108 mg, 148 μmol, 0.100 equiv.). The reaction was stirred at 105 °C under a nitrogen atmosphere for 2 hours. The mixture was concentrated in vacuo to give a residue. The crude material was purified by preparative TLC (DCM / MeOH=10 / 1) to give the compound 1-methyl-4-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine (210 mg, 662 μmol, 44.7% yield) as a brown oil. LC-MS [M+H]: 318.3.

[0452] [ka]

[0453] An eleventh exemplary intermediate C, intermediate C-11, can be used to synthesize compounds of Formula I or Formula II, where R 1is a trisubstituted heteroaryl. To a solution of 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 450 μmol, 1.00 equiv.) and (2S)-2-methyloxirane (392 mg, 6.75 mmol, 473 μL, 15.0 equiv.) was added cesium carbonate (29.3 mg, 90.1 μmol, 0.20 equiv.). The reaction mixture was stirred at 50° C. for 16 hours and then concentrated in vacuo to give a residue. The crude residue was purified by preparative TLC (SiO, petroleum ether:ethyl acetate=1:1) to give (2S)-1-[3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-2-ol (56.0 mg, 44.4% yield) as a yellow oil. LC-MS [M+H]: 281.3.

[0454] [ka]

[0455] A twelfth exemplary intermediate C, intermediate C-12, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl. HATU (727 mg, 1.91 mmol, 1.50 equiv) was added to a solution of 4-bromo-3-chlorobenzoic acid (300 mg, 1.27 mmol, 1.00 equiv), DIEA (490 mg, 3.79 mmol, 660 μL, 3.00 equiv), and N,N-dimethylamine (2.00 M in THF, 1.27 mL, 2.00 equiv) in DMF (3.00 mL). The mixture was stirred at room temperature for 2 hours, followed by the addition of water (15.0 mL) to quench the reaction mixture. The mixture was extracted with dichloromethane (20.0 mL × 3). The combined organic layers were washed with water (30.0 mL) and concentrated to give the crude mixture. The resulting residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 5 / 1 to 2 / 1) to give 4-bromo-3-chloro-N,N-dimethyl-benzamide (430 mg, 983 μmol, yield 77.0%, purity 60.0%) as a white solid. LC-MS [M+H]: 264.0.

[0456] 1 H NMR (400MHz, CDCl3) δ=7.67(d,J=8.2Hz,1H),7.53(d,J=1.6Hz,1H),7.18(dd,J=2.0,8.4Hz,1H),3.11(s,3H),2.99(s,3H).

[0457] To a solution of 4-bromo-3-chloro-N,N-dimethyl-benzamide (150 mg, 343 μmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (870 mg, 3.43 mmol, 10.0 equiv.), and potassium acetate (67.0 mg, 683 μmol, 2.00 equiv.) in dioxane (10.0 mL) was added Pd(PPh3)2Cl2 (24.0 mg, 34.2 μmol, 0.10 equiv.). The tube was flushed with nitrogen, and the mixture was stirred at 100 °C for 1 h. The reaction mixture was cooled to room temperature and filtered through a pad of Celite. Preparative TLC (SiO2, petroleum ether / ethyl acetate=2 / 1) gave [2-chloro-4-(dimethylcarbamoyl)phenyl]boronic acid (200 mg) as a yellow solid. LC-MS [M+H]: 228.0.

[0458] [ka]

[0459] A thirteenth exemplary intermediate C, intermediate C-13, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted aryl. A mixture of 4-bromo-3-methyl-benzaldehyde (500 mg, 2.51 mmol, 1.00 equiv.) and N,N-dimethylamine (2 M in THF, 6.3 mL, 12.6 mmol, 5.00 equiv.) in methanol (10.0 mL) was stirred at 40 °C for 30 min. Sodium triacetoxyborohydride (1.60 g, 7.54 mmol, 3.00 equiv.) was then added, and the mixture was stirred for an additional 3 h. The solution was concentrated under reduced pressure to give a residue. The crude residue was purified by column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 0 / 1, then dichloromethane / methanol = 20 / 1 to 10 / 1) to give 1-(4-bromo-3-methyl-phenyl-N,N-dimethyl-methanamine) (570 mg) as a brown oil.

[0460] 1H NMR (400MHz, CD3OD) δ=7.61(d,J=8.0Hz,1H),7.38(d,J=1.6Hz,1H),7.16(dd,J=1.6,8.0Hz,1H),3.96(s,2H),2.63(s,6H),2.42(s,3H).

[0461] A mixture of 1-(4-bromo-3-methyl-phenyl)-N,N-dimethyl-methanamine (470 mg, 2.06 mmol, 1.00 equiv), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (785 mg, 3.09 mmol, 1.50 equiv), potassium acetate (404 mg, 4.12 mmol, 2.00 equiv), and Pd(dppf)Cl (151 mg, 206 μmol, 0.100 equiv) in dioxane (8.00 mL) was purged with nitrogen and stirred at 105 °C for 2 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (dichloromethane / methanol = 50 / 1 to 10 / 1) to give N,N-dimethyl-1-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanamine (70.0 mg, 185 μmol, yield 8.99%, purity 72.8%) as a brown oil. LC-MS [M+H]: 275.6.

[0462] [ka]

[0463] A fourteenth exemplary intermediate C, intermediate C-14, can be used to synthesize compounds of Formula I or Formula II, where R 1is a monosubstituted aryl. To a solution of 4-bromobenzenesulfonyl chloride (200 mg, 783 μmol, 1.00 equiv.) in THF (2.00 mL) was added ammonia (7N in MeOH, 224 μL, 1.57 mmol, 2.00 equiv.). The reaction mixture was stirred at 25 °C for 30 min. The mixture was concentrated in vacuo to give a residue, which was poured into water (10.0 mL). The aqueous phase was extracted with ethyl acetate (10.0 mL × 3), and the combined organic phase was washed with brine (3.00 mL × 3), dried over anhydrous sodium sulfate, and concentrated to give 4-bromobenzenesulfonamide (180 mg, 762 μmol, 97.4% yield) as a white solid.

[0464] 1 H NMR (400MHz, DMSO-d6) δ=7.82-7.72(m,4H),7.46(s,2H).

[0465] To a solution of 4-bromobenzenesulfonamide (100 mg, 424 μmol, 1.00 equiv.) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (129 mg, 508 μmol, 1.20 equiv.) in DMSO (2.00 mL) was added potassium acetate (83.1 mg, 847 μmol, 2.00 equiv.) and Pd(dppf)Cl (31.0 mg, 42.4 μmol, 0.10 equiv.) under a nitrogen atmosphere. The mixture was stirred at 80 °C for 3 h and then concentrated in vacuo to give a residue. The residue was poured into water (10.0 mL), and the aqueous phase was extracted with ethyl acetate (10.0 mL × 3). The combined organic phase was washed with brine (5.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (95.0 mg, 336 μmol, 79.2% yield) as a red solid.

[0466] 1 H NMR (400MHz, CDCl3) δ=7.96-7.88(m,4H),7.26(s,2H),1.35(s,12H).

[0467] [ka]

[0468] A fifteenth exemplary intermediate C, intermediate C-15, can be used to synthesize compounds of Formula I or Formula II, wherein R 1 is a monosubstituted heteroaryl. To a solution of 2-methoxyethanol (236 mg, 3.10 mmol, 245 μL, 1.50 equiv) in tetrahydrofuran (2.00 mL), sodium hydride (99.3 mg, 60.0%, 2.48 mmol, 1.20 equiv) was added portionwise at 0 °C. The mixture was stirred at this temperature for 45 minutes, followed by the dropwise addition of 5-bromo-2-chloro-pyrimidine (400 mg, 2.07 mmol, 1.00 equiv) at room temperature. The resulting reaction mixture was stirred for an additional 4 hours. The mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate = 10 / 1) to give 5-bromo-2-(2-methoxyethoxy)pyrimidine (150 mg, 644 μmol, 31.1% yield) as a white solid.

[0469] 1 H NMR (400MHz, CD3OD) δ=8.54(s,2H),4.42-4.37(m,2H),3.68-3.62(m,2H),3.30(s,3H).

[0470] A mixture of 5-bromo-2-(2-methoxyethoxy)pyrimidine (150 mg, 644 μmol, 1.00 equiv), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (327 mg, 1.29 mmol, 2.00 equiv), potassium acetate (126 mg, 1.29 mmol, 2.00 equiv), and Pd(dppf)Cl (47.1 mg, 64.4 μmol, 0.10 equiv) in dioxane (1.00 mL) was purged with nitrogen and stirred at 100° C. for 2 h. The reaction was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate=1 / 1) to give 2-(2-methoxyethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (130 mg, 464 μmol, yield 72.1%) as a yellow oil.

[0471] 1 H NMR (400MHz, CDCl3) δ=8.83-8.79(m,2H),4.61-4.54(m,2H),3.82-3.76(m,2H),3.44(s,3H),1.36(s,12H).

[0472] [ka]

[0473] A sixteenth exemplary intermediate C, intermediate C-16, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted heteroaryl. To a solution of ethylene glycol (310 mg, 5.00 mmol, 280 μL, 2.00 equiv.) and 5-bromo-4-methyl-pyridine-2-carbaldehyde (500 mg, 2.50 mmol, 1.00 equiv.) in toluene (20.0 mL) was added p-toluenesulfonic acid (47.6 mg, 250 μmol, 0.10 equiv.). The mixture was stirred at 110 °C for 12 h and then concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 5:1) to give 5-bromo-2-(1,3-dioxolan-2-yl)-4-methylpyridine (320 mg, 1.24 mmol, 49.6% yield) as a colorless oil.

[0474] 1 H NMR (400MHz, CDCl3) δ=8.64(s,1H),7.42(s,1H),5.80(s,1H),4.19-4.14(m,2H),4.10-4.05(m,2H),2.42(s,3H).

[0475] To a solution of 5-bromo-2-(1,3-dioxolan-2-yl)-4-methylpyridine (300 mg, 1.23 mmol, 1.00 equiv) in diethyl ether (20.0 mL) was added n-butyllithium (2.5 M, 737 μL, 1.50 equiv) under a nitrogen atmosphere at −78° C. The mixture was stirred at −78° C. for 0.5 h, followed by the addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (457 mg, 2.46 mmol, 501 μL, 2.00 equiv). The mixture was warmed to 0° C. and stirred for an additional 1.5 h. The mixture was quenched with water (15.0 mL), and the resulting mixture was extracted with ethyl acetate (20.0 mL × 2). The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure to give 2-(1,3-dioxolan-2-yl)-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (150 mg, crude) as a yellow oil. LC-MS [M+H]: 292.15.

[0476] [ka]

[0477] A seventeenth exemplary intermediate C, intermediate C-17, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a bicyclic heteroaryl. A mixture of paraformaldehyde (350 mg, 3.63 mmol, 2.20 equiv.) in methanol (1.00 mL) was stirred at 60 °C for 1 h and then cooled to 40 °C. To the mixture was added AcOH (1 drop) and 6-bromo-1,2,3,4-tetrahydroisoquinoline (350 mg, 1.65 mmol, 1.00 equiv.), followed by NaCNBH3 (114 mg, 1.82 mmol, 1.1 equiv.). The mixture was stirred at 40 °C for 1 h, then filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate = 2 / 1) to give 6-bromo-2-methyl-3,4-dihydro-1H-isoquinoline (360 mg, 1.59 mmol, 96.5% yield) as a yellow oil.

[0478] 1 H NMR(400MHz,CD3OD) δ=7.32(s,1H),7.28(dd,J=2.0,8.4Hz,1H),7.00(d,J=8.0Hz,1H),3.57(s,2H),2.94(t,J=6.0Hz,2H),2.75-2.72(m,2H),2.46(s,3H).

[0479] A mixture of 6-bromo-2-methyl-3,4-dihydro-1H-isoquinoline (220 mg, 973 μmol, 1.00 equiv), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (494 mg, 1.95 mmol, 2.00 equiv), potassium acetate (191 mg, 1.95 mmol, 2.00 equiv), and Pd(dppf)Cl (71.2 mg, 97.3 μmol, 0.10 equiv) in dioxane (3.00 mL) was purged with nitrogen and then stirred at 100° C. for 2 h. The mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate=2 / 1) to give 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline (150 mg, crude) as a white solid.

[0480] [ka]

[0481] An eighteenth exemplary intermediate C, intermediate C-18, can be used to synthesize compounds of Formula I or Formula II, where R 1 is an N-protected bicyclic heteroaryl. To a solution of 6-bromo-1,2,3,4-tetrahydroisoquinoline (400 mg, 1.89 mmol, 1.00 equiv.) in tetrahydrofuran (2.00 mL), BocO (617 mg, 2.83 mmol, 1.50 equiv.) and dimethylaminopyridine (46.1 mg, 377 μmol, 0.20 equiv.) were added. The mixture was stirred at 25 °C for 3 h, then filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 3 / 1) to give tert-butyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (150 mg, 480 μmol, 25.5% yield) as a white solid.

[0482] 1H NMR (400MHz, CD3OD) δ=7.38-7.32(m,2H),7.07(d,J=8.0Hz,1H),4.52(br s,2H),3.64(br t,J=6.0Hz,2H),2.84(t,J=6.0Hz,2H),1.51(s,9H).

[0483] A mixture of tert-butyl 6-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate (140 mg, 448 μmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (228 mg, 897 μmol, 2.00 equiv.), Pd(dppf)Cl (32.8 mg, 44.8 μmol, 0.10 equiv.), and potassium acetate (88.0 mg, 897 μmol, 2.00 equiv.) in dioxane (1.00 mL) was purged with nitrogen and then stirred at 100° C. for 2 h. The mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (100 mg, 278 μmol, yield 62.1%) as a yellow oil.

[0484] 1 H NMR(400MHz,CD3OD) δ=7.58-7.54(m,2H),7.13(d,J=8.0Hz,1H),4.58(br s,2H),3.65(br t,J=6.0Hz,2H),2.84(t,J=6.0Hz,2H),1.35(s,12H),1.19(br s,1H),1.22(s,9H).

[0485] [ka]

[0486] A 19th exemplary intermediate C, intermediate C-19, can be used to synthesize compounds of Formula I or Formula II, where R 1is a monosubstituted aryl. A mixture of paraformaldehyde (133 mg, 4.42 mmol, 122 μL, 10.0 equiv) and methyl alcohol (1.00 mL) was stirred at 60°C for 1 hour and then cooled to 0°C. To this mixture was added acetic acid (52.5 mg, 874 μmol, 0.05 mL, 1.98 equiv) and 2-(4-bromophenyl)pyrrolidine (100 mg, 442 μmol, 1.00 equiv). The mixture was stirred at room temperature for 1 hour, then sodium cyanoborohydride (83.4 mg, 1.33 mmol, 3.00 equiv) was added and stirred for an additional hour. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=3 / 1) to give 2-(4-bromophenyl)-1-methyl-pyrrolidine (100 mg, 413 μmol, 93.3% yield, 99.1% purity) as a white solid. LC-MS [M+H]: 240.1.

[0487] 1 H NMR(400MHz, CDCl3) δ=7.48-7.41(m,2H),7.26-7.21(m,2H),3.33-3.14(m,1H),3.02(t,J=8.4Hz,1H),2.29 (q,J=9.2Hz,1H),2.16(s,3H),2.06-1.89(m,1H),1.86-1.77(m,1H),1.76-1.69(m,2H).

[0488] A mixture of 2-(4-bromophenyl)-1-methyl-pyrrolidine (48.0 mg, 200 μmol, 1.00 equiv), bis(pinacolato)diboron (76.1 mg, 300 μmol, 1.50 equiv), potassium acetate (58.9 mg, 600 μmol, 3.00 equiv), and Pd(dppf)Cl (14.6 mg, 20.0 μmol, 0.10 equiv) in dioxane (1.00 mL) was purged with nitrogen and then stirred at 90° C. for 2 h. The mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 3 / 1) to give 1-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine (23.0 mg, 73.3 μmol, 36.7% yield, 91.5% purity) as a white solid. LC-MS [M+H]: 288.0.

[0489] [ka]

[0490] A twentieth exemplary intermediate C, intermediate C-20, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a monosubstituted aryl. A mixture of 2-(4-bromophenyl)pyrrolidine (50.0 mg, 221 μmol, 1.00 equiv.), di-tert-butyl dicarbonate (57.9 mg, 265 μmol, 1.20 equiv.), and dimethylaminopyridine (2.70 mg, 22.1 μmol, 0.10 equiv.) in tetrahydrofuran (1.00 mL) was purged with nitrogen and then stirred at 25 °C for 2 h. The mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate = 10 / 1) to give tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate (55.0 mg, 163 μmol, 73.6% yield, 96.5% purity) as a yellow oil. LC-MS [M-55]: 272.1.

[0491] A mixture of tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate (46.6 mg, 138 μmol, 1.00 equiv.), bis(pinacolato)diboron (52.5 mg, 207 μmol, 1.50 equiv.), potassium acetate (40.6 mg, 414 μmol, 3.00 equiv.), and Pd(dppf)Cl (10.1 mg, 13.8 μmol, 0.10 equiv.) in dioxane (1.00 mL) was purged with nitrogen and then stirred at 90° C. for 2 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 5 / 1) to give tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine-1-carboxylate (45.0 mg, 102 μmol, 74.3% yield, 85.0% purity) as a yellow solid. LC-MS [M-55]: 318.2.

[0492] 1 H NMR(400MHz,CDCl3) δ=7.75(br d,J=7.6Hz,2H),7.17(br d,J=7.6Hz,2H),4.80(br s,1H),3.63(br s,2H),2.32(br s, 1H), 1.98-1.75 (m, 3H), 1.58 (s, 9H), 1.35 (br s, 12H).

[0493] [ka]

[0494] A twenty-first exemplary intermediate C, intermediate C-21, can be used to synthesize compounds of Formula I or Formula II, where R 1is a monosubstituted heteroaryl. To a solution of 1-(4-bromophenyl)-4-chlorobutan-1-one (1.00 g, 3.82 mmol, 1.00 equiv) in methanol (13.0 mL) was added NaBH4 (300 mg, 7.93 mmol, 2.07 equiv) in small portions at room temperature. The mixture was stirred at room temperature for 2 hours and then quenched by the addition of water (10.0 mL). The mixture was diluted with dichloromethane (20 mL), and the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product, 1-(4-bromophenyl)-4-chlorobutan-1-ol (1.00 g, 3.79 mmol, 99.2% yield), as a pale yellow oil.

[0495] 1 H NMR (400MHz, CDCl3) δ=7.49(d,J=8.4Hz,2H),7.24(d,J=8.4Hz,2H),4.71(br t,J=6.0Hz,1H),3.54(s,2H),2.01-1.72(m,4H).

[0496] A solution of 1-(4-bromophenyl)-4-chlorobutan-1-ol (500 mg, 1.90 mmol, 1.00 equiv.) and t-BuOK (1.0 M in THF, 1.90 mL, 1.00 equiv.) was stirred at room temperature for 2 hours. The reaction was quenched with water and extracted with ether (2 × 20.0 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 2-(4-bromophenyl)tetrahydrofuran (420 mg, 1.85 mmol, 97.5% yield) as a white solid.

[0497] 1 H NMR(400MHz, CDCl3) δ=7.49-7.42(m,2H),7.24-7.18(m,2H),4.85(t,J=7.2Hz,1H),4.13-4.05(m,1 H),3.97-3.90(m,1H),2.38-2.27(m,1H),2.06-1.95(m,2H),1.80-1.70(m,1H).

[0498] To a mixture of 2-(4-bromophenyl)tetrahydrofuran (150 mg, 661 μmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (252 mg, 992 μmol, 1.50 equiv.), and potassium acetate (195 mg, 1.99 mmol, 3.01 equiv.) in dioxane (5.00 mL) was added Pd(dppf)Cl (48.3 mg, 66.0 μmol, 0.10 equiv.) The mixture was stirred at 105 °C for 1 h, cooled to room temperature, and filtered through a pad of Celite. The filtrate was concentrated to give a residue, which was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 2 / 1) to give 4,4,5,5-tetramethyl-2-(4-tetrahydrofuran-2-ylphenyl)-1,3,2-dioxaborolane (240 mg, 639 μmol, 96.8% yield, 73% purity) as a colorless oil. LC-MS [M+1]: 275.1.

[0499] 1 H NMR(400MHz, CDCl3) δ=7.78(d,J=8.4Hz,2H),7.34(d,J=7.6Hz,2H),4.92(t,J=7.2Hz,1H),4.17-4.06(m,1H), 4.00-3.90(m,1H),2.41-2.27(m,1H),2.09-1.91(m,2H),1.85-1.73(m,1H),1.35(s,12H).

[0500] [ka]

[0501] A 22nd exemplary intermediate C, intermediate C-22, can be used to synthesize compounds of Formula I or Formula II, where R 1is a monosubstituted aryl. To a cooled solution of 2-(4-bromophenyl)ethanamine (200 mg, 1.0 mmol, 155 μL, 1.00 equiv) in formalin (300 mg, 9.99 mmol, 275 μL, 10.0 equiv) was added HCOOH (5.00 mL), and the solution was stirred under nitrogen at 110 °C for 16 h. The reaction mixture was concentrated to give a residue. To the residue was added HCl (3N, 1.00 mL), and the mixture was washed with ethyl acetate (310 mL). The aqueous phase was basified with NaOH (10 N, 1.00 mL) to pH = 14 and then extracted with ethyl acetate (3 × 15.0 mL). The combined organic phases were washed with brine (2×15.0 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to give 2-(4-bromophenyl)-N,N-dimethyl-ethanamine (200 mg, 877 μmol, 87.7% yield) as a colorless oil.

[0502] 1 H NMR (400MHz, CDCl3) δ=7.40(d,J=8.4Hz,2H),7.09(d,J=8.4Hz,2H),2.73(d,J=8.4Hz,2H),2.56-2.48(m,2H),2.29(s,6H).

[0503] A mixture of 2-(4-bromophenyl)-N,N-dimethyl-ethanamine (160 mg, 701 μmol, 1.00 equiv), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (268 mg, 1.06 mmol, 1.50 equiv), Pd(dppf)Cl (51.2 mg, 70.0 μmol, 0.10 equiv), and potassium acetate (206 mg, 2.10 mmol, 3.00 equiv) in dioxane (8.00 mL) was purged with nitrogen and stirred at 100 °C for 1 h. The mixture was concentrated to give a residue, which was purified by preparative TLC (SiO, dichloromethane / methanol=10 / 1) to give N,N-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanamine (350 mg, crude) as a black oil. LC-MS [M+1]: 276.2.

[0504] [ka]

[0505] A 23rd exemplary intermediate C, intermediate C-23, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a monosubstituted aryl. To a solution of 1-bromo-4-iodo-benzene (200 mg, 707 μmol, 1.00 equiv.) and diethyl phosphite (97.6 mg, 707 μmol, 91.2 μL, 1.00 equiv.) in tetrahydrofuran (2.00 mL) was added Pd(OAc)2 (4.76 mg, 21.2 μmol, 0.03 equiv.), potassium acetate (9.02 mg, 91.9 μmol, 0.13 equiv.), DPPF (23.5 mg, 42.4 μmol, 0.06 equiv.), and triethylamine (107 mg, 1.06 mmol, 147 μL, 1.50 equiv.). The tube was flushed with nitrogen and stirred at 68 °C for 1 h. The mixture was concentrated in vacuo to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=1 / 1) to give 1-bromo-4-diethoxyphosphoryl-benzene (110 mg, 341 μmol, 48.2% yield, 90.8% purity) as a red solid. LC-MS [M+3]: 294.9.

[0506] 1 H NMR (400MHz, CDCl3) δ=7.73-7.57(m,4H),4.22-3.99(m,4H),1.32(t,J=7.2Hz,6H).

[0507] A solution of 1-bromo-4-diethoxyphosphoryl-benzene (100 mg, 341 μmol, 1.00 equiv.) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-1,3,2-dioxaborolane) (104 mg, 409 μmol, 1.20 equiv.) in dioxane (2.00 mL) was added to Pd(dppf)Cl (24.9 mg, 34.1 μmol, 0.10 equiv.) and acetic acid. Potassium (67.0 mg, 682 μmol, 2.00 equiv.) was added under a nitrogen atmosphere. The mixture was stirred at 100° C. for 2 hours and then concentrated in vacuo to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=1 / 1) to give 2-(4-diethoxyphosphorylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (55.0 mg, 162 μmol, 47.4% yield) as a red oil.

[0508] 1 H NMR (400MHz, CDCl3) δ=7.93-7.87(m,2H),7.85-7.76(m,2H),4.21-4.01(m,4H),1.36(s,12H),1.32(t,J=7.2Hz,6H).

[0509] [ka]

[0510] A 24th exemplary intermediate C, intermediate C-24, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl. To a solution of 2-(4-bromo-3-methyl-phenyl)pyrrolidine (500 mg, 2.08 mmol, 1.00 equiv.) in dichloromethane (5.00 mL), BocO (1.05 g, 4.79 mmol, 1.10 mL, 2.30 equiv.) and dimethylaminopyridine (25.4 mg, 208 μmol, 0.10 equiv.) were added. The mixture was stirred at 25 °C for 1 h, then filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 30 / 1 to 20 / 1) to give tert-butyl 2-(4-bromo-3-methyl-phenyl)pyrrolidine-1-carboxylate (600 mg, 84.7% yield) as a yellow oil.

[0511] 1 H NMR(400MHz,CD3OD) δ=7.46(br d,J=8.4Hz,1H),7.10(d,J=1.6Hz,1H),6.92(dd,J=1.6,8.0Hz,1H),4.73(br s,1H),3.65-3.51(m,2H),2.37(s,3H),2.34-2.27(m,1H),1.93-1.82(m,2H),1.82-1.73(m,1H),1.45(br s,3H),1.24-1.13(m,6H).

[0512] A mixture of 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (268 mg, 1.06 mmol, 1.20 equiv), tert-butyl 2-(4-bromo-3-methyl-phenyl)pyrrolidine-1-carboxylate (300 mg, 882 μmol, 1.00 equiv), Pd(dppf)Cl (64.1 mg, 88.2 μmol, 0.10 equiv), and potassium acetate (173 mg, 1.76 mmol, 2.00 equiv) in dioxane (3.00 mL) was purged with nitrogen, and the mixture was stirred at 100° C. for 1.5 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give tert-butyl 2-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine-1-carboxylate (260 mg, yield 76.1%) as a white solid.

[0513] 1 H NMR(400MHz,CDCl3) δ=7.68(br d,J=7.6Hz,1H),7.0-6.94(m,2H),4.98-4.66(m,1H),3.61(br s,2H),2.52(s,3H),2.36(br s,1H),1.93-1.76(m,3H),1.35(br s,12H),1.29-1.25(m 3H),1.21(br s,6H).

[0514] [ka]

[0515] A 25th exemplary intermediate C, intermediate C-25, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl. To a solution of 4-bromo-3-methyl-benzaldehyde (2.00 g, 10.1 mmol, 1.00 equiv.) in toluene (100 mL), TsOH-HO (191 mg, 1.00 mmol, 0.10 equiv.) and ethylene glycol (1.25 g, 20.1 mmol, 1.12 mL, 2.00 equiv.) were added. The mixture was stirred at 130 °C for 12 h and then cooled to room temperature. The pH was adjusted to 9 with DMAP and then concentrated in vacuo. The residue was purified by column chromatography (neutral Al2O3, petroleum ether / ethyl acetate = 1 / 0 to 100 / 1) to give 2-(4-bromo-3-methyl-phenyl)-1,3-dioxolane (2.30 g, 9.46 mmol, 94.2% yield) as a yellow oil.

[0516] 1 H NMR(400MHz, CDCl3) δ=7.54(d,J=8.4Hz,1H),7.36(d,J=1.6Hz,1H),7.17(dd,J=2.4,8.0Hz,1H),5.76(s,1H),4.15-4.08(m,2H),4.08-4.00(m,2H),2.42(s,3H).

[0517] A mixture of 2-(4-bromo-3-methyl-phenyl)-1,3-dioxolane (2.50 g, 10.3 mmol, 1.00 equiv), Pin2B2 (3.39 g, 13.4 mmol, 1.30 equiv), KOAc (2.02 g, 20.6 mmol, 2.00 equiv), and Pd(dppf)Cl (376 mg, 514 μmol, 0.05 equiv) in dioxane (30.0 mL) was purged with N and then stirred at 100° C. for 6 h. The mixture was filtered and concentrated in vacuo. The residue was purified by column chromatography (neutral Al2O3, petroleum ether / ethyl acetate = 1 / 0 to 50 / 1) to give 2-[4-(1,3-dioxolan-2-yl)-2-methyl-phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.60 g, 8.96 mmol, 87.1% yield) as a green oil.

[0518] 1H NMR (400MHz, CDCl3) δ=7.78(d,J=7.6Hz,1H),7.29-7.25(m,2H),5.81(s,1H),4.15-4.08(m,2H),4.07-4.01(m,2H),2.56(s,3H),1.35(s,12H).

[0519] [ka]

[0520] A 26th exemplary intermediate C, intermediate C-26, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a monosubstituted heteroaryl. A mixture of tert-butyl N-[(5-bromopyrimidin-2-yl)methyl]carbamate (100 mg, 347 μmol, 1.00 equiv.), Pin2B2 (176 mg, 694 μmol, 2.00 equiv.), KOAc (68.1 mg, 694 μmol, 2.00 equiv.), and Pd(dppf)Cl2 (25.4 mg, 34.7 μmol, 0.10 equiv.) in dioxane (2.00 mL) was purged with N2 and then stirred at 100 °C for 2 h. The reaction mixture was filtered and concentrated in vacuo to give [2-[(tert-butoxycarbonylamino)methyl]pyrimidin-5-yl]boronic acid (100 mg, crude) as a red oil. LC-MS [M-55]: 198.1.

[0521] [ka]

[0522] A 27th exemplary intermediate C, intermediate C-27, can be used to synthesize compounds of Formula I or Formula II, where R 1is a bicyclic heteroaryl. A mixture of 6-bromo-3,4-dihydro-2H-isoquinolin-1-one (150 mg, 664 μmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (253 mg, 996 μmol, 1.50 equiv.), Pd(dppf)Cl2 (48.55 mg, 66.35 μmol, 0.10 equiv.), and potassium acetate (195 mg, 1.99 mmol, 3.00 equiv.) in dioxane (5.00 mL) was purged with nitrogen and then stirred at 95 °C for 2 h. The reaction mixture was cooled and filtered through a pad of Celite, and the filtrate was concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 3 / 1 to 1 / 1) to give 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-isoquinolin-1-one (180 mg, 659 μmol, 99.32% yield) as an off-white solid. LC-MS [M+1]: 274.1.

[0523] 1 H NMR(400MHz, CDCl3) δ=8.07(d,J=8.0Hz,1H),7.80(d,J=7.6Hz,1H),7.67(s,1H),6.04(s,1H),3.57(dt,J=2.8,6.4Hz,2H),3.02(t,J=6.4Hz,2H),1.37(s,12H).

[0524] [ka]

[0525] A 28th exemplary intermediate C, intermediate C-28, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted bicyclic heteroaryl. To a suspension of NaH (79.1 mg, 60%, 1.98 mmol, 2.00 equiv) in DMF (3.00 mL) at 0 °C was added dropwise a solution of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-isoquinolin-1-one (270 mg, 989 μmol, 1.00 equiv) in DMF. The mixture was stirred at this temperature for an additional 30 min, and then CHI (1.40 g, 9.89 mmol, 615 μL, 10.0 equiv) was added dropwise at 0 °C. The mixture was warmed to room temperature and stirred for 3 h. The reaction was quenched by the addition of 20.0 mL of water, followed by extraction with diethyl ether (3 × 30.0 mL). The combined organic layers were washed with water (50.0 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1-one (300 mg, crude) as a black oil. LC-MS [M+1]: 288.1.

[0526] 1 H NMR(400MHz,CHCl3-d) δ=8.07(d,J=7.6Hz,1H),7.77(d,J=7.6Hz,1H),7.63(s,1H),3.56(t,J=6.8Hz,2H),3.16(s,3H),3.01(t,J=6.8Hz,2H),1.36(s,12H).

[0527] [ka]

[0528] A 29th exemplary intermediate C, intermediate C-29, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl. A mixture of 5-bromo-2-(bromomethyl)benzonitrile (100 mg, 364 μmol, 1.00 equiv.), diisopropylethylamine (141 mg, 1.09 mmol, 190 μL, 3.00 equiv.), and dimethylamine (2.00 M, 1.82 mL, 10.0 equiv.) in dimethylformamide (2.00 mL) was stirred at room temperature for 3 hours. The reaction mixture was quenched with 5.00 mL of water and extracted with ethyl acetate (5.00 mL × 3). The combined organic layers were washed with brine (3.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate=3 / 1) to give 5-bromo-2-[(dimethylamino)methyl]benzonitrile (50.0 mg, 209 μmol, 57.5% yield) as a yellow oil. LC-MS [M+1]: 239.2.

[0529] 1 H NMR (400MHz, CDCl3) δ=7.77(d,J=2.0Hz,1H),7.69(dd,J=2.0,8.4Hz,1H),7.46(d,J=8.4Hz,1H),3.59(s,2H),1.59(br s,6H).

[0530] A mixture of 5-bromo-2-[(dimethylamino)methyl]benzonitrile (30.0 mg, 125 μmol, 1.00 equiv.), bis(pinacolato)diboron (63.7 mg, 251 μmol, 2.00 equiv.), potassium acetate (36.9 mg, 376 μmol, 3.00 equiv.), and Pd(dppf)Cl.CHCl (3.07 mg, 3.76 μmol, 0.03 equiv.) in dioxane (1.00 mL) was purged with nitrogen and then stirred at 90 °C for 4 h. The mixture was filtered and concentrated under reduced pressure to give the crude product, 2-[(dimethylamino)methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (40.0 mg) as a black oil, which was used in the next step without further purification.

[0531] [ka]

[0532] A 30th exemplary intermediate C, intermediate C-30, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted heteroaryl. To a solution of Ir(COD)2(OMe)2 (5.00 mg, 7.54 μmol, 0.02 equiv.) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (68.5 mg, 535 μmol, 77.7 μL, 1.50 equiv.) in n-pentane (0.50 mL) was added 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine (5.00 mg, 18.6 μmol, 0.05 equiv.), and the mixture was stirred at 25 °C for 20 min. To this mixture was added a solution of methyl 1-methylpyrazole-3-carboxylate (50.0 mg, 357 μmol, 1.00 equiv.) in n-pentane (0.50 mL) and THF (0.50 mL), and the mixture was stirred at 25 °C for 24 h. The mixture was partitioned between ethyl acetate (10.0 mL) and water (10.0 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to give the crude product, methyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-3-carboxylate (50.0 mg, 113 μmol, 31.6% yield, 60.0% purity) as a black oil.

[0533] 1 H NMR (400MHz, CDCl3) δ=7.28(s,1H),4.15(s,3H),3.93(s,3H),1.35(s,12H).

[0534] [ka]

[0535] A 31st exemplary intermediate C, intermediate C-31, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl, with one substituent having two hydrogens replaced with deuterium. To a solution of 4-bromo-N,N,3-trimethyl-benzamide (500 mg, 2.07 mmol, 1.00 equiv) in THF (5.00 mL) was added lithium tetradeuterioalumanide (235 mg, 6.20 mmol, 3.00 equiv). The mixture was stirred at 0 °C for 1.5 h, then warmed to room temperature and stirred for an additional 1 h. The reaction mixture was cooled to 0 °C and diluted with THF (10.0 mL). The reaction was quenched by the dropwise addition of deuterium oxide (0.24 mL), 15% NaOD solution in deuterium oxide (0.24 mL) at 0 °C, and finally deuterium oxide (0.72 mL). The mixture was stirred at room temperature for 10 minutes, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, dichloromethane / methanol = 50 / 1 to 20 / 1) to give 1-(4-bromo-3-methyl-phenyl)-1,1-dideuterio-N,N-dimethyl-methanamine (220 mg, crude) as a brown oil. LC-MS [M+1]: 232.1.

[0536] [ka]

[0537] A 32nd exemplary intermediate C, intermediate C-32, can be used to synthesize compounds of Formula I or Formula II, where R 1is a disubstituted aryl. To a solution of 4-bromo-3-methyl-aniline (4.00 g, 21.5 mmol, 1.00 equiv.) in concentrated sulfuric acid (40.0 mL) and water (40.0 mL), sodium nitrite (1.62 g, 23.4 mmol, 1.09 equiv.) was added at 0 °C, and the mixture was stirred for 90 min. Subsequently, potassium thiocyanate (2.82 g, 29.0 mmol, 2.82 mL, 1.35 equiv.) and copper thiocyanato (6.80 g, 55.9 mmol, 2.60 equiv.) in water (16.0 mL) were added to the suspension at 5 °C. After stirring at 5 °C for 2 h, the mixture was stirred at room temperature for 10 h. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether) to give (4-bromo-3-methyl-phenyl)thiocyanate (2.00 g, 8.77 mmol, 40.8% yield) as a yellow oil.

[0538] 1 H NMR (400MHz, CDCl3) δ=7.52(d,J=8.4Hz,1H),7.33(d,J=2.4Hz,1H),7.14(dd,J=2.4,8.4Hz,1H),2.36(s,3H).

[0539] A mixture of (4-bromo-3-methyl-phenyl)thiocyanate (500 mg, 2.19 mmol, 1.00 equiv.), trimethyl(trifluoromethyl)silane (1.00 g, 7.04 mmol, 3.21 equiv.), and tetrabutylammonium fluoride (1.00 M, 701 μL, 0.32 equiv.) in tetrahydrofuran (1.00 mL) was stirred at room temperature for 4 h. The mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether) to give 1-bromo-2-methyl-4-(trifluoromethylsulfanyl)benzene (450 mg, 1.66 mmol, 75.7% yield) as a colorless oil.

[0540] 1H NMR (400MHz, CDCl3) δ=7.59(d,J=8.0Hz,1H),7.52(d,J=2.0Hz,1H),7.34(dd,J=2.4,8.0Hz,1H),2.44(s,3H).

[0541] A mixture of 1-bromo-2-methyl-4-(trifluoromethylsulfanyl)benzene (450 mg, 1.66 mmol, 1.00 equiv) and m-chloroperbenzoic acid (2.02 g, 85.0%, 9.96 mmol, 6.00 equiv) in chloroform (10.0 mL) was stirred at room temperature for 2 h. The mixture was heated to 60 °C and stirred for an additional 10 h. The mixture was diluted with saturated sodium bicarbonate (15.0 mL) and extracted with dichloromethane (5.00 mL × 3). The combined organic phase was washed with sodium sulfite (5.00 mL) and brine (5.00 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO 2 , petroleum ether) to give 1-bromo-2-methyl-4-(trifluoromethylsulfonyl)benzene (400 mg, 1.32 mmol, 79.5% yield) as a white solid.

[0542] 1 H NMR (400MHz, CDCl3) δ=7.88(d,J=2.0Hz,1H),7.86(d,J=8.4Hz 1H),7.71(dd,J=2.4,8.4Hz,1H),2.55(s,3H).

[0543] A mixture of 1-bromo-2-methyl-4-(trifluoromethylsulfonyl)benzene (100 mg, 330 μmol, 1.00 equiv.), bis(pinacolato)diboron (168 mg, 660 μmol, 2.00 equiv.), potassium acetate (97.1 mg, 990 μmol, 3.00 equiv.), and Pd(dppf)Cl (24.1 mg, 33.0 μmol, 0.10 equiv.) in dioxane (2.00 mL) was purged with nitrogen and then stirred at 90° C. for 2 h. The mixture was filtered and concentrated under reduced pressure to give 4,4,5,5-tetramethyl-2-[2-methyl-4-(trifluoromethylsulfonyl)phenyl]-1,3,2-dioxaborolane (200 mg, crude) as a black solid, which was used in the next step without further purification.

[0544] [ka]

[0545] A 33rd exemplary intermediate C, intermediate C-33, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a monosubstituted heteroaryl. To a solution of diisopropylamine (243 mg, 2.40 mmol, 339 μL, 1.30 equiv) in THF (4.00 mL) was added n-BuLi (2.50 M, 961 μL, 1.3 equiv) dropwise at −78 °C, and the reaction was then stirred at −78 °C for 30 minutes. 1-Cyclopropylpyrazole (200 mg, 1.85 mmol, 1.00 equiv) was added, and the reaction was stirred at −78 °C for 1 hour. Tributyl(chloro)stannane (602 mg, 1.85 mmol, 498 μL, 1.00 equiv) was added dropwise, and the reaction was stirred at −78 °C for an additional 30 minutes. The reaction mixture was partitioned between ethyl acetate (5.00 mL) and saturated ammonium chloride (5.00 mL). The organic phase was separated, washed with brine (5.00 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give tributyl-(2-cyclopropylpyrazol-3-yl)stannane (1.00 g, crude) as a colorless oil, which was used in the next step without further purification.

[0546] 1 H NMR(400MHz, CDCl3) δ=7.51(d,J=1.6Hz,1H),6.32(d,J=1.6Hz,1H),3.54-3.49(m,1H),1.61 -1.50(m,6H),1.37-1.31(m,6H),1.21-1.13(m,6H),0.97-0.89(m,13H).

[0547] [ka]

[0548] A 34th exemplary intermediate C, intermediate C-34, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a disubstituted heteroaryl. To a solution of 4-chloropyridazin-3-ol (300 mg, 2.30 mmol, 1.00 equiv) and methyl iodide (3.26 g, 23.0 mmol, 1.43 mL, 10.0 equiv) in dioxane (6.00 mL) was added silver oxide (533 mg, 2.30 mmol, 1.00 equiv). The mixture was stirred at 60 °C for 5 h. The mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate = 1 / 1) to give 4-chloro-2-methyl-pyrazin-3-one (110 mg, 761 μmol, 33.1% yield) as a yellow solid.

[0549] 1 H NMR (400MHz, DMSO-d6) δ=7.87(d,J=4.4Hz,1H),7.78(d,J=4.4Hz,1H),3.72(s,3H).

[0550] To a solution of 4-chloro-2-methyl-pyrazin-3-one (110 mg, 761 μmol, 1.00 equiv.) and hexamethylditin (998 mg, 3.04 mmol, 631 μL, 4.00 equiv.) in dioxane (2.00 mL) was added Pd(PPh3)4 (87.93 mg, 76.09 μmol, 0.10 equiv.) under nitrogen. The mixture was stirred at 110 °C for 2 h, then filtered and concentrated in vacuo. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate = 1 / 1) to give 2-methyl-4-trimethylstannyl-pyrazin-3-one (130 mg, 476 μmol, 62.6% yield) as a white solid.

[0551] 1 H NMR (400MHz, CD3OD) δ=7.79(d,J=3.6Hz,1H),7.51(d,J=3.6Hz,1H),3.73(s,3H),0.32(s,9H).

[0552] [ka]

[0553] A 35th exemplary intermediate C, intermediate C-35, can be used to synthesize compounds of Formula I or Formula II, where R 1is a trisubstituted heteroaryl. To a solution of 2,5-dibromo-3-fluoropyridine (0.50 g, 1.96 mmol, 1.00 equiv) in THF (10.0 mL) was added n-BuLi (2.50 M, 1.18 mL, 1.50 equiv) dropwise at −65°C. The mixture was stirred at −65°C for 0.5 h, followed by the addition of N-isopropylpropan-2-amine (397 mg, 3.92 mmol, 554 μL, 2.00 equiv) in one portion and stirring at this temperature for an additional 30 min. To this mixture was added methyl iodide (334 mg, 2.35 mmol, 147 μL, 1.20 equiv), and the mixture was stirred at −65°C for 1 h. The reaction mixture was quenched by the addition of saturated aqueous NH4Cl (10.0 mL), and the resulting mixture was extracted with ethyl acetate (20.0 mL × 3). The combined organic phase was washed with brine (30.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC (acidic condition) to give 2,5-dibromo-3-fluoro-4-methyl-pyridine (300 mg, 1.12 mmol, 56.9% yield) as a yellow solid. LC-MS [M+1]: 269.7.

[0554] To a solution of 2,5-dibromo-3-fluoro-4-methyl-pyridine (0.80 g, 2.97 mmol, 1.00 equiv.) in THF (10.0 mL) was added n-BuLi (2.5 M, 1.19 mL, 1.00 equiv.) at −65° C. The resulting mixture was stirred for 0.5 h, followed by the dropwise addition of DMF (326 mg, 4.46 mmol, 343 μL, 1.50 equiv.). After stirring at −65° C. for an additional 30 min, the reaction mixture was quenched with saturated aqueous NH4Cl (5.00 mL), and the resulting mixture was extracted with ethyl acetate (30.0 mL × 2). The combined organic phases were washed with brine (30.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 100 / 1) to give 5-bromo-3-fluoro-4-methyl-pyridine-2-carbaldehyde (300 mg, 1.38 mmol, yield 46.3%) as a yellow solid.

[0555] 1 H NMR (400MHz, CDCl3) δ=10.20(d,J=0.8Hz,1H),8.69(s,1H),2.48(d,J=2.4Hz,3H).

[0556] To a solution of 5-bromo-3-fluoro-4-methyl-pyridine-2-carbaldehyde (300 mg, 1.38 mmol, 1.00 equiv.) in Toluene (10.0 mL), TsOH-HO (26.2 mg, 138 μmol, 0.10 equiv.) and ethylene glycol (171 mg, 2.75 mmol, 14 μL, 2.00 equiv.) were added. The mixture was stirred at 120 °C for 2 h. The reaction mixture was concentrated under reduced pressure to give the crude residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 100 / 1) to give 5-bromo-2-(1,3-dioxolan-2-yl)-3-fluoro-4-methyl-pyridine (250 mg, 954 μmol, 69.3% yield) as a colorless oil.

[0557] 1 H NMR (400MHz, CDCl3) δ=8.49(s,1H),6.13(s,1H),4.32-4.20(m,2H),4.14-4.04(m,2H),2.39(d,J=2.4Hz,3H).

[0558] To a solution of 5-bromo-2-(1,3-dioxolan-2-yl)-3-fluoro-4-methyl-pyridine (450 mg, 1.72 mmol, 1.00 equiv) in EtO (10.0 mL) was added n-BuLi (2.5 M, 756 μL, 1.10 equiv) dropwise at −70° C. The mixture was stirred at −70° C. for 0.5 h, followed by the addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (639 mg, 3.43 mmol, 701 μL, 2.00 equiv). The mixture was stirred at −70° C. for 1 h and then quenched with saturated aqueous NH4Cl (10 mL). The mixture was extracted with DCM (30 mL × 3), and the combined organic phases were washed with brine (50.0 mL × 2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude solid. The crude material was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate = 1 / 1) to give [6-(1,3-dioxolan-2-yl)-5-fluoro-4-methyl-3-pyridyl]boronic acid (220 mg, 940 μmol, 54.8% yield, 97.0% purity) as a pale yellow oil. LC-MS [M+1]: 228.0.

[0559] [ka]

[0560] A 36th exemplary intermediate C, intermediate C-36, can be used to synthesize compounds of Formula I or Formula II, where R 1 is a monosubstituted aryl. To a solution of 3-phenylmorpholine (500 mg, 3.06 mmol, 1.00 equiv) in tetrahydrofuran (5.00 mL) was added triethylamine (512 μL, 3.68 mmol, 1.20 equiv) and di-tert-butyl dicarbonate (669 mg, 3.06 mmol, 704 μL, 1.00 equiv). The mixture was stirred at 20 °C for 1 h. The mixture was concentrated under reduced pressure to give a residue (1.30 g, crude), which was used directly in the next step.

[0561] tert-Butyl 3-phenylmorpholine-4-carboxylate (580 mg, 2.20 mmol, 1.00 equiv) in dichloromethane (6.00 mL) was added to a solution of phenyl-λ 3 Iodanediyl bis(2,2,2-trifluoroacetate) (1.04 g, 2.42 mmol, 1.10 equiv.) and iodine (559 mg, 2.20 mmol, 444 μL, 1.00 equiv.) were added. The reaction mixture was stirred at 20 °C for 2 h. The mixture was diluted with sodium bicarbonate solution (20 mL) and extracted with dichloromethane (10 mL × 3). The combined organic layers were washed with saturated sodium thiosulfate solution (20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give tert-butyl 3-(4-iodophenyl)morpholine-4-carboxylate (260 mg, 668 μmol, 30.3% yield) as a white oil.

[0562] 1 H NMR(400MHz,DMSO-d6) δ=7.73(br d,J=8.4Hz,2H),7.16(br d,J=8.0Hz,2H),4.92(br s,1H),4.20(br d,J=12.0Hz,1H),3.84-3.78(m,1H),3.76-3.65(m,2H),3.50-3.40(m,1H),3.04-2.93(m,1H),1.39(s,9H).

[0563] A mixture of tert-butyl 3-(4-iodophenyl)morpholine-4-carboxylate (260 mg, 668 μmol, 1.00 equiv.), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (254 mg, 1.00 mmol, 1.50 equiv.), potassium acetate (131 mg, 1.34 mmol, 2.00 equiv.), and Pd(dppf)Cl (48.9 mg, 66.8 μmol, 0.10 equiv.) in dioxane (2.00 mL) was purged and then stirred under a nitrogen atmosphere at 100° C. for 2 h. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give tert-butyl 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine-4-carboxylate (100 mg, 257 μmol, 38.5% yield) as a white oil.

[0564] 1 H NMR(400MHz,DMSO-d6) δ=7.67(d,J=8.0Hz,2H),7.37(d,J=7.6Hz,2H),4.98(br s,1H),4.29-4.23(m,1H),3.86-3.66(m,3H),3.51-3.42(m,1H),3.07-2.96(m,1H),1.41-1.38(m,9H),1.30(s,12H).

[0565] [Table 1-1]

[0566] [Table 1-2]

[0567] [Table 1-3]

[0568] The following examples are intended to illustrate more specific embodiments of the present invention, but are not intended to limit the scope of the invention. [Example]

[0569] Example 1 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)benzenesulfonamide

[0570] [ka]

[0571] A mixture of Intermediate A-1 (30.0 mg, 80.0 μmol, 1.00 equiv.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (45.3 mg, 160 μmol, 2.00 equiv.), sodium bicarbonate (20.2 mg, 240 μmol, 9.33 μL, 3.00 equiv.), and Pd(dppf)Cl (5.85 mg, 8.00 μmol, 0.10 equiv.) in dioxane (1.00 mL) and water (0.20 mL) was degassed and purged with nitrogen three times, then stirred under a nitrogen atmosphere at 100 °C for 2 h. The mixture was filtered and concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC [column: Waters Xbridge 150 * Purification with 25 5 μl of hexane (25% hexanes, 5% CO₂O, 10% HCl; mobile phase: Phase A - water (10 mM NH₄HCO₃), Phase B - ACN [B%: 25%-55%] gave the title compound 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)benzenesulfonamide (18.3 mg, 37.0 μmol, 46.3% yield, 91.2% purity) as an off-white solid. LC-MS [M+1]: 452.0.

[0572] 1H NMR(400MHz,DMSO-d6) δ=10.03(s,1H),9.41(s,1H),8.77(br t,J=4.8Hz,1H),8.44(s,1H),7.96(d,J=8.4Hz,2H),7.76(d,J=8.4Hz,2H),7.46(br s,2H),6.93(t,J=9.2Hz,1H),6.67(dd,J=3.6,8.4Hz,1H),4.76(br d,J=4.8Hz,2H),4.53(t,J=8.4Hz,2H),3.32-3.28(m,2H).

[0573] Examples 2-14 were prepared according to the procedures specified in Example 1, using the general reaction schemes and intermediates described herein.

[0574] [Table 2-1]

[0575] [Table 2-2]

[0576] [Table 2-3]

[0577] [Table 2-4]

[0578] [Table 2-5]

[0579] Example 15 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide

[0580] [ka]

[0581] Step A: A mixture of 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (130 mg, 346 μmol, 1.00 equiv.), methyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-3-carboxylate (230 mg, 866 μmol, 2.50 equiv.), bis(tri-tert-butylphosphine)palladium(0) (35.4 mg, 69.3 μmol, 0.20 equiv.), and potassium carbonate (239 mg, 1.73 mmol, 5.00 equiv.) in dioxane (3.00 mL) and water (0.50 mL) was degassed and purged with nitrogen three times. The mixture was then stirred at 90° C. under a nitrogen atmosphere for 1 hour. After completion of the reaction, the reaction mixture was filtered and concentrated in vacuo to give a residue, which was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 3 / 1 to 1 / 1) to give the product methyl 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxylate (160 mg, crude) as a pale yellow solid.

[0582] 1 H NMR(400MHz,DMSO-d6) δ=10.03(d,J=1.2Hz,1H),9.16(d,J=1.2Hz,1H),8.88(s,1H),8.46(s,1H),6.98(s,1H),6.93(t,J=8.8Hz,1H),6.6 8(dd,J=4.0,8.8Hz,1H),4.77(d,J=5.2Hz,2H),4.54(t,J=8.8Hz,2H),3.83(s,3H),3.76(s,3H),3.39-3.33(m,2H).

[0583] Step B: To a solution of methyl 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxylate (140 mg, 322 μmol, 1.00 equiv) in methanol (5.00 mL) was added sodium hydroxide (1.00 M in water, 967 μL, 3.00 equiv) until the pH was adjusted to >12. The mixture was stirred at 50° C. for 1 hour. After completion of the reaction, the mixture was acidified with hydrochloric acid solution (1.00 M in water) to pH=7. During this period, a white precipitate formed and the suspension was filtered, and the filter cake was collected and dried under vacuum to give the crude product 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (120 mg, 285 μmol, 88.6% yield) as a yellow solid, which was used without further purification.

[0584] 1 H NMR(400MHz,DMSO-d6) δ=12.72(s,1H),10.03(d,J=1.2Hz,1H),9.16(d,J=1.2Hz,1H),8.87(t,J=5.2Hz,1H),8.46(s,1H),6.91(m,2 H),6.68(dd,J=4.0,8.8Hz,1H),4.77(d,J=4.8Hz,2H),4.54(t,J=8.8Hz,2H),3.74(s,3H),3.30-3.29(m,2H).

[0585] Example 15: To a solution of 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (30.0 mg, 71.4 μmol, 1.00 equiv.) and dimethylamine hydrochloride (25.3 mg, 214 μmol, 36.0 μL, 3.00 equiv., hydrochloride salt) in DMF (1.00 mL) was added diisopropylethylamine (46.1 mg, 357 μmol, 62.0 μL, 5.00 equiv.) and HATU (40.70 mg, 107 μmol, 1.50 equiv.), and the mixture was stirred at 25° C. for 1 hour. After completion of the reaction, the mixture was triturated with water (20.0 mL). The suspension was filtered and the filter cake was dried under reduced pressure to give the crude product. The crude product was purified by preparative HPLC [column: Phenomenex Synergi C18 150 × 25 × 10 μm; mobile phase: Phase A - water (0.05% HCl), Phase B - ACN; B%: 18%-48%] to give 5-[5-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]pyrido[3,4-d]pyridazin-8-yl]-N,N,1-trimethyl-pyrazole-3-carboxamide (12.4 mg, 27.6 μmol, yield 38.7%, purity 99.7%) as a yellow solid. LC-MS [M+1]: 448.0.

[0586] 1 H NMR(400MHz,CD3OD) δ=10.19(d,J=1.2Hz,1H),9.31(d,J=1.2Hz,1H),8.81(s,1H),6.88-6.77(m,2H),6.60(dd,J=4. 0,8.8Hz,1H),4.87(s,2H),4.54(t,J=8.8Hz,2H),3.77(s,3H),3.42-3.33(m,5H),3.09(s,3H).

[0587] Example 16 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carbonitrile

[0588] [ka]

[0589] Step A: To a solution of 5-[5-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]pyrido[3,4-d]pyridazin-8-yl]-1-methyl-pyrazole-3-carboxylic acid (Example 15, Step B; 50.0 mg, 119 μmol, 1.00 equiv.) and ammonium chloride (19.0 mg, 355 μmol, 2.99 equiv.) in DMF (2.00 mL) was added diisopropylethylamine (50.0 mg, 387 μmol, 67.4 μL, 3.25 equiv.) and HATU (67.8 mg, 178 μmol, 1.50 equiv.). The mixture was stirred at 25° C. for 1 hour. After completion of the reaction, the reaction mixture was triturated with water (20.0 mL). The suspension was filtered, and the filter cake was collected and concentrated under reduced pressure to give the crude product 5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxamide (40.0 mg, 95.4 μmol, 80.2% yield) as a yellow solid.

[0590] 1 H NMR(400MHz,DMSO-d6) δ=10.02(d,J=1.2Hz,1H),9.17(d,J=1.2Hz,1H),8.85(t,J=5.2Hz,1H),8.45(s,1H),7.57(s,1H),7.26(s,1H),7.00-6.89(m ,1H),6.83(s,1H),6.68(dd,J=4.0,8.4Hz,1H),4.76(d,J=4.8Hz,2H),4.53(t,J=8.8Hz,2H),3.73(s,3H),3.33-3.31(m,3H).

[0591] Example 16: To a mixture of 55-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-1-methyl-1H-pyrazole-3-carboxamide (30.0 mg, 71.53 μmol, 1.00 equiv) and triethylamine (146 mg, 1.44 mmol, 201 μL, 20.2 equiv) in anhydrous THF (0.50 mL) was added trifluoroacetic anhydride (135 mg, 643 μmol, 89.4 μL, 8.99 equiv) at 0° C. The resulting mixture was warmed to 25° C. and stirred for 0.5 hours. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (15.0 mL × 3). The combined organic layers were washed with brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give N-(8-(3-cyano-1-methyl-1H-pyrazol-5-yl)pyrido[3,4-d]pyridazin-5-yl)-2,2,2-trifluoro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)acetamide (40.0 mg). This compound was dissolved in methanol (0.80 mL), and potassium carbonate (20.0 mg, 144 μmol, 2.00 equiv.) in water (0.20 mL) was added to the methanol solution. The mixture was stirred at 15 °C for 30 minutes, and then the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [column: Phenomenex Synergi C18 150 × 30 mm × 4 μm; mobile phase: Phase A - water (0.05% HCl, Phase B - ACN) B%: 40%-60%] to give 5-[5-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]pyrido[3,4-d]pyridazin-8-yl]-1-methyl-pyrazole-3-carbonitrile (20.3 mg, 50.3 μmol, yield 70.4%, purity 99.5%) as a yellow solid. LC-MS [M+1]: 402.2.

[0592] 1H NMR(400MHz,CD3OD) δ=10.24(d,J=1.2Hz,1H),9.32(d,J=0.8Hz,1H),8.84(s,1H),7.08(s,1H),6.88(t,J=9.2Hz,1H),6 .67(dd,J=4.0,8.8Hz,1H),4.94(s,2H),4.61(t,J=8.8Hz,2H),3.87(s,3H),3.44(t,J=8.8Hz,2H).

[0593] Example 17 N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)pyrido[3,4-d]pyridazin-5-amine

[0594] [ka]

[0595] Step A: tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (57.5 mg, 160 μmol, 1.20 equiv.), 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (50.0 mg, 160 μmol, 1.20 equiv.). A mixture of Pd(dppf)Cl (33.6 mg, 399 μmol, 15.5 μL, 3.00 equiv), sodium bicarbonate (33.6 mg, 399 μmol, 15.5 μL, 3.00 equiv), and Pd(dppf)Cl (9.75 mg, 13.3 μmol, 0.10 equiv) in dioxane (1.00 mL) and water (0.20 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 100° C. for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=0 / 1) to give tert-butyl 6-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (60.0 mg, 85.3% yield) as a yellow solid. LC-MS [M+1]: 527.9.

[0596] Step B: To a solution of tert-butyl 6-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (50.0 mg, 94.8 μmol, 1.00 equiv) in DCM (2.00 mL) was added trifluoroacetic acid (924 mg, 8.10 mmol, 0.60 mL, 85.5 equiv). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was adjusted to pH 9 with aqueous potassium carbonate in water (3.00 mL) and extracted with dichloromethane / methanol = 10 / 1 (5.00 mL × 3). The combined organic layers were washed with brine (5.00 mL × 2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(1,2,3,4-tetrahydroisoquinolin-6-yl)pyrido[3,4-d]pyridazin-5-amine (30.0 mg, crude) as a yellow solid.

[0597] 1 H NMR(400MHz,CD3OD) δ=9.81(d,J=1.2Hz,1H),9.38(d,J=1.2Hz,1H),8.38(s,1H),7.27-7.21,(m,3H),6.90-6.78(m,1H),6.61(dd,J=3.6,8.4Hz,1 H),4.84-4.83(m,1H),4.55(t,J=8.8Hz,2H),4.06(s,2H),3.36(t,J=8.8Hz,2H),3.16(t,J=6.0Hz,2H),2.93(t,J=6.0Hz,2H).

[0598] Example 17: A mixture of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(1,2,3,4-tetrahydroisoquinolin-6-yl)pyrido[3,4-d]pyridazin-5-amine (30.0 mg, 70.2 μmol, 1.00 equiv), acetic acid (4.21 mg, 70.2 μmol, 4.01 μL, 1.00 equiv), and paraformaldehyde (90.0 mg) in methanol (1.00 mL) was stirred at 45° C. for 0.5 hours, and then sodium triacetoxyborohydride (44.6 mg, 210 μmol, 3.00 equiv) was added to the mixture. The reaction was stirred at 45° C. under a nitrogen atmosphere for 1 hour. The mixture was then filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative HPLC [column: Xtimate C18 10u 250 mm × 80 mm; mobile phase: Phase A - water (0.05% ammonia hydroxide v / v), Phase B - ACN; B%: 40%-60%] to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)pyrido[3,4-d]pyridazin-5-amine (7.17 mg, 22.6% yield, 97.8% purity) as a yellow solid. LC-MS [M+1]: 442.3.

[0599] 1 H NMR(400MHz,DMSO-d6) δ=9.99(d,J=0.8Hz,1H),9.40(d,J=1.2Hz,1H),8.59(t,J=5.2Hz,1H),8.36(s,1H),7.28-7.23(m,2H),7.22-7.18(m,1H),6.92(t ,J=8.8Hz,1H),6.67(dd,J=4.0,8.8Hz,1H),4.75(d,J=4.8Hz,2H),4.53(t,J=8.4Hz,2H),3.56(s,2H),3.29-3.28(m,2H),2.90(br t,J=5.6Hz,2H),2.64(br t,J=5.6Hz,2H),2.37(s,3H).

[0600] Example 18 8-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine

[0601] [ka]

[0602] Step A: To a solution of 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (100 mg, 267 μmol, 1.00 equiv) in THF (1.00 mL) was added DMAP (3.26 mg, 26.7 μmol, 0.10 equiv) and di-tert-butyl dicarbonate (87.3 mg, 400 μmol, 91.9 μL, 1.50 equiv). The mixture was stirred at 80° C. for 30 minutes and then concentrated in vacuo to give a residue. The residue was triturated with petroleum ether (5.00 mL) to give tert-butyl (8-bromopyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (90.0 mg, 190 μmol, yield 71.0%) as a yellow solid.

[0603] 1 H NMR(400MHz, CDCl3) δ=9.80(d,J=1.2Hz,1H),9.33(d,J=0.4Hz,1H),8.92(s,1H),6.63-6.57(m,1H),6.55-6.50(m,1H),5.23(s,2H),4.58(t,J=8.8Hz,2H),3.35(br t,J=8.4Hz,2H),1.33(s,9H).

[0604] To a solution of tert-butyl (8-bromopyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (90.0 mg, 189 μmol, 1.00 equiv.) in dioxane (1.00 mL) was added Pd(PPh3)2Cl2 (13.3 mg, 18.9 μmol, 0.10 equiv.) and tributyl(1-ethoxyvinyl)tin (68.4 mg, 189 μmol, 63.9 μL, 1.00 equiv.) under a nitrogen atmosphere. The mixture was stirred at 100 °C for 1 h. After this time, potassium fluoride solution (3.00 mL) was added and the mixture was stirred at 25 °C for 15 min. The aqueous phase was extracted with ethyl acetate (3.00 mL × 2). The combined organic phase was washed with brine (3.00 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl (8-(1-ethoxyvinyl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (85.0 mg, 182 μmol, 96.2% yield) as a yellow solid.

[0605] 1 H NMR(400MHz, CDCl3) δ=9.93(d,J=1.2Hz,1H),9.36(d,J=1.2Hz,1H),8.85(s,1H),6.64-6.58(m,1H),6.54-6.50(m,1H),5.25 (s,2H),4.65(d,J=2.8Hz,1H),4.60(d,J=2.8Hz,1H),4.56(t,J=8.8Hz,2H),4.13-4.06(m,2H),3.34(br t,J=8.2Hz,2H),1.33(s,9H),0.93(t,J=7.2Hz,3H).

[0606] Step B: To a solution of tert-butyl (8-(1-ethoxyvinyl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (85.0 mg, 182 μmol, 1.00 equiv.) in DMF (1.00 mL) and water (0.50 mL), pyridinium p-toluenesulfonate (91.6 mg, 364 μmol, 2.00 equiv.) was added, and the mixture was stirred at 25° C. for 1 hour. The residue was poured into water (6.00 mL) and stirred for 15 minutes. The aqueous phase was extracted with ethyl acetate (6.00 mL × 3). The combined organic phase was washed with brine (6.00 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl (8-acetylpyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (70.0 mg, 160 μmol, 87.6% yield) as a yellow solid.

[0607] 1 H NMR(400MHz,DMSO-d6) δ=10.34(d,J=1.2Hz,1H),9.51(s,1H),9.32(s,1H),6.79-6.69(m,1H),6.57(dd,J=4.0,8. 8Hz, 1H), 5.23 (s, 2H), 4.52 (t, J=8.8Hz, 2H), 3.30-3.25 (m, 2H), 2.80 (s, 3H), 1.26 (s, 9H).

[0608] A solution of tert-butyl (8-acetylpyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (70.0 mg, 194 μmol, 1.00 equiv.) in DMF-DMA (1.00 mL) was stirred at 100° C. for 1 h. The mixture was concentrated in vacuo to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=0 / 1) to give tert-butyl (E)-(8-(3-(dimethylamino)acryloyl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (70.0 mg, 142 μmol, 88.8% yield) as a yellow solid.

[0609] 1 H NMR(400MHz,CDCl3) δ=10.20(br s,1H),9.37(d,J=1.2Hz,1H),9.00(s,1H),7.84(br s,1H),6.63-6.56(m,1H),6.55-6.49(m,1H),5.57(d,J=12.4Hz,1H),5.27(s,2H),4.57(t,J=8.8Hz,2H),3.36(br t,J=8.8Hz,2H),3.24(s,3H),2.99(s,3H),1.32(s,9H).

[0610] Step C: To a solution of tert-butyl (E)-(8-(3-(dimethylamino)acryloyl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (70.0 mg, 142 μmol, 1.00 equiv) in ethanol (1.00 mL) was added 2-hydrazinyl-N,N-dimethylethan-1-amine (17.6 mg, 170 μmol, 1.20 equiv). The mixture was stirred at 80° C. for 1 h, and then the mixture was concentrated in vacuo to provide tert-butyl (8-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (35.0 mg, 65.6 μmol, crude) as a yellow solid, which was used without further purification.

[0611] Example 18: To a solution of tert-butyl (8-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)pyrido[3,4-d]pyridazin-5-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (20.0 mg, 37.5 μmol, 1.00 equiv) in DCM (1.00 mL) was added TFA (0.30 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was adjusted to pH=8 with ammonium hydroxide and concentrated in vacuo to provide a residue. The residue was purified by preparative HPLC (column: Waters Xbridge 150 × 25 mm × 5 μm; mobile phase: Phase A - water (10 mM NH4HCO3), Phase B - ACN; B%: 20%-50%) to give 8-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (9.00 mg, 20.5 μmol, yield 54.7%, purity 98.7%) as a yellow solid. LC-MS [M+1]: 434.3.

[0612] 1H NMR(400MHz, CDCl3) δ=9.47(s,1H),9.27(s,1H),8.41(s,1H),7.70(d,J=1.2Hz,1H),6.88(t,J=9.2Hz,1H),6.68(dd,J=4.0,8.8Hz,1H),6.37(d,J=1.6Hz,1H),6.19(br s,1H),4.89(d,J=5.6Hz,2H),4.63(t,J=8.8Hz,2H),4.05(t,J=6.4Hz,2H),3.42(t,J=8.8Hz,2H),2.64(t,J=6.4Hz,2H),1.95(s,6H).

[0613] Example 19 N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-4-((methylamino)methyl)phenyl)pyrido[3,4-d]pyridazin-5-amine

[0614] [ka]

[0615] Step A: A mixture of 8-bromo-N-[(5-fluoro-2,3-dihydrobenzofuran-4-ylmethyl]pyrido[3,4-d]pyridazin-5-amine (60.0 mg, 152 μmol, 1.00 equiv.), (4-formyl-2-methylphenyl)boronic acid (40.0 mg, 244 μmol, 1.60 equiv.), sodium bicarbonate (25.6 mg, 305 μmol, 11.9 μL, 2.00 equiv.), and Pd(dppf)Cl (11.2 mg, 15.2 μmol, 0.10 equiv.) in dioxane (1.50 mL) and water (0.30 mL) The mixture was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 100 °C for 1 hour. The reaction mixture was cooled and filtered through a pad of Celite, and the filtrate was evaporated to give a residue. The residue was purified by preparative TLC (SiO, dichloromethane / methanol = 10 / 1) to give 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl-3-methylbenzaldehyde (60.0 mg, 124 μmol, 81.7% yield, 86.0% purity) as a yellow solid.

[0616] Example 19: To a solution of 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl-3-methylbenzaldehyde (20.0 mg, 41.5 μmol, 1.00 equiv), methylamine (2.00 M in THF, 104 μL, 5.00 equiv), and titanium(IV) isopropoxide (35.4 mg, 125 μmol, 36.8 μL, 3.00 equiv) in 1,2-dichloromethane (1.00 mL) was added acetic acid (2.49 mg, 41.50 μmol, 2.37 μL, 1.00 equiv). The pH was adjusted to 6-7 by adding HCl, and the reaction mixture was stirred for 30 minutes. Sodium triacetoxyborohydride (17.6 mg, 83.0 μmol, 2.00 equiv.) was then added, and the reaction mixture was stirred at 25°C for 1.5 hours. The reaction mixture was diluted with ammonium chloride solution (20.0 mL), the suspension was filtered, and the filtrate was extracted with ethyl acetate (20.0 mL x 2). The combined organic layers were washed with saturated aqueous sodium chloride solution (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC [column: Phenomenex Purification with Synergi C18 150 × 25 × 10 μm; mobile phase: Phase A - water (0.05% HCl), Phase B - ACN; B%: 20%-40% gave N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-4-((methylamino)methyl)phenyl)pyrido[3,4-d]pyridazin-5-amine (11.6 mg, 24.9 μmol, 60.0% yield, hydrochloride salt) as a yellow solid. LC-MS [M+1]: 430.3.

[0617] 1H NMR(400MHz,CD3OD) δ=10.28(s,1H),9.01(d,J=0.8Hz,1H),8.67(s,1H),7.59(s,1H),7.54-7.48(m,1H),7.42(d,J=8.0Hz,1H),6.92-6.84(m,1H),6. 67(dd,J=4.0,8.8Hz,1H),4.87-4.97(m,2H),4.60(t,J=8.8Hz,2H),4.28(s,2H),3.43(t,J=8.8Hz,2H),2.79(s,3H),2.20(s,3H).

[0618] Example 20 8-(4-((ethylamino)methyl)-2-methylphenyl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine

[0619] [ka]

[0620] To a solution of 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)-3-methylbenzaldehyde (Example 19, Step A; 30.0 mg, 72.4 μmol, 1.00 equiv.), ethylamine (16.3 mg, 362 μmol, 5.00 equiv.), and tetraisopropoxytitanium (61.7 mg, 217 μmol, 64.1 μL, 3.00 equiv.) in 1,2-dichloromethane (1.00 mL), the pH was adjusted to 5-6 by adding acetic acid (8.69 mg, 145 μmol, 8.28 μL, 2.00 equiv.), and the reaction mixture was stirred at 40° C. for 0.5 h. After this time, sodium triacetoxyborohydride (30.7 mg, 145 μmol, 2.00 equiv) was added and the reaction mixture was stirred at 40° C. for an additional 1 h. The reaction mixture was diluted with ammonium chloride solution (20.0 mL), the suspension was filtered, and the filtrate was extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (30.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [Column: Waters Xbridge 150 × 25 mm × 5 μm; Mobile phase: Phase A - water (10 mM NH₄HCO₃), Phase B - ACN; B%: 27%-51%] to give 8-(4-((ethylamino)methyl)-2-methylphenyl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyridazin-5-amine (8.50 mg, 19.1 μmol, 26.4% yield, 99.6% purity) as a white solid. LC-MS [M+1]: 444.4.

[0621] 1H NMR(400MHz,CD3OD) δ=9.83(d,J=1.6Hz,1H),8.90(d,J=1.2Hz,1H),8.29(s,1H),7.40(s,1H), 7.33(d,J=7.6Hz,1H),7.23(d,J=7.6Hz,1H),6.89-6.81(m,1H),6.62(dd,J =4.0,8.8Hz,1H),4.79-4.83(m,2H),4.56(t,J=8.8Hz,2H),3.84(s,2H),3. 37(t,J=8.8Hz,2H),2.77-2.68(m,2H),2.10(s,3H),1.19(t,J=7.2Hz,3H).

[0622] Example 21 N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(-methyl-4-((methylamino)methyl)phenyl)pyrido[3,4-d]pyridazin-5-amine

[0623] [ka]

[0624] Step A: A mixture of 8-bromo-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]pyrido[3,4-d]pyridazin-5-amine (40.0 mg, 106 μmol, 1.00 equiv), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde (49.5 mg, 213 μmol, 2.00 equiv), Pd(dppf)Cl (7.80 mg, 10.7 μmol, 0.10 equiv), and sodium bicarbonate (26.9 mg, 320 μmol, 12.4 μL, 3.00 equiv) in dioxane (2.00 mL) and water (0.40 mL) was degassed and then heated to 80° C. under a nitrogen atmosphere for 12 h. The reaction mixture was poured into water (10.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic phase was washed with brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to give 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)benzaldehyde (40.0 mg, crude) as a brown solid, which was used in the next step without further purification. LC-MS [M+1]: 401.1.

[0625] Example 21: Methylamine (2.00 M in THF, 374 μL, 10 equiv) was added to a mixture of 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyridazin-8-yl)benzaldehyde (30.0 mg, 75.0 μmol, 1.00 equiv) and AcOH (1 drop) in THF (1 mL), and the reaction mixture was stirred at 15° C. for 30 minutes. After this time, sodium triacetoxyborohydride (47.6 mg, 225 μmol, 3.00 equiv) was added to the mixture, and the mixture was degassed and purged with nitrogen three times and stirred under a nitrogen atmosphere at 15° C. for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated and purified by preparative HPLC [Column: Phenomenex Synergi C18 150 × 30 mm × 4 μm; Mobile phase: Phase A - water (0.05% HCl), Phase B - ACN; B%: 17%-37%] to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(-methyl-4-((methylamino)methyl)phenyl)pyrido[3,4-d]pyridazin-5-amine (6.00 mg, 14.4 μmol, 19.3% yield, 100% purity) as a yellow solid. LC-MS[M+1]: 416.1.

[0626] 1 H NMR(400MHz,CD3OD) δ=10.24(s,1H),9.47(d,J=1.2Hz,1H),8.83(s,1H),7.79-7.67(m,4H),6.94-6.84(m,1H),6.68(dd,J =4.0,8.8Hz,1H),4.93(s,2H),4.62(t,J=8.8Hz,2H),4.34(s,2H),3.43(t,J=8.8Hz,2H),2.81(s,3H).

[0627] Example 22 8-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[4,3-d]pyrimidin-5-amine

[0628] [ka]

[0629] A mixture of Intermediate A-2 (50.0 mg, 118 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (52.6 mg, 237 μmol, 2.00 equiv.), Pd(dppf)Cl (8.67 mg, 11.8 μmol, 0.10 equiv.), and sodium carbonate (37.7 mg, 355 μmol, 3.00 equiv.) in dioxane (2.00 mL) and water (0.40 mL) was degassed and then heated at 80 °C under a N atmosphere for 12 h. The reaction mixture was poured into water (10.0 mL) and extracted with dichloromethane / methanol (10 / 1) (20.0 mL × 3). The organic phase was washed with brine (10.0 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to give a residue which was purified by preparative HPLC (column: Xtimate C18 150 * 25mm * Purification with HPLC (5 μm; mobile phase: [water (0.05% ammonia hydroxide v / v)-ACN]; B%: 28%-58%, 10 min) gave the title compound 8-(1,3-dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[4,3-d]pyrimidin-5-amine (16.0 mg, 40.0 μmol, 33.8% yield, 97.6% purity) as a yellow solid. LC-MS [M+1]: 391.3.

[0630] 1 H NMR(400MHz,DMSO-d6) δ=9.89(s,1H),9.29(s,1H),8.79(br s,1H),8.31(s,1H),6.93(t,J=9.6Hz,1H),6.68(dd,J=4.0,8.8Hz,1H),6.10(s,1H),4.75(br d,J=2.4Hz,2H),4.54(t,J=8.8Hz,2H),3.52(s,3H),3.32-3.29(m,2H),2.19(s,3H).

[0631] Examples 23-25 ​​were prepared following the procedures specified in Example 22 and using the general reaction scheme and intermediates described herein.

[0632] [Table 3]

[0633] Example 26 N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-4-((methylamino)methyl)phenyl)pyrido[4,3-d]pyrimidin-5-amine

[0634] [ka]

[0635] Step A: A mixture of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-iodopyrido[4,3-d]pyrimidin-5-amine (100 mg, 237 μmol, 1.00 equiv), (4-formyl-2-methylphenyl)boronic acid (77.7 mg, 474 μmol, 2.00 equiv), sodium carbonate (75.3 mg, 711 μmol, 3.00 equiv), and Pd(dppf)Cl (17.3 mg, 23.7 μmol, 0.10 equiv) in dioxane (2.00 mL) and water (0.40 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 80 °C for 2 h. The mixture was diluted with ethyl acetate (5.00 mL), washed with brine (5.00 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, dichloromethane / methanol = 10 / 1) to give 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[4,3-d]pyrimidin-8-yl)-3-methylbenzaldehyde (80.0 mg, 167 μmol, 70.7% yield, 86.7% purity) as a yellow solid. LC-MS [M+1]: 415.0.

[0636] 1 H NMR(400MHz,DMSO-d6) δ=9.97(s,1H),9.23(s,1H),8.71(br t,J=5.2Hz,1H),8.32(s,1H),8.26(s,1H),7.84(s,1H),7.79(d,J=7.6Hz,1H), 7.46(d,J=7.6Hz,1H),6.99-6.89(m,1H),6.69(dd,J=4.0,8.8Hz,1H),4.76(br d,J=4.8Hz,2H),4.55(t,J=8.8Hz,2H),3.31-3.30(m,2H),2.13(s,3H).

[0637] Example 26: A mixture of 4-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[4,3-d]pyrimidin-8-yl)-3-methylbenzaldehyde (40.0 mg, 96.5 μmol, 1.00 equiv) and methylamine (2.00 M in THF, 483 μL, 10.0 equiv) was adjusted to pH=5 with acetic acid (105 mg, 1.75 mmol, 0.10 mL, 18.1 equiv). The mixture was stirred at 40° C. for 30 minutes, then sodium triacetoxyborohydride (61.4 mg, 290 μmol, 3.00 equiv) was added, and the mixture was stirred at 15° C. under a nitrogen atmosphere for 2.5 hours. The mixture was diluted with ethyl acetate (5.00 mL), washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide a residue. The residue was purified by preparative HPLC [column: Waters Xbridge 150 * Purification with 25 ml of 5 mL of 100 mL of 1000 kJ / ml hexane (mobile phase: Phase A - water (10 mM NH4HCO3), Phase B - ACN; B%: 32%-59%) afforded N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methyl-4-((methylamino)methyl)phenyl)pyrido[4,3-d]pyrimidin-5-amine (11.8 mg, 26.5 μmol, 27.4% yield, 96.2% purity) as a yellow solid. LC-MS [M+1]: 430.2.

[0638] 1H NMR(400MHz,DMSO-d6) δ=9.86(s,1H),9.20(s,1H),8.55(t,J=5.2Hz,1H),8.18(s,1H),7.22(s,1H) ,7.18-7.07(m,2H),6.97-6.87(m,1H),6.67(dd,J=3.6,8.4Hz,1H),4.73(br d,J=4.8Hz,2H),4.53(t,J=8.8Hz,2H),3.65(s,2H),3.34-3.33(m,2H),2.30(s,3H),2.00(s,3H).

[0639] Example 27 8-(1,3-Dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-(methylthio)pyrido[4,3-d]pyrimidin-5-amine

[0640] [ka]

[0641] Step A:2 To a solution of 2-(methylthio)pyrido[4,3-d]pyrimidin-5(6H)-one (500 mg, 2.59 mmol, 1.00 equiv.) and potassium carbonate (716 mg, 5.18 mmol, 2.00 equiv.) in acetonitrile (100 mL) was added NIS (757 mg, 3.36 mmol, 1.30 equiv.) in portions. The resulting suspension was heated to 75 °C for 3 h. The reaction was cooled, filtered, washed with acetonitrile, and the cake was collected. A minimal amount of water was added, the mixture was sonicated, filtered, and the resulting solid was dried in vacuo to give 8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidin-5(6H)-one (900 mg, crude) as a yellow solid. LC-MS [M+1]: 319.9.

[0642] 1 H NMR (400MHz, DMSO-d6) δ=8.95(s,1H),8.88(s,1H),8.42(s,1H),8.16(s,1H),2.63-2.51(m,6H).

[0643] To a solution of 8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidin-5(6H)-one (200 mg, 627 μmol, 1.00 equiv.), benzyltriethylammonium chloride (286 mg, 1.25 mmol, 2.00 equiv.), and DIPEA (105 mg, 815 μmol, 142 μL, 1.30 equiv.) in acetonitrile (10.0 mL) was slowly added phosphoryl chloride (288 mg, 1.88 mmol, 174 μL, 3.00 equiv.). The reaction mixture was then heated to 80 °C and stirred for 14 h. The suspension was cooled, diluted with ethyl acetate (5.00 mL), and slowly poured into ice-water (10 mL). The resulting brown suspension was separated and the organic layer was concentrated to give 5-chloro-8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidine (200 mg, 592 μmol, 94.5% yield) as a yellow solid. LC-MS [M+1]: 337.9.

[0644] Step B: To a solution of 5-chloro-8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidine (200 mg, 592 μmol, 1.00 equiv.) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (119 mg, 712 μmol, 1.20 equiv.) in DMF (3.00 mL) was added DIEA (153 mg, 1.18 mmol, 206 μL, 2.00 equiv.). The mixture was stirred at 80° C. for 1 h, cooled, triturated in water (20.0 mL), and collected by filtration. The solid was evaporated to remove the solvent and water to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidin-5-amine (250 mg, 534 μmol, 90.1% yield) as a yellow solid.

[0645] 1H NMR(400MHz,DMSO-d6) δ=9.46(s,1H),8.66-8.52(m,2H),6.91(t,J=9.2Hz,1H),6.66(dd,J=4.0,8.8Hz,1H),4.66(br d,J=4.8Hz,2H),4.50(br t,J=8.8Hz,2H),3.24(br t,J=8.8Hz,2H),2.65(s,3H).

[0646] Example 27: To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-iodo-2-(methylthio)pyrido[4,3-d]pyrimidin-5-amine (250 mg, 534 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (291 mg, 1.31 mmol, 2.45 equiv.), and sodium carbonate (170 mg, 1.60 mmol, 3.00 equiv.) in dioxane (4.00 mL) and water (0.80 mL) was added Pd(dppf)Cl (39.1 mg, 53.4 μmol, 0.10 equiv.). The reaction solution was purged with nitrogen three times, heated to 80 °C, and stirred for 1.5 hours. The reaction mixture was cooled and evaporated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3 / 1 to 1 / 1) to give the crude product. The crude product was purified by preparative HPLC (Phenomenex Synergi C18 150 * 30mm * Purification with 4 μm; mobile phase: (A - water (0.05% HCl) and B - ACN; B%: 22%-42%) gave the title compound 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-(methylthio)pyrido[4,3-d]pyrimidin-5-amine (35.0 mg, 76.2 μmol, 83.1% yield, 95% purity) as a yellow solid. LC-MS [M+1]: 437.1.

[0647] 1H NMR(400MHz,DMSO-d6) δ=9.72(s,1H),9.08(s,1H),8.23(s,1H),7.01-6.87(m,1H),6.69(dd,J=4.0,8.8Hz,1H),6.18(s,1H),4.75(br d,J=4.4Hz,2H),4.53(t,J=8.8Hz,2H),3.58(s,3H),3.30(br t,J=8.8Hz,2H),2.47(s,3H),2.21(s,3H).

[0648] Example 28 8-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxypyrido[4,3-d]pyrimidin-5-amine

[0649] [ka]

[0650] Example 28: Example 26 (25.0 mg, 54.4 μmol, 1.00 equiv.) was added to a solution of sodium methoxide (15.0 mg, 278 μmol, 5.10 equiv.) in methanol (1.50 mL), and the reaction was stirred at 70° C. for 12 h. The reaction mixture was evaporated, and the residue was purified by preparative HPLC (Phenomenex Synergi C18 150 * 30mm * Purification with 4 μm; mobile phase: (A - water (0.05% HCl) and B - ACN; B%: 22%-42%) gave the title compound 8-(1,3-dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxypyrido[4,3-d]pyrimidin-5-amine (18.2 mg, 42.9 μmol, 78.9% yield, 99.2% purity) as a yellow solid. LC-MS [M+1]: 421.2.

[0651] 1H NMR(400MHz,DMSO-d6) δ=9.90(s,1H),9.47(s,1H),8.16(s,1H),7.01-6.86(m,1H),6.71(dd,J=4.0,8.8Hz,1H),6.21(s,1H),4.80(br d,J=4.0Hz,2H),4.54(t,J=8.8Hz,2H),3.93(s,3H),3.62(s,3H),3.31(t,J=8.8Hz,2H),2.22(s,3H).

[0652] Example 29 4-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine

[0653] [ka]

[0654] A mixture of 4-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (Intermediate A-3, 110 mg, 294 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (165 mg, 743 μmol, 2.53 equiv.), sodium bicarbonate (74.1 mg, 882 μmol, 34.3 μL, 3.00 equiv.), and Pd(dppf)Cl (21.5 mg, 29.4 μmol, 0.10 equiv.) in dioxane (0.50 mL) and water (0.10 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred at 95 °C under a nitrogen atmosphere for 2 h. The reaction mixture was filtered and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, dichloromethane / methanol = 1 / 0 to 10 / 1) to give the crude product. The crude product was purified by preparative HPLC (Phenomenex Synergi C18 150 * 30mm *Further purification with 4 μm; mobile phase (A - water (0.05% HCl) and B - ACN; B%: 22%-42%) afforded the title compound 4-(1,3-dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (55.5 mg, 143 μmol, 48.5% yield, 100% purity) as a yellow solid. LC-MS [M+1]: 390.3.

[0655] 1 H NMR(400MHz,DMSO-d6) δ=10.17(s,1H),9.66( s,1H),8.67(d,J=6.8Hz,1H),8.40(s,1H),7.63(d,J=6.4Hz,1H),6.94(t,J=8.8Hz,1H),6.70(dd,J=4.0,8.8Hz,1H),6.25(s,1H),4.80(br d,J=4.4Hz,2H),4.54(br t,J=8.8Hz,2H),3.57(s,3H),3.34(t,J=8.8Hz,2H),2.24(s,3H).

[0656] Examples 30-31 were prepared according to the procedures specified in Example 29, using the general reaction scheme and intermediates described herein.

[0657] [Table 4]

[0658] Example 32 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide

[0659] [ka]

[0660] Process A: A mixture of 4-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (Intermediate A-3, 200 mg, 534 μmol, 1.00 equiv.), methyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-3-carboxylate (213 mg, 802 μmol, 1.50 equiv.), potassium carbonate (369 mg, 2.67 mmol, 5.00 equiv.), and bis(tri-tert-butylphosphine)palladium(0) (27.3 mg, 53.5 μmol, 0.10 equiv.) in dioxane (5.00 mL) and water (1.00 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred at 80° C. under a nitrogen atmosphere for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give methyl 5-[1-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]-2,7-naphthyridin-4-yl]-1-methyl-pyrazole-3-carboxylate (300 mg, crude) as a brown solid. The crude product was used without further purification. LC-MS [M+1]: 434.2.

[0661] Step B: A mixture of methyl 5-[1-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]-2,7-naphthyridin-4-yl]-1-methyl-pyrazole-3-carboxylate (280 mg, 646 μmol, 1.00 equiv.) and lithium hydroxide (46.4 mg, 1.94 mmol, 3.00 equiv.) in THF (10.0 mL) and water (3.00 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 25 ° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (250 mg, crude) as a brown solid. LC-MS[M+1]: 420.2.

[0662] Example 32: A mixture of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (100 mg, 238 μmol, 1.00 equiv), DIEA (108 mg, 835 μmol, 145 μL, 3.50 equiv), and HATU (181 mg, 477 μmol, 2.00 equiv) in DMF (1.00 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 25° C. for 0.5 h. Dimethylamine (2.00 M in THF, 596 μL, 5.00 equiv) was then added, and the mixture was stirred under a nitrogen atmosphere at 25° C. for 1.5 h. The reaction mixture was quenched with 10.0 mL of water and extracted with ethyl acetate (15.0 mL × 3). The combined organic layers were washed with brine (15.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [Column: Phenomenex Gemini C18 150 × 25 mm × 10 μm; Mobile phase: Phase A - water (10 mM NH4HCO3), Phase B - ACN]; B%: 25%-55%] to give the title compound 5-[1-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]-2,7-naphthyridin-4-yl]-N,N,1-trimethyl-pyrazole-3-carboxamide (12.3 mg, 27.3 μmol, 11.4% yield, 98.9% purity) as a white solid. LC-MS [M+1]: 447.1.

[0663] 1 H NMR(400MHz,DMSO-d6) δ=9.71(s,1H),8.63(d,J=5.6Hz,2H),8.17(s,1H),7.22(d,J=6.0Hz,1H),6.92(t,J=9.2Hz,1H),6.70-6.62(m,2H),4.76(br d,J=4.8Hz,2H),4.53(t,J=8.8Hz,2H),3.66(s,3H),3.34(s,3H),3.30-3.27(s,2H),3.00(s,3H).

[0664] Example 33 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide

[0665] [ka]

[0666] Step A: A mixture of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (Example 32, Step B; 130 mg, 310 μmol, 1.00 equiv), DIEA (140 mg, 1.08 mmol, 189 μL, 3.50 equiv), and HATU (236 mg, 620 μmol, 2.00 equiv) in DMF (1.00 mL) was degassed and purged with nitrogen three times, and the mixture was stirred under a nitrogen atmosphere at 25° C. for 0.5 h. Ammonium chloride (82.9 mg, 1.55 mmol, 5.00 equiv) was then added, and the mixture was stirred at 25° C. for 1.5 h. The reaction mixture was diluted with 10.0 mL of water and extracted with ethyl acetate (15.0 mL × 3), and the combined organic layers were washed with brine (15.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxamide (160 mg, crude) as a white solid, which was used in the next step without further purification. LC-MS [M+1]: 419.4.

[0667] Example 33: To a solution of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxamide (50.0 mg, 120 μmol, 1.00 equiv) and TEA (121 mg, 1.19 mmol, 166 μL, 10.0 equiv) in THF (2.00 mL) at 0° C. was added TFAA (125 mg, 597 μmol, 83.1 μL, 5.00 equiv) and the reaction was stirred at 25° C. for 1.5 h. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (15.0 mL × 3), and the combined organic layers were washed with brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give N-[4-(5-cyano-2-methyl-pyrazol-3-yl)-2,7-naphthyridin-1-yl]-2,2,2-trifluoro-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]acetamide (60.0 mg, crude) as a yellow solid. To a solution of N-[4-(5-cyano-2-methyl-pyrazol-3-yl)-2,7-naphthyridin-1-yl]-2,2,2-trifluoro-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]acetamide (60.0 mg, 121 μmol, 1.00 equiv) in methanol (0.80 mL) was added a solution of potassium carbonate (33.4 mg, 242 μmol, 2.00 equiv) in water (0.20 mL). The mixture was stirred at 30° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (hydrochloric acid condition) to give the title compound 5-[1-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamino]-2,7-naphthyridin-4-yl]-1-methyl-pyrazole-3-carbonitrile (13.6 mg, 31.1 μmol, yield 25.8%, purity 91.7%) as a white solid. LC-MS [M+1]: 401.1.

[0668] 1H NMR(400MHz,DMSO-d6) δ=10.2(s,1H),9.68(br s,1H),8.67(d,J=6.4Hz,1H),8.47(s,1H),7.62(d,J=6.4Hz,1H),7.20(s,1H),6.94(t,J=9.6Hz,1H),6.70(dd,J=3.6,8.4Hz,1H),4.80(br d,J=4.4Hz,2H),4.54(t,J=8.8Hz,2H),3.75(s,3H),3.34(br t,J=8.4Hz,2H).

[0669] Example 34 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine

[0670] [ka]

[0671] A mixture of intermediate A-4 (150 mg, 371 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (206 mg, 928 μmol, 2.50 equiv.), Pd(dppf)Cl (27.8 mg, 38.0 μmol, 0.01 equiv.), and sodium bicarbonate (93.8 mg, 1.12 mmol, 43.4 μL, 3.01 equiv.) in dioxane (3.50 mL) and water (0.50 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 100 °C for 1 h. The reaction mixture was cooled and filtered through a pad of Celite. The filtrate was evaporated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 5 / 1 to 3 / 1) to give the title compound 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (90.0 mg, 215 μmol, yield 57.8%) as an off-white solid.

[0672] 1 H NMR(400MHz, CDCl3) δ=8.93(s,1H),7.96(s,1H),6.91-6.83(m,1H),6.67(dd,J=4.0,8.8Hz,1H),6.63(s,1H),6.10(s,1H),5.94(s, 1H), 4.86(d,J=5.6Hz,2H),4.62(t,J=8.8Hz,2H),3.99(s,1H),3.63(s,3H),3.42(t,J=8.8Hz,2H),2.35(s,3H).

[0673] Example 35 5-(1,3-Dimethylamino-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-3(2H)-one

[0674] [ka]

[0675] A mixture of 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (80.0 mg, 191 μmol, 1.00 equiv.) and pyridine; hydrochloride (110 mg, 954 μmol, 5.00 equiv.) was heated at 130° C. for 0.5 h. The reaction was triturated with water (5.0 mL) to form a white precipitate. The suspension was filtered, and the filter cake was collected and dried under vacuum to give the crude product. The crude product was purified by preparative HPLC (Phenomenex Synergi C18 150 * 30mm *Purification with 4 μm; mobile phase: (A - water (0.05% HCl) and B - ACN; B%: 22%-42%) gave the title compound 5, 5-(1,3-dimethylamino-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-3(2H)-one (31.8 mg, 76.3 μmol, 40.0% yield, 97.3% purity) as a yellow solid. LC-MS [M+1]: 406.2.

[0676] 1 H NMR(400MHz,DMSO-d6) δ=10.07(s,1H),9.37(br d,J=6.8Hz,1H),7.53(s,1H),7.02(t,J=8.8Hz,1H),6.80(dd,J=4.0,8.8Hz,1H),6.21(s,1H), 5.92(s,1H),4.79(s,2H),4.59(t,J=8.8Hz,2H),3.60(s,3H),3.34-3.24(m,2H),2.23(s,3H).

[0677] Examples 36-41 were prepared following the procedures specified in Examples 34 and 35, using the general reaction schemes and intermediates described herein.

[0678] [Table 5-1]

[0679] [Table 5-2]

[0680] Example 42 4-(1,3-Dimethylamino-1H-pyrazol-5-yl)-6-ethoxy-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine

[0681] [ka]

[0682] Step A: A mixture of 5-(1,3-dimethyl-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-3(2H)-one (Example 35, 200 mg, 493 μmol, 1.00 equiv), DMAP (6.03 mg, 49.3 μmol, 0.10 equiv), DIEA (128 mg, 987 μmol, 172 μL, 2.00 equiv), and di-tert-butyl dicarbonate (215 mg, 987 μmol, 227 μL, 2.00 equiv) in THF (10.0 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 60° C. for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure to give tert-butyl 8-((tert-butoxycarbonyl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-5-(1,3-dimethyl-1H-pyrazol-5-yl)-3-oxo-2,7-naphthyridine-2(3H)-carboxylate (200 mg, 330 μmol, 66.9% yield) as a white solid.

[0683] A mixture of tert-butyl 8-((tert-butoxycarbonyl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-5-(1,3-dimethyl-1H-pyrazol-5-yl)-3-oxo-2,7-naphthyridine-2(3H)-carboxylate (200 mg, 330 μmol, 1.00 equiv.) and potassium carbonate (91.3 mg, 660 μmol, 2.00 equiv.) in methanol (5.00 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 25° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative TLC (silicon dioxide, petroleum ether / ethyl acetate=1 / 1) to give tert-butyl (4-(1,3-dimethyl-1H-pyrazol-5-yl)-6-oxo-6,7-dihydro-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (120 mg, 237 μmol, yield 71.9%) as a yellow solid. LC-MS [M+1]: 506.3.

[0684] To a solution of tert-butyl (4-(1,3-dimethyl-1H-pyrazol-5-yl)-6-oxo-6,7-dihydro-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (60.0 mg, 119 μmol, 1.00 equiv) and iodoethane (185 mg, 1.19 mmol, 94.9 μL, 10.0 equiv) in toluene (2.00 mL) was added silver oxide (82.5 mg, 666 μmol, 11.0 μL, 5.61 equiv). The mixture was stirred at 110° C. for 12 hours. The reaction mixture was then filtered and concentrated under reduced pressure to provide a residue. The residue was purified by TLC (silicon dioxide, petroleum ether / ethyl acetate=2 / 1) to give tert-butyl (4-(1,3-dimethyl-1H-pyrazol-5-yl)-6-ethoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (20.0 mg, 37.5 μmol, yield 31.6%) as a yellow solid.

[0685] 1 H NMR(400MHz,CDCl3) δ=8.96(s,1H),8.29(s,1H),6.68(s,1H),6.60(t,J=8.4Hz,1H),6.51(dd,J=3.6,8.4Hz,1H),6.21(s,1H),5.22(br s,2H),4.53(br t,J=8.4Hz,2H),4.43-4.37(m,2H),3.62(s,3H),3.34-3.26(m,2H),2.37(s,3H),1.42(t,J=7.2Hz,3H),1.37(s,9H). LC-MS[M+1]:534.6.

[0686] Example 42: A mixture of tert-butyl (4-(1,3-dimethyl-1H-pyrazol-5-yl)-6-ethoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (10.0 mg, 18.7 μmol, 1.00 equiv.) and trifluoroacetic acid (154 mg, 1.35 mmol, 100 μL, 72.1 equiv.) in DCM (1.00 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 25° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [Phenomenex Synergi C18 150 * 30mm * Purification with 4 μm column chromatography (mobile phase [A - water (0.05% HCl) and B: ACN; B%: 24%-44%)] afforded the title compound 4-(1,3-dimethylamino-1H-pyrazol-5-yl)-6-ethoxy-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (2.43 mg, 4.51 μmol, 29.9% yield, 97.8% purity) as a yellow solid. LC-MS [M+1]: 434.2.

[0687] 1H NMR(400MHz,DMSO-d6) δ=10.17(s,1H),9.73(s,1H),7.82(s,1H),7.0(t,J=8.8Hz,1H),6.76(dd,J=4.0,8.8Hz,1H),6.47(s,1H),6.25(s,1H),4.88(br d,J=4.8Hz,2H),4.56(t,J=8.8Hz,2H),4.44-4.38(m,2H),3.59(s,3H),3.31(t,J=8.8Hz,3H),2.24(s,3H),1.33(t,J=7.2Hz,3H).

[0688] Examples 43-45 were prepared following the procedures specified in Example 42 and using the general reaction scheme and intermediates described herein.

[0689] [Table 6]

[0690] Example 46 5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-3(2H)-one

[0691] [ka]

[0692] Step A: To a mixture of intermediate A-4 (130 mg, 322 μmol, 1.00 equiv.) in di-tert-butyl dicarbonate (1.90 g, 8.71 mmol, 2 mL, 27.1 equiv.), DMAP (3.93 mg, 32.2 μmol, 0.1 equiv.) was added. The mixture was stirred under nitrogen at 50 °C for 4 h. The reaction mixture was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give tert-butyl (4-bromo-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (140 mg, crude) as a colorless oil. LC-MS [M+1]: 506.1.

[0693] Step B: To a degassed solution of tert-butyl (4-bromo-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (140 mg, 278 μmol, 1.00 equiv.) and tributyl(1-ethoxyvinyl)stannane (130 mg, 361 μmol, 122 μL, 1.30 equiv.) in dioxane (5.00 mL) under a N atmosphere, Pd(PPh3)2Cl2 (39.0 mg, 55.5 μmol, 0.20 equiv.) was added. The reaction was stirred at 100 °C for 2.5 h. The reaction mixture was used directly in the next step without purification. To the crude reaction mixture was added HO (2.50 mL) and pyridinium para-toluenesulfonate (284 mg, 1.13 mmol, 4.00 equiv.). The mixture was stirred at 40° C. for 4 hours, then diluted with ethyl acetate (4.00 mL) and treated with aqueous potassium fluoride (140 mg potassium fluoride in 4 mL water). The mixture was stirred vigorously for 1 hour and then filtered through Celite. The filtrate was diluted with ethyl acetate (5.00 mL), and the organic phase was washed with saturated sodium bicarbonate solution and then brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a residue that was purified by preparative TLC (petroleum ether / ethyl acetate=1 / 1) to give tert-butyl (4-acetyl-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (100 mg, 214 μmol, 75.7% yield) as a yellow solid.

[0694] 1 H NMR(400MHz, CDCl3) δ=8.97(s,1H),8.95(s,1H),8.18(d,J=0.8Hz,1H),6.59(t,J=8.8Hz,1H),6.51( dd,J=8.8,4.0Hz,1H),5.24(s,2H),4.56(t,J=8.8Hz,2H),4.06(s,3H),3.35(br t,J=8.8Hz,2H),2.75(s,3H),1.30(s,9H).

[0695] Step C: tert-Butyl (4-acetyl-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (100 mg, 213.91 μmol, 1 equiv.) was dissolved in DMF-DMA (2.24 g, 18.82 mmol, 2.50 mL, 87.98 equiv.) and stirred at 100° C. under a nitrogen atmosphere for 0.5 h. After cooling to 15° C., the DMF-DMA was removed by distillation in vacuo to give tert-butyl (E)-(4-(3-(dimethylamino)acryloyl)-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (100 mg, crude) as a brown solid. LC-MS[M+1]: 523.5.

[0696] Step D: 2-Hydrazino-N,N-dimethyl-ethanamine hydrochloride (53.4 mg, 382 μmol, 4.00 equiv.) and tert-butyl (E)-(4-(3-(dimethylamino)acryloyl)-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (100 mg, crude) were dissolved in ethyl alcohol (5.00 mL). The reaction mixture was stirred under nitrogen at 80° C. for 0.5 h. The solvent was removed under reduced pressure to give tert-butyl (4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (80.0 mg, crude) as a gray solid. LC-MS [M+1]: 563.4.

[0697] To a mixture of tert-butyl (4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-6-methoxy-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (80.0 mg, 142 μmol, 1.00 equiv.) in DCM (3.00 mL), TFA (1.54 g, 13.5 mmol, 1.00 mL, 95.0 equiv.) was added in one portion under a nitrogen atmosphere at 20°C, and the reaction mixture was stirred for 2 h. The solvent was removed under reduced pressure. The residue was then purified by preparative HPLC [Xtimate C18 150 * 25mm * Purification using a 5 μm column (mobile phase: Phase A - water, Phase B - ACN (0.04% NH3HO), Phase B - ACN) B%: 33%-63%) gave 4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (29.0 mg, 61.5 μmol, 43.3% yield, 98.1% purity) as a white solid. LC-MS [M+1]: 463.4.

[0698] 1 H NMR(400MHz, CDCl3) δ=8.93(s,1H),7.99(s,1H),7.64(d,J=1.6Hz,1H),6.86(t,J=9.6Hz,1H),6.67(dd,J=4.0,8.8Hz,1H),6.57(s,1H),6.29(d,J=1.6Hz,1H),5.97(br t,J=5.2Hz,1H),4.86(d,J=5.2Hz,2H),4.62(t,J=8.8Hz,2H),4.02(br t,J=7.2Hz,2H),3.97(s,3H),3.41(t,J=8.8Hz,2H),2.65(t,J=7.2Hz,2H),2.12-2.03(s,6H).

[0699] Example 46: A mixture of 4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-6-methoxy-2,7-naphthyridin-1-amine (16.0 mg, 34.6 μmol, 1.00 equiv.) in pyridine hydrochloride (12.0 mg, 104 μmol, 3.00 equiv.) was stirred at 130° C. for 0.5 hours. The mixture was adjusted to pH=8 with saturated aqueous sodium carbonate (3.00 mL), and the aqueous phase was extracted with ethyl acetate (2.00 mL×3). The combined organic phases were washed with brine (2.00 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was triturated with methanol (1.00 mL) to give the title compound 5-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,7-naphthyridin-3(2H)-one (11.0 mg, 23.6 μmol, yield 68.1%, purity 96.0%) as a yellow solid. LC-MS [M+1]: 449.3

[0700] 1 H NMR(400MHz,CD3OD) δ=8.89(br s,1H),7.73(s,1H),7.63(br s,1H),6.84(br t,J=9.2Hz,1H),6.62(dd,J=3.2,8.0Hz,1H),6.34(br s,1H),6.07(s,1H),4.75(br s,2H),4.55(br t,J=8.8Hz,2H),4.06(t,J=5.2Hz,2H),3.45-3.33(m,2H),2.69(t,J=5.2Hz,2H),2.11(s,6H).

[0701] Example 47 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-oxo-6,7-dihydro-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide

[0702] [ka]

[0703] Step A: 4-bromo-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-6-methoxy-2,7-naphthyridin-1-amine (Intermediate A-4, 620 mg, 1.38 mmol, 1.00 equiv.), methyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-3-carboxylate ( A mixture of Intermediate C45 (844 mg, 3.17 mmol, 2.30 equiv), potassium carbonate (954 mg, 6.90 mmol, 5.00 equiv), and Pd(t-BuP) (70.6 mg, 138 μmol, 0.10 equiv) in dioxane (6.00 mL) and water (1.00 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 95 °C for 1 h. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to give 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (520 mg, 81.3% yield) as a yellow solid. LC-MS [M+1]: 464.1.

[0704] Step B: To a solution of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylic acid (520 mg, 1.12 mmol, 1.00 equiv) in THF (50.0 mL) and water (10.0 mL) was added sodium hydroxide (135 mg, 3.37 mmol, 3.00 equiv). The mixture was stirred at 45° C. for 1 hour. The reaction mixture was concentrated in vacuo, and the aqueous solution was adjusted to pH=6 with aqueous hydrochloric acid (6.00 M, 3.00 mL). The suspension was filtered and the filter cake was washed with water (2 mL × 2) and dried in vacuo to give methyl 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylate (450 mg, 89.2% yield) as a yellow solid. LC-MS [M+1]: 450.1.

[0705] 1 H NMR(400MHz,DMSO-d6) δ=9.45(s,1H),8.55(br s,1H),7.94(s,1H),6.91(t,J=9.2Hz,1H),6.65(br dd,J=3.6,8.8Hz,1H),6.48(br s,1H),6.39(br s,1H),4.74(br d,J=4.4Hz,2H),4.51(br t,J=8.4Hz,2H),3.92(s,3H),3.60(br s,3H),3.27(m,2H).

[0706] Step C: To a solution of methyl 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carboxylate (100 mg, 222 μmol, 1.00 equiv) in DMF (1.50 mL) was added HATU (211 mg, 556 μmol, 2.50 equiv), N-methylmethanamine (2.00 M, 334 μL, 3.00 equiv), and DIEA (86.3 mg, 668 μmol, 113 μL, 3.00 equiv). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was diluted with water (3.00 mL), and then the suspension was filtered and washed with water (1.00 mL×3). The filter cake was collected and concentrated under reduced pressure to give 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide (60 mg, 56.6% yield) as a yellow solid. LC-MS [M+1]: 477.1.

[0707] Example 47: A mixture of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide (50.0 mg, 105 μmol, 1.00 equiv) in pyridine hydrochloride (121 mg, 1.05 mmol, 10.0 equiv) was stirred at 130° C. for 1 hour. The reaction mixture was cooled to 25°C, diluted with water (1.00 mL), and the crude product was purified by preparative HPLC [column: Phenomenex Synergi C18 150 x 25 x 10 μm; (mobile phase: phase A - water (0.05% HCl), phase B - ACN) B%: 0% to 30%] to give the title compound 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-oxo-6,7-dihydro-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide (12.2 mg, yield 24.5%, purity 97.2%) as a yellow solid. LC-MS [M+1]: 463.1.

[0708] 1 H NMR(400MHz,CD3OD) δ=9.25(s,1H),7.55(s,1H),6.97(t,J=9.6Hz,1H),6.83-6.77(m,2H) ,6.14(s,1H),4.80(s,2H),4.65(t,J=8.8Hz,2H),3.81(s,3H),3.42(br s,3H),3.38-3.33(m,2H),3.14(br s,3H).

[0709] Example 48 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-oxo-6,7-dihydro-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carbonitrile

[0710] [ka]

[0711] Step A: To a solution of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-N,N,1-trimethyl-1H-pyrazole-3-carboxamide (Example 42, Step C; 140 mg, 312 μmol, 1.00 equiv) and triethylamine (632 mg, 6.24 mmol, 869 μL, 20.0 equiv) in tetrahydrofuran (2.00 mL) was added trifluoroacetic anhydride (656 mg, 3.12 mmol, 434 μL, 10.0 equiv) dropwise at 0° C. The mixture was stirred at 25° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=1 / 1) to give 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carbonitrile (70 mg, crude) as a white solid. LC-MS [M+1]: 431.1.

[0712] Example 48: A mixture of 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-methoxy-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carbonitrile (70.0 mg, 163 μmol, 1.00 equiv.) and pyridine hydrochloride (140 mg, 1.21 mmol, 7.45 equiv.) was stirred at 130° C. for 1 hour. The reaction mixture was cooled to 25° C. and then diluted with water (2.00 mL). The crude product was then purified by preparative HPLC [column: Phenomenex Synergi C18 150 * twenty five * 10 μm; mobile phase: Phase A - water (0.05% HCl), Phase B - ACN) B%: 15%-45%] to give the title compound 5-(1-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-6-oxo-6,7-dihydro-2,7-naphthyridin-4-yl)-1-methyl-1H-pyrazole-3-carbonitrile (24.1 mg, 35.5% yield, 99.8% purity) as a yellow solid. LC-MS [M+1]: 417.0.

[0713] 1 H NMR(400MHz,CD3OD) δ=9.22(s,1H),7.58(s,1H),6.99(s,1H),6.96(d,J=10.0Hz,1H),6.78(dd,J=4.0,8.8H z,1H),6.07(s,1H),4.79(s,2H),4.65(t,J=8.8Hz,2H),3.85(s,3H),3.38-3.33(m,2H).

[0714] Example 49 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N 1 -((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-N 6 ,N 6 -Dimethyl-2,7-naphthyridine-1,6-diamine

[0715] [ka]

[0716] Step A: To a solution of 1,6-dichloro-2,7-naphthyridine (200 mg, 1.00 mmol, 1.00 equiv) and (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (168 mg, 1.00 mmol, 1.00 equiv) in DMF (4.00 mL) was added potassium fluoride (175 mg, 3.01 mmol, 70.6 μL, 3.00 equiv), and the reaction mixture was stirred under a nitrogen atmosphere at 120° C. for 3 hours. Water (15.0 mL) was added to the reaction mixture, and the precipitate was filtered and dried in vacuo to give 6-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (230 mg, 697 μmol, 69.4% yield) as a white solid.

[0717] 1 H NMR(400MHz,DMSO-d6) δ=9.46(s,1H),8.38(br t,J=4.8Hz,1H),8.10(d,J=5.6Hz,1H),7.78(s,1H),6.94-6.86(m,2H),6.65 (dd,J=3.6,8.4Hz,1H),4.70(d,J=5.2Hz,2H),4.50(t,J=8.8Hz,2H),3.25(br t,J=8.8Hz,3H).

[0718] Step B: To a solution of 6-chloro-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-2,7-naphthyridin-1-amine (230 mg, 697 μmol, 1.00 equiv) in DCM (4.00 mL) was added NBS (124 mg, 697 μmol, 1.00 equiv) at 0° C., and the reaction mixture was stirred at 0° C. for 0.5 h. The reaction mixture was diluted with DCM (50.0 mL), washed with brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 4-bromo-6-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (280 mg, 685 μmol, 98.2% yield) as a yellow solid.

[0719] 1 H NMR(400MHz,DMSO-d6) δ=9.52(s,1H),8.70(br s,1H),8.33(s,1H),7.69(s,1H),6.91(t,J=9.2Hz,1H),6.66(dd,J=4.4,8.4Hz,1H),4.69(br d,J=4.8Hz,2H),4.52(t,J=8.4Hz,2H),3.25(br t,J=8.8Hz,2H).

[0720] Step C: To a solution of 4-bromo-6-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (280 mg, 685 μmol, 1.00 equiv) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (228 mg, 1.03 mmol, 1.50 equiv) in dioxane (4.00 mL) and water (0.80 mL) was added sodium bicarbonate (173 mg, 2.06 mmol, 79.9 μL, 3.00 equiv) and Pd(dppf)Cl (50.1 mg, 68.5 μmol, 0.10 equiv) under nitrogen, and the reaction mixture was stirred at 100 °C under nitrogen for 1 h. The reaction was filtered and concentrated in vacuo to give a residue which was purified by preparative TLC (petroleum ether / ethyl acetate=1 / 1) to give 6-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (260 mg, crude) as a brown solid.

[0721] 1 H NMR(400MHz,DMSO-d6) δ=9.57(s,1H),8.70(t,J=5.2Hz,1H),8.14(s,1H),7.22(s,1H),6.97-6.88(m,1H),6.68(dd,J=4.0,8.8Hz, 1H),6.18(s,1H),4.75(d,J=4.8Hz,2H),4.53(t,J=8.8Hz,2H),3.55(s,3H),3.31-3.26(m,2H),2.23(s,3H).

[0722] Example 49: In a sealed tube, a mixture of 6-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (50.0 mg, 118 μmol, 1.00 equiv.) in dimethylamine (2.00 M in THF, 2.50 mL, 42.4 equiv.) was stirred at 140° C. for 12 hours. The reaction was concentrated in vacuo to give a residue which was purified by preparative TLC (petroleum ether / ethyl acetate=2 / 1) to give the crude product. The crude product was further triturated with petroleum ether / ethyl acetate=3 / 1 (2.00 mL), filtered, and the filter cake was collected and dried in vacuo to give the title compound 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N 1 -((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-N 6 ,N 6 -Dimethyl-2,7-naphthyridine-1,6-diamine (11.4 mg, 26.1 μmol, 22.1% yield, 98.8% purity) was obtained as a yellow solid. LC-MS [M+1]: 433.2.

[0723] 1 H NMR(400MHz,CD3OD) δ=9.17(s,1H),7.73(s,1H),6.86(t,J=9.2Hz,1H),6.64(dd,J=4.0,8.4Hz,1H),6.18(s,1H),6.09(s ,1H),4.79(s,2H),4.55(t,J=8.8Hz,2H),3.61(s,3H),3.32-3.27(m,2H),3.10(s,6H),2.32(s,3H).

[0724] Example 50 4-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N 1 -((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridine-1,6-diamine

[0725] [ka]

[0726] Step A: A mixture of 6-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,7-naphthyridin-1-amine (Example 43, Step C; 50.0 mg, 118 μmol, 1.00 equiv.), di-tert-butyl dicarbonate (30.9 mg, 142 μmol, 32.5 μL, 1.20 equiv.), diisopropylethylamine (45.7 mg, 354 μmol, 61.6 μL, 3.00 equiv.), and dimethylaminopyridine (1.44 mg, 11.8 μmol, 0.10 equiv.) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 25° C. for 2 hours. The reaction mixture was diluted with ethyl acetate (5.00 mL) and concentrated under reduced pressure to provide a residue. The residue was triturated with petroleum ether (2.00 mL) to give tert-butyl (6-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (50.0 mg, 80.7 μmol, yield 68.4%, purity 84.6%) as a yellow solid. LC-MS [M+1]: 524.5.

[0727] Step B: tert-butyl (6-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (50.0 mg, 95.4 μmol, 1.00 equiv.), tert-butyl carbamate (55.9 mg, 477 μmol, 5.00 equiv.) A mixture of Pd(dba) (1.75 mg, 1.91 μmol, 0.02 equiv.), cesium carbonate (125 mg, 382 μmol, 4.00 equiv.), and Xantphos (1.10 mg, 1.91 μmol, 0.02 equiv.) in dioxane (1.00 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 100 °C for 12 h. The mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (dichloromethane / methyl alcohol = 10 / 1) to give tert-butyl (6-((tert-butoxycarbonyl)amino)-4-(1,3-dimethyl-1H-pyrazol-5-yl)-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (15.0 mg, 24.8 μmol, yield 26.0%) as a yellow oil. LC-MS [M+1]: 606.0.

[0728] Example 50: A mixture of tert-butyl (6-((tert-butoxycarbonyl)amino)-4-(1,3-dimethyl-1H-pyrazol-5-yl)-2,7-naphthyridin-1-yl)((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)carbamate (15.0 mg, 24.8 μmol, 1.00 equiv.) and trifluoroacetic acid (1.54 g, 13.5 mmol, 1.00 mL, 544 equiv.) in dichloromethane (1.00 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under nitrogen atmosphere at 25° C. for 1 hour. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [column: Waters Xbridge 150 * 25 5μ; Mobile phase: Phase A - 10mM NH4HCO3 in water, Phase B - ACN; B%: 25%-65%] to obtain the title compound 4-(2,5-dimethylpyrazol-3-yl)-N1 -[(5-Fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-2,7-naphthyridine-1,6-diamine (8.72 mg, 20.9 μmol, 84.3% yield, 97.0% purity) was obtained as a yellow solid. LC-MS [M+1]: 405.4.

[0729] 1 H NMR(400MHz,DMSO-d6) δ=9.16(s,1H),8.05(br t,J=4.8Hz,1H),7.69(s,1H),6.89(t,J=9.2Hz,1H),6.64(dd,J=4.0,8.8Hz,1H),6.31(s,2H),6.06(s,1H),6.04(s,1H),4.67(br d,J=4.8Hz,2H),4.51(t,J=8.8Hz,2H),3.49(s,3H),3.28-3.22(m,2H),2.19(s,3H).

[0730] Example 51 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1,6-naphthyridin-5-amine

[0731] [ka]

[0732] To a solution of intermediate A-5 (40.0 mg, 107 μmol, 1.00 equiv.) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (30.9 mg, 139 μmol, 1.30 equiv.) in dioxane (0.50 mL) and water (0.10 mL), Pd(dppf)Cl (7.82 mg, 10.7 μmol, 0.10 equiv.) and sodium bicarbonate (18.0 mg, 214 μmol, 8.31 μL, 2.00 equiv.) were added under a nitrogen atmosphere. The mixture was stirred at 100 °C for 1 h. The mixture was concentrated in vacuo to give a residue. The residue was purified by preparative HPLC [Waters Xbridge 150 *The resulting mixture was purified with 25 5 μl of hexane (mobile phase [A: water (10 mM NH4HCO3), B: ACN; B%: 20%-50%] to give the title compound 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-1,6-naphthyridin-5-amine (25.0 mg, 64.2 μmol, 60.1% yield, 100% purity) as a white solid. LC-MS [M+1]: 390.3.

[0733] 1 H NMR(400MHz,DMSO-d6) δ=8.96-8.91(m,1H),8.81(br d,J=7.6Hz,1H),8.25(br t,J=4.8Hz,1H),8.08(s,1H),7.55(dd,J=4.4,8.4Hz,1H),6.91(t,J=9.6Hz,1H),6.66(dd,J=4.0,8.8Hz,1H),6.05(s,1H),4.72(br d,J=4.8Hz,2H),4.52(t,J=8.8Hz,2H),3.47(s,3H),3.30-3.25(m,2H),2.18(s,3H).

[0734] Example 52 8-(1,3-Dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine

[0735] [ka]

[0736] Step A: To a solution of 3-bromo-6-methoxy-2-methylpyridine (5.00 g, 24.8 mmol, 1.00 equiv) in THF (50.0 mL) was added n-butyllithium (2.5 M, 9.90 mL, 1.00 equiv) dropwise at −78° C., and the reaction mixture was then stirred at −78° C. for 0.5 h. Carbon dioxide (15 psi) was bubbled into the reaction mixture over 30 min. The mixture was warmed to 25° C. and stirred for 1 h. Water (50.0 mL) was added to quench the reaction mixture, and the aqueous solution was adjusted to pH = 6 with aqueous hydrochloric acid (6.00 M in water, 20.0 mL). The suspension was filtered, and the filter cake was washed with water (50.0 mL × 2) and dried in vacuo to give 6-methoxy-2-methylnicotinic acid (3.30 g, 79.8% yield) as a white solid. LC-MS [M+1]: 168.2.

[0737] 1 H NMR (400MHz, DMSO-d6) δ=12.9(brs,1H),8.10(d,J=8.4Hz,1H),6.72(d,J=8.4Hz,1H),3.90(s,3H),2.67(s,3H).

[0738] To a solution of 6-methoxy-2-methylnicotinic acid (3.30 g, 19.7 mmol, 1.00 equiv) in DMF (40.0 mL) was added ammonium chloride (3.17 g, 59.2 mmol, 3.00 equiv), DIEA (7.65 g, 59.2 mmol, 10.3 mL, 3.00 equiv), and HATU (11.3 g, 29.6 mmol, 1.50 equiv). The mixture was stirred at 25 °C for 1 h. After this time, water (40.0 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (20.0 mL × 5). The combined organic phase was washed with brine, dried over sodium sulfate, filtered, and concentrated to give a residue. The residue was triturated with petroleum ether (20.0 mL) to give a suspension, the precipitate was filtered, and the filter cake was collected and dried in vacuo to give 6-methoxy-2-methylnicotinamide (1.45 g, 44.2% yield) as a white solid.

[0739] 1H NMR (400MHz, CD3OD) δ=7.73(d,J=8.4Hz,1H),6.63(d,J=8.4Hz,1H),3.92(s,3H),2.57(s,3H).

[0740] Step B: To a solution of 6-methoxy-2-methylnicotinamide (1.45 g, 8.73 mmol, 1.00 equiv.) was added DMF-DMA (23.4 g, 196 mmol, 26.1 mL, 22.5 equiv.). The mixture was stirred at 115° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was triturated with petroleum ether (10.0 mL) and filtered. The filter cake was collected and dried in vacuo to give (E)-N-((dimethylamino)methylene)-6-methoxy-2-methylnicotinamide (1.74 g, crude) as a white solid.

[0741] 1 H NMR (400MHz, CDCl3) δ=8.58(s,1H),8.41(d,J=8.4Hz,1H),6.57(d,J=8.4Hz,1H),3.97(s,3H),3.19(s,3H),3.18(s,3H),2.82(s,3H).

[0742] To a solution of (E)-N-((dimethylamino)methylene)-6-methoxy-2-methylnicotinamide (1.60 g, 7.23 mmol, 1.00 equiv) in THF (17.0 mL) was added potassium tert-butoxide (1.00 M in THF, 9.40 mL, 1.30 equiv) dropwise. The mixture was stirred at 80 °C for 3 h. After this time, water (10.0 mL) was added to the mixture, and the pH was adjusted to 5 with aqueous hydrochloric acid (2.00 M, 5.00 mL). The reaction was extracted with ethyl acetate (20.0 mL × 4). The organic phase was collected, dried over sodium sulfate, and then concentrated in vacuo to give 2-methoxy-1,6-naphthyridin-5-ol (780 mg, crude) as a yellow solid.

[0743] 1H NMR (400MHz, CD3OD) δ=8.41(d,J=8.8Hz,1H),7.39(d,J=7.6Hz,1H),6.89(d,J=8.8Hz,1H),6.66(d,J=7.2Hz,1H),4.04(s,3H). LC-MS[M+1]:177.2.

[0744] Step C: To a solution of 2-methoxy-1,6-naphthyridin-5-ol (580 mg, 3.29 mmol, 1.00 equiv) in phosphorus oxychloride (6.00 mL) was added DIEA (851 mg, 6.58 mmol, 1.15 mL, 2.00 equiv). The mixture was stirred at 120 °C for 5 hours. The reaction mixture was concentrated in vacuo, and the residue was then diluted with dichloromethane (15.0 mL), and the mixture was poured onto ice. After stirring for 15 minutes, the mixture was adjusted to pH = 8 with saturated aqueous sodium bicarbonate (10.0 mL). The organic layer was separated, washed with water (10.0 mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 50 / 1 to 20 / 1) to give 5-chloro-2-methoxy-1,6-naphthyridine (410 mg, crude) as a yellow solid.

[0745] 1 H NMR (400MHz, CD3OD) δ=8.50(dd,J=0.8,9.2Hz,1H),8.36(d,J=5.6Hz,1H),7.69(dd,J=0.4,6.0Hz,1H),7.17(d,J=9.2Hz,1H),4.11(s,3H).

[0746] Step D: A mixture of 5-chloro-2-methoxy-1,6-naphthyridine (200 mg, 832 μmol, 1.00 equiv.), (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (209 mg, 1.25 mmol, 1.50 equiv.), [2-(2-aminoethyl)phenyl]chloropalladium; dicyclohexyl-[3,6-dimethoxy-2-(2,4,6-triisopropylphenyl)phenyl]phosphane (66.5 mg, 83.2 μmol, 0.10 equiv.), and sodium tert-butoxide (160 mg, 1.66 mmol, 2.00 equiv.) in dioxane (2.00 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 100° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (110 mg, 40.6% yield) as a yellow solid. LC-MS [M+1]: 326.1.

[0747] 1 H NMR(400MHz, CDCl3) δ=8.16(d,J=6.0Hz,1H),7.89(d,J=9.2Hz,1H),7.00(d,J=6.0Hz,1H),6.87-6.80(m,2H),6.64(dd,J=3.6,8. 4Hz,1H),5.36-5.22(m,1H),4.79(d,J=5.2Hz,2H),4.60(t,J=8.4Hz,2H),4.06(s,3H),3.37(t,J=8.4Hz,2H).

[0748] Step E: To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (80.0 mg, 246 μmol, 1.00 equiv) in dichloromethane (1.50 mL) was added NBS (39.4 mg, 221 μmol, 0.90 equiv) at 0° C. The mixture was stirred at 0° C. for 5 minutes. The reaction mixture was quenched with water (2.00 mL) and extracted with ethyl acetate (3.00 mL × 3). The combined organic layers were washed with brine (3.00 mL × 2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 5 / 1) to give 8-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (60.0 mg, 60.4% yield) as a yellow solid.

[0749] 1 H NMR(400MHz,CDCl3) δ=8.36(s,1H),7.88(d,J=8.8Hz,1H),6.87(d,J=9.2Hz,1H),6.87-6.82(m,1H),6.64(dd,J=3.6,8.4Hz,1H),5.34(br s,1H),4.76(d,J=5.6Hz,2H),4.60(t,J=8.8Hz,2H),4.14(s,3H),3.37(t,J=8.8Hz,2H).

[0750] Example 52: A mixture of 8-bromo-N-[(5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl]-2-methoxy-1,6-naphthyridin-5-amine (60.0 mg, 148 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (49.5 mg, 222 μmol, 1.50 equiv.), sodium bicarbonate (37.4 mg, 445 μmol, 17.3 μL, 3.00 equiv.), and Pd(dppf)Cl (10.9 mg, 14.8 μmol, 0.10 equiv.) in dioxane (1.00 mL) and water (0.20 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 100° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 1 / 1). The crude product was triturated with methanol (2.00 mL), the suspension was filtered, and the filter cake was collected and dried in vacuo to give the title compound 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (35.0 mg, yield 55.4%, purity 98.5%) as a white solid. LC-MS [M+1]: 420.3.

[0751] 1 H NMR(400MHz,CDCl3) δ=8.18(s,1H),7.95(d,J=9.2Hz,1H),6.88-6.82(m,2H),6.66(dd,J=4.0,8.4Hz,1H),6.11(s,1H),5.48(br t,J=4.8Hz,1H),4.82(d,J=5.6Hz,2H),4.62(t,J=8.8Hz,2H),3.92(s,3H),3.70(s,3H),3.42(t,J=8.8Hz,2H),2.35(s,3H).

[0752] Example 53 8-(1,3-Dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine

[0753] [ka]

[0754] To a solution of 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (Example 46, 20.0 mg, 47.0 μmol, 1.00 equiv.) was added pyridine hydrochloride (78.8 mg, 682 μmol, 14.5 equiv.). The mixture was stirred at 130° C. for 0.5 h. The reaction mixture was cooled to room temperature, diluted with water (1.00 mL), and purified by preparative HPLC [Phenomenex Synergi C18 150 * 30mm * 4 μm; mobile phase: (Phase A - water (0.05% HCl), Phase B - ACN) B%: 20%-50%), followed by lyophilization to give the title compound 8-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2-methoxy-1,6-naphthyridin-5-amine (8.67 mg, 44.9% yield, 98.6% purity) as a white solid. LC-MS [M+1]: 406.3.

[0755] 1 H NMR(400MHz,DMSO-d6) δ=10.2(br s,1H),8.29(br d,J=10.0Hz,1H),7.89(s,1H),7.78(br s,1H),6.89(br t,J=8.8Hz,1H),6.69-6.59(m,1H),6.42(br d,J=9.6Hz,1H),6.11(s,1H),4.64(br d,J=4.4Hz,2H),4.51(br t,J=8.4Hz,2H),3.53(s,3H),3.26-3.24(m,2H),2.19(s,3H).

[0756] Example 54 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-5-methoxy-2,6-naphthyridin-1-amine

[0757] [ka]

[0758] Step A: To a solution of 1-bromo-2,6-naphthyridine (1.60 g, 7.65 mmol, 1.00 equiv.) in dichloromethane (30.0 mL) was added metachloroperbenzoic acid (2.33 g, 11.5 mmol, 85.0% purity, 1.50 equiv.) at 0 °C. The resulting mixture was warmed to 25 °C and stirred for 16 h. The reaction mixture was diluted with water (50.0 mL) and extracted with dichloromethane (100 mL × 2). The combined organic layers were washed with saturated aqueous sodium bicarbonate (100 mL) and then brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 5-bromo-2,6-naphthyridine 2-oxide (1.40 g, 6.22 mmol, 81.3% yield) as a white solid.

[0759] A solution of 5-bromo-2,6-naphthyridine 2-oxide (1.40 g, 6.22 mmol, 1.00 equiv) and phosphorus oxychloride (20.0 mL) was stirred at 90 °C for 16 h. The phosphorus oxychloride was removed under reduced pressure to give a residue, which was diluted with ethyl acetate (200 mL) and quenched with ice-water (300 mL). The organic phase was separated, washed with saturated sodium bicarbonate (100 mL) and brine (100 mL), dried, and concentrated to give a yellow solid. The crude product was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give 1,5-dichloro-2,6-naphthyridine (540 mg, 2.71 mmol, 43.6% yield) as a white solid.

[0760] 1H NMR (400MHz, CDCl3) δ=8.56(d,J=5.6Hz,2H),8.07(d,J=5.6Hz,2H).

[0761] Step B: A mixture of 1,5-dichloro-2,6-naphthyridine (500 mg, 2.51 mmol, 1.00 equiv.), (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (420 mg, 2.51 mmol, 1.00 equiv.), and potassium fluoride (437 mg, 7.52 mmol, 176 μL, 2.99 equiv.) in DMSO (10 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 120 °C for 2 h. The reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (60 mL × 2). The combined organic layers were washed with brine (100 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to give 5-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (600 mg, 1.82 mmol, yield 72.4%) as a white solid.

[0762] 1 H NMR(400MHz,DMSO-d6) δ=8.36(d,J=5.6Hz,1H),8.24(dd,J=0.8,5.6Hz,1H),8.21(t,J=5.2Hz,1H),8.16(d,J=6.0Hz,1H),7.11(d,J=6.0Hz,1 H),6.94-6.84(m,1H),6.64(dd,J=4.0,8.8Hz,1H),4.69(d,J=5.2Hz,2H),4.50(t,J=8.8Hz,2H),3.23(t,J=8.8Hz,2H).

[0763] Step C: To a solution of 5-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (500 mg, 1.52 mmol, 1.00 equiv) in dichloromethane (60.0 mL) was added NBS (243 mg, 1.36 mmol, 0.90 equiv) in small portions. The reaction was stirred at −40 °C for 4 h and then evaporated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give 4-bromo-5-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (280 mg, 685 μmol, 45.2% yield) as a yellow solid.

[0764] 1 H NMR(400MHz,DMSO-d6) δ=8.46(d,J=5.6Hz,1H),8.42-8.37(m,1H),8.33(s,1H),8.30(d,J=5.6Hz,1H),6.92-6.86(m,1 H),6.65(dd,J=4.0,8.8Hz,1H),4.65(d,J=5.2Hz,2H),4.50(t,J=8.8Hz,2H),3.24-3.20(m,2H).

[0765] Step D: A mixture of 4-bromo-5-chloro-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (200 mg, 489 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (217 mg, 979 μmol, 2.00 equiv.), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (31.9 mg, 48.9 μmol, 0.10 equiv.), and cesium carbonate (159 mg, 489 μmol, 1.00 equiv.) in tetrahydrofuran (4.00 mL) and water (0.80 mL) was degassed and purged with nitrogen three times. The mixture was then stirred at 70°C under a nitrogen atmosphere for 1 hour. After completion of the reaction, the reaction mixture was evaporated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 3 / 1 to 1 / 1) to give 5-chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (170 mg, 401 µmol, 82.0% yield) as a yellow solid.

[0766] 1 H NMR(400MHz,DMSO-d6) δ=8.50-8.45(m,1H),8.44(d,J=5.6Hz,1H),8.33(d,J=5.6Hz,1H),7.98(s,1H),6.96-6.86(m,1H),6.66(dd,J=4. 0,8.8Hz,1H),6.05(s,1H),4.77-4.64(m,2H),4.52(t,J=8.8Hz,2H),3.39(s,3H),3.29-3.26(m,2H),2.18(s,3H).

[0767] Example 54: 5-Chloro-4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (50.0 mg, 118 μmol, 1.00 equiv.) was added to a solution of sodium methoxide (20.0 mg, 370 μmol, 3.14 equiv.) in methanol (2.00 mL), and the solution was stirred at 70° C. for 6 hours. After completion of the reaction, the reaction mixture was diluted with water (20.0 mL) and extracted with dichloromethane (20.0 mL×2). The combined organic layers were washed with brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC [Phenomenex Synergi C18 150 * 30mm * 4 μm; mobile phase: (Phase A - water (0.05% HCl), Phase B - ACN) B%: 20%-50%) to give the title compound 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-5-methoxy-2,6-naphthyridin-1-amine (16.0 mg, 34.7 μmol, yield 29.4%, purity 90.9%) as a white solid. LC-MS [M+1]: 420.2.

[0768] 1 H NMR(400MHz,CD3OD) δ=8.18(d,J=5.6Hz,1H),7.82(s,1H),7.71(d,J=5.6Hz,1H),6.90-6.80(m,1H),6.64(dd,J=4.0,8.8Hz,1H) ,6.07(s,1H),4.79(s,2H),4.55(t,J=8.8Hz,2H),3.80(s,3H),3.47(s,3H),3.30-3.28(m,2H),2.30(s,3H).

[0769] Example 55 8-(1,3-Dimethylamino-1H-pyrazol-5-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,6-naphthyridin-1(2H)-one

[0770] [ka]

[0771] A mixture of 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-5-methoxy-2,6-naphthyridin-1-amine (25.0 mg, 59.6 μmol, 1.00 equiv.) in HCl and dioxane (8.00 mL) was heated at 90° C. for 0.5 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC [column: Xtimate C18 150 * 25mm * 5 μm; mobile phase: Phase A - water (0.05% ammonia hydroxide v / v), Phase B - ACN; B%: 20%-60%] to give the title compound 8-(1,3-dimethylamino-1H-pyrazol-5-yl)-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-2,6-naphthyridin-1(2H)-one (9.30 mg, 21.9 μmol, 36.8% yield, 95.5% purity) as an off-white solid. LC-MS [M+1]: 406.1.

[0772] 1 H NMR(400MHz,DMSO-d6) δ=7.71(s,1H),7.67(s,1H),7.31(d,J=7.2Hz,1H),6.93-6.81(m,2H),6.63(dd,J=4.0,8.8Hz,1H ),5.82(s,1H),4.62(s,2H),4.51(t,J=8.8Hz,2H),3.29-3.25(m,2H),3.17(s,3H),2.14(s,3H).

[0773] Example 56 4-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine

[0774] [ka]

[0775] Step A: A mixture of 1-chloro-2,6-naphthyridine (50.0 mg, 304 μmol, 1.00 equiv.), (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (50.8 mg, 303 μmol, 1.00 equiv.), [2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (24.3 mg, 30.4 μmol, 0.10 equiv.), and sodium tert-butoxide (58.4 mg, 608 μmol, 2.00 equiv.) in dioxane (1.00 mL) was degassed and purged with nitrogen three times, and then the mixture was stirred under a nitrogen atmosphere at 95° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to provide a residue. The residue was purified by preparative TLC (SiO2, petroleum ether / ethyl acetate=1 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (30.0 mg, 33.4% yield) as a yellow solid.

[0776] 1 H NMR(400MHz, CDCl3) δ=9.13(s,1H),8.59(d,J=5.6Hz,1H),8.17(d,J=5.6Hz,1H),7.50(d,J=6.0Hz,1H) ,7.05(d,J=5.6Hz,1H),6.85(t,J=9.2Hz,1H),6.66(dd,J=3.6,8.4Hz,1H),5.56(br s,1H),4.82(d,J=5.2Hz,2H),4.61(t,J=8.8Hz,2H),3.39(t,J=8.8Hz,2H).

[0777] Step B: To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (50.0 mg, 169 μmol, 1.00 equiv) in dichloromethane (2.00 mL) was added NBS (25.6 mg, 144 μmol, 0.85 equiv). The mixture was stirred at 0° C. for 10 minutes. The reaction mixture was quenched with water (2.00 mL) and then extracted with ethyl acetate (3.00 mL×3). The combined organic layers were washed with brine (3.00 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate=2 / 1) to give 4-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (50.0 mg, yield 78.9%) as a yellow solid.

[0778] 1 H NMR(400MHz,CDCl3) δ=9.44(s,1H),8.72-8.66(m,1H),8.26(d,J=2.0Hz,1H),7.47(br d,J=4.4Hz,1H),6.84(br t,J=8.8Hz,1H),6.69-6.61(m,1H),5.67(br s,1H),4.79(br d,J=4.4Hz,2H),4.66-4.58(m,2H),3.38(br t,J=8.8Hz,2H).

[0779] Example 56: A mixture of 4-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (50.0 mg, 134 μmol, 1.00 equiv.), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (29.7 mg, 134 μmol, 1.00 equiv.), sodium bicarbonate (33.7 mg, 401 μmol, 15.6 μL, 3.00 equiv.), and Pd(dppf)Cl (9.78 mg, 13.4 μmol, 0.10 equiv.) in dioxane (1.00 mL) and water (0.20 mL) was degassed and purged with nitrogen three times, then the mixture was stirred under a nitrogen atmosphere at 100° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by preparative TLC (SiO, petroleum ether / ethyl acetate = 0 / 100) to obtain a crude product. The crude product was triturated with methanol (2.00 mL), the suspension was filtered, and the filter cake was collected and dried in vacuo to obtain the title compound 4-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-2,6-naphthyridin-1-amine (11.7 mg, 22.3% yield, 99.2% purity) as a white solid. LC-MS [M+1]: 390.1.

[0780] 1 H NMR(400MHz, CDCl3) δ=8.99(s,1H),8.66(d,J=5.6Hz,1H),8.08(s,1H),7.56(d,J=5.6Hz,1H),6.87(t,J=9.2Hz,1H),6.68(dd,J=4.0,8.8Hz,1H),6.18(s,1H),5.80(br t,J=5.2Hz,1H),4.85(d,J=5.2Hz,2H),4.63(t,J=8.8Hz,2H),3.67(s,3H),3.42(t,J=8.4Hz,2H),2.37(s,3H).

[0781] Example 57 5-(1,3-Dimethylamino-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine

[0782] [ka]

[0783] Step A: To a solution of methyl 3-amino-2-chloroisonicotinate (5.00 g, 26.8 mmol, 1.00 equiv) in methanol (25.0 mL) and water (25.0 mL), sodium hydroxide (3.22 g, 80.4 mmol, 3.00 equiv) was added and the reaction mixture was stirred at 25 °C for 1 h. The reaction was concentrated in vacuo to remove methanol, and the aqueous solution was then adjusted to pH = 6 with acetic acid. The precipitate was filtered, and the solid was collected and dried in vacuo to give 3-amino-2-chloroisonicotinic acid (4.20 g, 24.3 mmol, 90.8% yield) as a white solid.

[0784] 1 H NMR (400MHz, DMSO-d6) δ=7.61(d,J=4.8Hz,1H),7.59(d,J=4.8Hz,1H),6.82(br.s,2H).

[0785] A solution of 3-amino-2-chloroisonicotinic acid (2.20 g, 12.8 mmol, 1.00 equiv) in formamide (20.0 mL) was stirred at 140° C. for 12 hours. Water (100 mL) was added to the reaction mixture. The resulting precipitate was filtered, and the solid was collected and dried in vacuo to give 8-chloropyrido[3,4-d]pyrimidin-4-ol (1.6 g, crude) as a yellow solid.

[0786] 1 H NMR (400MHz, DMSO-d6) δ=12.7(brs,1H),11.9(brs,1H),8.10(s,1H),7.31(d,J=6.8Hz,1H),6.58(d,J=6.8Hz,1H).

[0787] Step B: To a solution of 8-chloropyrido[3,4-d]pyrimidin-4-ol (400 mg, 2.20 mmol, 1.00 equiv) in POCl (5.00 mL) was added DIEA (569 mg, 4.41 mmol, 767 μL, 2.00 equiv) and the reaction was stirred at 120 °C for 12 h. The reaction was concentrated in vacuo under reduced pressure to remove POCl to give 4,8-dichloropyrido[3,4-d]pyrimidine (400 mg, crude) as a brown oil, which was used directly in the next step. LC-MS [M+1]: 199.8.

[0788] To a solution of 4,8-dichloropyrido[3,4-d]pyrimidine (150 mg, 750 mL, 1.00 equiv) in DCM (4.00 mL) was added DIEA (485 mg, 3.75 mmol, 653 μL, 5.00 equiv) at −40° C. The reaction was stirred at −40° C. for 30 min, then a solution of sodium methoxide (40.5 mg, 750 μmol, 1.00 equiv) in methanol (1 mL) was added dropwise, and the reaction was slowly warmed to 25° C. and stirred for 1 h. The reaction was diluted with DCM (20.0 mL), washed with brine (10.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 8-chloro-4-methoxypyrido[3,4-d]pyrimidine (120 mg, 613 μmol, 81.8% yield) as a brown solid.

[0789] 1 H NMR (400MHz, CDCl3) δ=9.02(s,1H),8.49(d,J=5.6Hz,1H),7.90(d,J=5.2Hz,1H),4.25(s,3H).

[0790] Step C: To a solution of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (92.3 mg, 552 μmol, 1.20 equiv) and 8-chloro-4-methoxypyrido[3,4-d]pyrimidine (90.0 mg, 460 μmol, 1.00 equiv) in dioxane (3.00 mL) was added potassium fluoride (80.2 mg, 1.38 mmol, 32.3 μL, 3.00 equiv) and the reaction was stirred under a nitrogen atmosphere at 120° C. for 12 hours. The reaction was filtered and the filtrate was concentrated in vacuo to provide a residue. The residue was purified by preparative TLC (petroleum ether / ethyl acetate = 1 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (76.0 mg, 233 μmol, yield 50.6%) as a brown solid.

[0791] 1 H NMR(400MHz,CD3OD) δ=8.73(s,1H),8.04(d,J=6.0Hz,1H),7.06(d,J=5.6Hz,1H),6.85(t,J=9.2Hz,1H),6.62(dd,J=4.0,8.8Hz,1H),4.78(s,2H),4.54(br t,J=8.8Hz,2H),4.19(s,3H),3.31-3.25(m,2H).

[0792] Step D: To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (76.0 mg, 233 μmol, 1.00 equiv) in DCM (1.00 mL) was added NBS (41.5 mg, 233 μmol, 1.00 equiv) at 0° C. and the reaction was stirred at 0° C. for 0.5 h. After this time, the reaction was concentrated in vacuo at 25° C. to afford 5-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (80.0 mg, crude) as a brown solid, which was used directly in the next step.

[0793] 1H NMR(400MHz,DMSO-d6) δ=8.84(s,1H),8.17(s,1H),8.06-8.01(m,1H),6.92-6.83(m,1H),6.61(dd,J=4.0,8.8H z,1H),4.68(d,J=6.0Hz,2H),4.48(t,J=8.4Hz,2H),4.11(s,3H),3.24(t,J=8.8Hz,2H).

[0794] Example 57: To a solution of 5-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (70.0 mg, 173 μmol, 1.00 equiv.) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (57.6 mg, 259 μmol, 1.50 equiv.) in dioxane (2.00 mL) and water (0.40 mL) was added sodium bicarbonate (43.5 mg, 518 μmol, 20.2 μL, 3.00 equiv.) and Pd(dppf)Cl (12.6 mg, 17.3 μmol, 0.10 equiv.). The mixture was stirred at 110° C. under a nitrogen atmosphere for 1 hour. The reaction mixture was filtered and concentrated in vacuo to give a residue, which was purified by preparative TLC (petroleum ether / ethyl acetate = 1 / 1) to give the crude product. The crude product was triturated with methanol (1.00 mL) and filtered. The filter cake was collected and dried in vacuo to give the title compound 5-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (27.5 mg, 64.8 μmol, 37.5% yield, 99.1% purity) as a yellow solid. LC-MS [M+1]: 421.4.

[0795] 1H NMR(400MHz,CD3OD) δ=8.77(s,1H),7.92(s,1H),6.89-6.80(m,1H),6.62(dd,J=3.6,8.4Hz,1H),6.05(s,1H),4. 82(s,2H),4.55(t,J=8.8Hz,2H),3.92(s,3H),3.48(s,3H),3.39-3.34(m,2H),2.29(s,3H).

[0796] Example 58 5-(1,3-dimethyl-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyrimidin-4(3H)-one

[0797] [ka]

[0798] A mixture of 5-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-4-methoxypyrido[3,4-d]pyrimidin-8-amine (Example 57, 16.0 mg, 37.7 μmol, 1.00 equiv.) and pyridine hydrochloride (87.2 mg, 754 μmol, 20.0 equiv.) was stirred at 140° C. for 10 minutes. Water (10.0 mL) was added to the reaction mixture, and the precipitate was filtered and dried in vacuo to give the title compound 5-(1,3-dimethyl-1H-pyrazol-5-yl)-8-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)pyrido[3,4-d]pyrimidin-4(3H)-one (7.71 mg, 17.8 μmol, 47.1% yield, 93.6% purity) as a white solid. LC-MS [M+1]: 407.2.

[0799] 1H NMR(400MHz,DMSO-d6) δ=12.6(br s,1H),8.17(br d,J=3.6Hz,1H),7.78(s,1H),7.59(br t,J=5.6Hz,1H),6.89(br t,J=9.2Hz,1H),6.63(br dd,J=3.6,8.4Hz,1H),5.90(s,1H),4.68(br d,J=5.6Hz,2H),4.51(br t,J=8.8Hz,2H),3.37(s,3H),3.32-3.28(m,2H),2.15(s,3H).

[0800] Example 59 5-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine

[0801] [ka]

[0802] Step A: To a solution of 4,8-dichloropyrido[3,4-d]pyrimidine (400 mg, 2.00 mmol, 1.00 equiv), DIEA (258 mg, 2.00 mmol, 348 μL, 1.00 equiv) in DCM (10.0 mL) was added p-toluenesulfonyl hydrazide (745 mg, 4.00 mmol, 2.00 equiv), and the reaction was stirred for 1 h at 25° C. The mixture was then diluted with DCM (20.0 mL), washed with aqueous hydrochloric acid (1.00 M, 20.0 mL × 3) and brine (10.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give N'-(8-chloropyrido[3,4-d]pyrimidin-4-yl)-4-methylbenzenesulfonohydrazide (360 mg, 1.03 mmol, yield 51.5%) as a brown solid.

[0803] 1H NMR(400MHz,DMSO-d6) δ=11.77-11.32(m,1H),10.20-9.49(m,1H),8.21(br s,1H),7.81(br d,J=6.4Hz,2H),7.69(br d,J=8.0Hz,1H),7.46-7.34(m,3H),2.40(br s,3H).

[0804] Step B: To a solution of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine (91.8 mg, 549 μmol, 1.20 equiv) and N'-(8-chloropyrido[3,4-d]pyrimidin-4-yl)-4-methylbenzenesulfonohydrazide (160 mg, 457 μmol, 1.00 equiv) in DMSO (3.00 mL) was added potassium fluoride (79.7 mg, 1.37 mmol, 32.2 μL, 3.00 equiv) and the reaction was stirred at 120° C. under a nitrogen atmosphere for 12 hours. The reaction was diluted with ethyl acetate (15.0 mL), washed with brine (10.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue which was purified by preparative TLC (petroleum ether / ethyl acetate = 1 / 1) to give N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine (40.0 mg, 135 μmol, 29.5% yield) as a brown solid.

[0805] 1 H NMR(400MHz,CDCl3) δ=9.24(s,1H),9.22(s,1H),8.17(d,J=6.0Hz,1H),6.99(br s,1H),6.89(d,J=6.0Hz,1H),6.88-6.82(m,1H),6.65(dd,J=4.0,8.8Hz,1H),4.83(d,J=5.6Hz,2H),4.60(t,J=8.8Hz,2H),3.37(t,J=8.8Hz,2H).

[0806] Step C: To a solution of N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine (35.0 mg, 118 μmol, 1.00 equiv) in DCM (2.00 mL) was added NBS (21.0 mg, 118 μmol, 1.00 equiv) at 0° C. and the reaction was stirred for 30 minutes at 0° C. The reaction was concentrated in vacuo at 25° C. to afford 5-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine (40.0 mg, crude) as a brown solid, which was used directly in the next step.

[0807] 1 H NMR(400MHz,CDCl3) δ=9.48(s,1H),9.28(s,1H),8.25(s,1H),7.08(br s,1H),6.89-6.80(m,1H),6.65(dd,J=4.0,8.8Hz,1H),4.80(d,J=5.6Hz,2H),4.60(t,J=8.8Hz,2H),3.36(t,J=8.8Hz,2H).

[0808] Example 59: To a solution of 5-bromo-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine (40.0 mg, 107 μmol, 1.00 equiv.) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (35.5 mg, 160 μmol, 1.50 equiv.) in dioxane (1.50 mL) and water (0.30 mL), sodium bicarbonate (26.9 mg, 320 μmol, 12.4 μL, 3.00 equiv.) and Pd(dppf)Cl (7.80 mg, 10.7 μmol, 0.10 equiv.) were added under a nitrogen atmosphere. The reaction mixture was stirred under nitrogen at 105° C. for 1 hour. The reaction was filtered, and the filtrate was concentrated in vacuo to give a residue that was purified by preparative TLC (dichloromethane / methanol=10 / 1), then triturated with methanol (1.00 mL), the precipitate was filtered, and the filter cake was collected and dried in vacuo to give 5-(1,3-dimethyl-1H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)pyrido[3,4-d]pyrimidin-8-amine (18.9 mg, 45.6 μmol, 42.7% yield, 94.2% purity) as a yellow solid. LC-MS [M+1]: 391.0.

[0809] 1 H NMR(400MHz,CD3OD) δ=9.29(s,1H),9.10(s,1H),8.09(s,1H),6.88-6.81(m,1H),6.62(dd,J=4.0,8.8Hz,1H),6.2 8(s,1H),4.87(s,2H),4.55(t,J=8.8Hz,2H),3.68(s,3H),3.38(t,J=8.8Hz,2H),2.34(s,3H).

[0810] The compounds of the present invention may have one or more asymmetric centers and, in such cases, are synthesized as stereoisomeric mixtures, i.e., isomers of identical constitution that differ in the arrangement of their atoms in space. The compounds may be used as mixtures, or the individual components / isomers may be separated using conventional stereoisomer and enantiomer isolation methods well known to those skilled in the art, using commercially available reagents and, for example, CHIRALPAK® (Sigma-Aldrich) or CHIRALCEL® (Diacel Corp) chiral chromatographic HPLC columns according to the manufacturer's instructions. Alternatively, the compounds of the present invention may be synthesized using optically pure, chiral reagents and intermediates to prepare the individual isomers or enantiomers. Unless otherwise specified, all chiral (enantiomers and diastereomers) and racemic forms are within the scope of the present invention.

[0811] Also contemplated within the scope of the present invention are variants of the compounds of the present invention in which one or more hydrogen atoms are replaced with deuterium. As exemplified herein, intermediate C-31 has one or more hydrogen atoms replaced with deuterium. Intermediates B-7 and B-8 further contain site-specifically substituted deuterium. By utilizing deuterium in place of one or more hydrogens on intermediates A-C exemplified herein, deuterated versions of the compounds of the present invention can be readily produced using methods well known in the art.

[0812] Example A This example illustrates the inhibition of PRC2 enzymatic activity by compounds of the present invention.

[0813] A 10-point dose-response curve for compounds of the present invention was determined using a Hot Spot HMT assay (see Reaction Biology Corp; Horiuchi et al., Assay Drug Dev Technol. (2013) 4:227-236 doi:10.1089 / adt.2012.480). The assay uses a purified human His-tagged PRC2 complex containing an N-terminally His-tagged EZH enzyme, an N-terminally Flag-tagged embryonic ectoderm development protein (EED), an N-terminally His-tagged suppressor of zeste 12 (SUZ12), an N-terminally His-tagged AEBP2, and an N-terminally His-tagged RbAp48. The assay quantifies the transfer of a tritiated methyl group from radiolabeled S-adenosylmethionine (SAM) to purified core histone proteins by EZH2 after filtration, determining the activity of the core PRC2 complex in the presence or absence of compounds.

[0814] Briefly, compounds of the present invention were solubilized in DMSO, and a total of 10 three-fold serial dilutions were made for each compound in 15% DMSO. The initial starting concentration for each compound serial dilution was 1.0 μM. Control samples lacking compound, EZH2 enzyme, or various reaction components were also prepared and processed in parallel with the test compound samples. SAH (S-(5-adenosyl)-L-homocysteine) was used as a positive control to validate the assay.

[0815] Using an Acoustic Technology instrument (Echo 550, LabCyte), 5 μl aliquots of each serial dilution of test compound containing reaction buffer (50 mM Tris-HCl (pH 8.), 0.01% Brij35, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 1% DMSO), 10 nM purified PRC2 complex, and 0.05 mg / ml core histone H3 were added to a 384-deep-well plate. The reactions were mixed gently and then preincubated at 30°C for 20 minutes. 1 μM S-adenosyl-L-[methyl- 3The enzymatic reaction was initiated by adding [H]methionine and incubated at 30°C for 1 h. After 1 h, the reaction products were detected using a filter-binding method, and the amount of tritiated H3 core histone was quantified using a scintillation counter. The IC of each compound was calculated from each 10-point dose-response curve using GraphPad Prism software. 50 The values ​​were determined, and the results for the compounds of the present invention, including compounds of formula (I) and formula (II), are shown in Table 6. Key: A=<100 nM, B=>100 nM to <250 nM, C=>250 nM.

[0816] [Table 7-1]

[0817] [Table 7-2]

[0818] Example B This example illustrates the inhibition of proliferation of tumor cells harboring a PRC2 complex containing an EZH2 activating mutation by compounds of the present invention.

[0819] The Pfeiffer cell line was established by intrapleural injection into a patient with metastatic diffuse large B-cell lymphoma (DLBCL). This cell line expresses a mutant form of the EZH2 enzyme (A677G), which enhances EZH2 activity and results in increased methylation of histone H3 Lys27. Increased trimethylation of histone H3 Lys27 is thought to contribute to tumorigenesis and poor clinical prognosis in lymphoma (McCabe et al., (2012) Nature 492:108-112).

[0820] Inhibition of PRC2-mediated histone H3 methylation by compounds of Formula (I) was measured by ELISA using a Tri-Methyl Histone H3 (Lys27) Sandwich ELISA Kit (Cell Signaling Tech #7866C) according to the manufacturer's instructions. Briefly, Pfeiffer cells were cultured in RPMI medium supplemented with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin at 37°C in 96-well plates to a density of 8000 cells / 90 μl / well, and then harvested. A series of three-fold dilutions of each test compound of Formula (I) were prepared in RPMI medium and added to the cells at final concentrations ranging from 1 μM to 0.15 nM. The plates were incubated at 37°C for 96 hours.

[0821] After incubation, cells were pelleted by centrifugation at 1,100 rpm for 10 minutes in a pre-chilled 4°C rotor, and the supernatant was aspirated. The cell pellet was resuspended in 55 μl of lysis buffer (0.4 M HCl) and incubated on ice for 30 minutes with periodic shaking. Lysed cells were centrifuged at 4,200 rpm for 10 minutes at 4°C, and the supernatant containing acid-soluble proteins was collected and discarded. The pH of the acid-soluble proteins was neutralized by adding 20 μl of neutralization buffer (1 M sodium phosphate, dibasic (pH 12.5), 2.5 mM DTT, and 1 mM PMSF), and the neutralized lysate was analyzed by ELISA.

[0822] A 65-μl aliquot of each cell lysate was added to a well of a microwell strip, the microwell sealed with tape, and incubated for 2 hours at 37°C or overnight at 4°C. After incubation, the tape was removed, and the microwells were washed four times with 200 μl of 1X wash buffer. A 100-μl aliquot of anti-trimethylhistone H3 Lys27 detection antibody solution was added to each washed microwell, and the microwells were incubated for 1 hour at 37°C. The detection antibody solution was aspirated off, and each well was washed four times with 200 μl of 1X wash buffer.

[0823] A 100 μl aliquot of HRP-conjugated secondary antibody was added to each well, the wells sealed with tape, and incubated at 37°C for 30 minutes. The HRP-conjugated secondary antibody solution was removed by aspiration, and the wells were washed four times with 200 μl of 1X wash buffer. A 100 μl aliquot of TMB substrate was added to each well, the wells sealed with tape, and incubated at 37°C for 10 minutes or at 25°C for 30 minutes. The reaction was stopped by adding a 100 μl aliquot of STOP solution, and the plate was gently shaken. The extent of histone H3 trimethylation was determined using a spectrophotometric readout by measuring absorbance at 450 nm and then calculating the amount of trimethylated histone H3. The results are shown in Table 7. A = ≤100 nM, B = >100 nM to ≤500 nM, C = >500 nM, ND = not determined.

[0824] [Table 8-1]

[0825] [Table 8-2]

[0826] Example C This example demonstrates that compounds of the present invention exhibit enhanced potency against DLBCL cell lines expressing an activated mutant form of the EZH2 enzyme compared to wild-type EZH2.

[0827] The Karpas422 cell line is a human B-cell non-Hodgkin's lymphoma cell line established from a female patient with DLBCL. This EZH2 heterozygous cell line expresses a mutant form (Y641N) of the EZH2 enzyme that increases histone H3 methylation, a mutation implicated in the tumorigenesis of lymphomas such as DLBCL.

[0828] Karpas 422 cells (PHE cat. no. 06101702) were cultured in RPMI medium supplemented with 20% fetal bovine serum and 1% penicillin / 1% streptomycin and seeded at a density of 1,000 cells / 90 μl / well in 96-well white assay plates. Dose-response curves for compounds of the present invention were determined over a concentration range from 10 μM to a final concentration of 1.5 nM using three-fold serial dilutions by adding 10 μl aliquots of various concentrations of compound stock solution to each well. Plates were incubated at 37°C for the indicated time periods: 4, 7, or 11 days. Cell viability was measured on days 4 and 7 using a CTG assay kit (Cell Titre Glo; Promega cat. no. G7573) according to the manufacturer's instructions.

[0829] To analyze plate viability at day 11, plates were centrifuged at 1100 rpm for 5 minutes on day 7 and the supernatant was aspirated off. Cells were resuspended in a 90 μl aliquot of the appropriate growth medium without compound, followed by the addition of 10 μl of a 10X stock of the same compound at the same concentration. Cell viability at day 11 was measured using the CTG assay kit described above according to the manufacturer's instructions. The IC of each compound at each given time point was calculated using Graphpad PRISM software. 50 The values ​​were calculated and the results are shown in Table 8. A = ≦250 nM, B = <250 nM to ≦500 nM, C = >500 nM, ND = not determined.

[0830] [Table 9]

[0831] While the invention has been described with respect to specific embodiments thereof, it will be understood that the invention is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the invention in accordance with the principles of the invention generally, including departures from the present disclosure as are within known or customary practice within the art to which the invention pertains, applicable to the essential features set forth above, and in accordance with the scope of the appended claims.

Claims

1. A compound of formula (I) shown below, or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 During the ceremony, 【Chemistry 2】 represents a single bond, Z is O or S; X is C(R ５ ) ２ and R １ is aryl, or heteroaryl, where aryl and heteroaryl are each independently selected from one or more R ２ and optionally replaced by Each R ２ are independently oxo, cyano, halogen, -PO ３ (C1-C3 alkyl) ２ , alkoxy, hydroxyalkyl, heteroalkyl, aralkyl, haloalkyl, -COOR ５ , -Y ２ -haloalkyl, -Y １ -C1-C6 alkyl, -Y ２ -C1-C6 alkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, -Y １ -heterocyclyl, -Y ２ -heterocyclyl, -L-N(R ５ ) ２ , -O-L-N(R ５ ) ２ , -C(CF ３ ) N (R ５ ) ２ , -Y １ -N(R ５ ) ２ , or -Y ２ -N(R ５ ) ２ and -Y is selected from the group consisting of aralkyl, -L-cycloalkyl, -L-heteroaryl, -L-heterocyclyl, and -Y １ The ring portion of the heterocyclyl may be one or more R ４ and optionally replaced by R ３ are independently C1-C3 alkyl or halogen; Each R ４ are independently oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -L-N(R ５ ) ２ , C1-C6 alkyl, or -Y １ -heterocyclyl, -Y １ Heterocyclyl is one or more R ７ and optionally replaced by L is a single bond or C1-C4 alkylene; Y １ is a single bond, —C(O)—, or —NHC(O)—, Y ２ is a single bond, -S-, -SO-, -SO ２ - or -NR ５ SO ２ - and Each R ５ are independently hydrogen or C1-C3 alkyl; R ６ is hydrogen, Each R ７ are independently oxo, cyano, hydroxyl, alkoxy, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, -L-N(R ５ ) ２ or C1-C6 alkyl, and n is 1 A compound or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, wherein Z is O, or a pharma- ceutically acceptable salt thereof.

3. R ３ 3. The compound according to claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein is fluorine.

4. R １ represents one or more independently selected R ２ 4. The compound of claim 1, wherein R is 1 or 2; or a pharma- ceutically acceptable salt thereof.

5. Each R ２ are independently halogen, haloalkyl, -COOR ５ , -Y １ -C1-C6 alkyl, -Y ２ -C1-C6 alkyl, -L-N(R ５ ) ２ , -O-L-N(R ５ ) ２ , -C(CF ３ ) N (R ５ ) ２ , -Y １ -N(R ５ ) ２ , -Y ２ -N(R ５ ) ２ , -Y ２ -haloalkyl, -L-heterocyclyl, or -Y １ -heterocyclyl, -L-heterocyclyl and -Y １ The heterocyclyl portion of the heterocyclyl is one or more independently selected R ４ 5. The compound of claim 4, optionally substituted by: or a pharma- ceutically acceptable salt thereof.

6. R １ is pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, pyridyl, pyridinyl-2-one, pyrazinyl, pyridazinyl, pyrimidinyl, isoxazolyl, isoindolinyl, naphthyridinyl, 1,2,3,4-tetrahydroisoquinolinyl, or 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, each of which is independently selected from one or more R ２ 4. The compound of claim 1, wherein the compound is an alkyl group or a phenyl group.

7. Each R ２ are independently cyano, halogen, -Y １ -C1-C6 alkyl, -Y ２ -C1-C6 alkyl, alkoxy, hydroxyalkyl, heteroalkyl, haloalkyl, -L-cycloalkyl, -L-N(R ５ ) ２ , -Y １ -N(R ５ ) ２ , -L-heteroaryl, -L-heterocyclyl, or -Y １ -heterocyclyl, the heteroaryl of -L-heteroaryl and -L-heterocyclyl and -Y １ The heterocyclyl portion of the heterocyclyl is one or more independently selected R ４ 7. The compound of claim 6, optionally substituted by: or a pharma- ceutically acceptable salt thereof.

8. The compound is 【Chemistry 3】 2. The compound of claim 1, wherein:

9. 【Chemical 4】 or a pharma- ceutically acceptable salt thereof.

10. 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.

11. 10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, excipient, or diluent, for use in a method for treating cancer.

12. The cancers include cardiac cancer: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; lung cancer: bronchogenic carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; gastrointestinal cancer: esophageal cancer (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), gastric cancer (carcinoma, lymphoma, leiomyosarcoma), pancreatic cancer (tubular adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, hepatic leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), colon cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), genitourinary tract cancer: kidney cancer (adenocarcinoma, Wilms' tumor (nephroblastoma), lymphoma, leukemia), bladder and urethral cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), testicular cancer (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenoid tumor, lipoma), liver cancer: hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, cholangiocarcinoma: gallbladder carcinoma, ampullary carcinoma, intrahepatic cholangiocarcinoma, bone cancer: osteogenic sarcoma (osteosarcoma) ), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum sarcoma), multiple myeloma, malignant giant cell tumor, chordoma (osteochondral exostosis), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor, cancers of the nervous system: cancer of the skull (osteoma, hemangioma, granuloma, xanthomatosis, osteitis deformans), cancer of the meninges (meningioma, meningeal sarcoma, gliomatosis), cancer of the brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma ), Gynecological cancer: uterine cancer (endometrial cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva cancer (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma), blood cancer: blood cancer (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma),The pharmaceutical composition according to claim 11, which is selected from the group consisting of skin cancers: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, angioma, dermatofibroma, keloid, psoriasis, and adrenal gland cancer: neuroblastoma.

13. The pharmaceutical composition of claim 11 or 12, wherein the cancer is a PRC2-associated cancer.

Images